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FOREWORD 
 
On behalf of the Public Health team in Warrington, I am pleased to be asked to reflect on the Integrated Monitoring System 
(IMS) database and its impact for Warrington.  
Warrington has been using the IMS database for many years now, and it has certainly helped in how we commission our services 
– both in the community and in our pharmacies.  In the main, the clients using NSP (Needle Syringe Programme) are not actively 
receiving treatment – so a challenge for all of us is how can we support this cohort and ensure they receive the right messages.  
The need for the information provided by the IMS is important, given the growing issues affecting drug and alcohol users. If our 
activities are evidence based, then this information has a place in how effectively our services are delivered. Key national issues 
around drug related deaths, changes in drug using patterns and the ever increasing numbers affected by alcohol are at the 
forefront of our minds. It is known that drug related deaths continue to rise across the region and the IMS data gives a much 
clearer picture of those people actively injecting prior to death. For those attending the NSP who use steroids, this population 
group has increased by 11% over the last 12 months while psychoactive NSP has had a slight dip. Of course, all of this is under an 
umbrella of revised and changing resources. 
In Warrington we work with our community services and pharmacies to show them the IMS data – so that they understand what 
they are completing and why. This has been a big learning curve and now providers understand what the information tells us as 
commissioners. This sharing of information enables a better service provision for our service users.  
The information provided within this report has many uses to support the local commissioning of a range of services and we 
hope you will find it useful and valuable.  
 
 
Cathy Fitzgerald 
Head of Substance Misuse and Commissioning Development 
Public Health - Warrington 
 
 
  
4  Integrated Monitoring System Annual Report 2016-17 
CONTENTS 
Acknowledgements ................................................................................................................................................................ 2 
Previous reports ..................................................................................................................................................................... 2 
Foreword ................................................................................................................................................................................ 3 
List of Tables ................................................................................................................................................................................... 7 
List of Figures .................................................................................................................................................................................. 9 
Executive Summary .............................................................................................................................................................. 11 
Introduction ......................................................................................................................................................................... 14 
1. Literature and Current Research ............................................................................................................................. 16 
Setting the scene - alcohol ............................................................................................................................................................ 16 
Some facts and figures about alcohol use, alcohol-related consequences and treatment ............................................ 16 
Setting the scene - drugs ............................................................................................................................................................... 17 
Some facts and figures about drug use, drug-related consequences and treatment .................................................... 18 
National, regional, and local literature ................................................................................................................................. 19 
 Alcohol ............................................................................................................................................................................ 19 
 Drugs ............................................................................................................................................................................... 22 
Examples of research within the Public Health Institute .............................................................................................................. 26 
National IPED Info Survey ............................................................................................................................................... 26 
Health responses to New Psychoactive Substances (NPS) ............................................................................................. 26 
Evaluation of the North Yorkshire Horizons Drug and Alcohol treatment and recovery service ................................... 27 
An exploration of the role of alcohol in the life experiences of the homeless population in Merseyside ..................... 27 
Alcohol’s harm to others: The harms from other people’s alcohol consumption in Wales ........................................... 27 
2. Integrated Monitoring System - Summary .............................................................................................................. 28 
2.1. IMS Cohort summary: ..................................................................................................................................................... 28 
2.2. Annual IMS figures 2013-14 to 2016-17 ......................................................................................................................... 30 
Annual Numbers Recorded, for All IMS Individuals ........................................................................................................ 30 
Annual Numbers Recorded, by Cohort Groups .............................................................................................................. 32 
2.3. Cross Matching - IMS, NDTMS, and Criminal Justice datasets ........................................................................................ 33 
Combined client group - Cheshire and Merseyside ........................................................................................................ 33 
Combined client group - Local Authority areas .............................................................................................................. 34 
IMS individuals matching to NDTMS ............................................................................................................................... 35 
IMS individuals matching to Criminal Justice data.......................................................................................................... 36 
3. NSP clients - IDU: Psychoactive Drugs ..................................................................................................................... 37 
3.1. Demographic Profile ....................................................................................................................................................... 37 
Age and Gender .............................................................................................................................................................. 37 
Ethnicity .......................................................................................................................................................................... 39 
3.2. Main Substances ............................................................................................................................................................. 40 
Primary Substance .......................................................................................................................................................... 40 
Secondary Substance ...................................................................................................................................................... 41 
3.3. Cohort Characteristics ..................................................................................................................................................... 42 
Accommodation Status ................................................................................................................................................... 42 
Employment Status ......................................................................................................................................................... 43 
Parental Status ................................................................................................................................................................ 44 
Disabilities or Chronic Conditions ................................................................................................................................... 45 
3.4. Geographic Profile .......................................................................................................................................................... 46 
Local Authority of residence ........................................................................................................................................... 46 
Postcode District of Residence ....................................................................................................................................... 47 
Location Maps ................................................................................................................................................................. 48 
3.5. Needle and Syringe Exchange Transactions .................................................................................................................... 49 
Integrated Monitoring System Annual Report 2016-17  5 
3.6. NSP New Individuals: 2016-17 ........................................................................................................................................ 50 
NSP Individuals by year of first presentation .................................................................................................................. 50 
New Individuals only - By Age and Gender ..................................................................................................................... 51 
Proportion of New individuals by age group .................................................................................................................. 52 
3.7. Annual Client Numbers ................................................................................................................................................... 53 
Prevalence Estimates  ..................................................................................................................................................... 54 
4. NSP clients - IDU: Steroid and IPEDs ........................................................................................................................ 55 
4.1. Demographic Profile ....................................................................................................................................................... 55 
Age and Gender .............................................................................................................................................................. 55 
Ethnicity .......................................................................................................................................................................... 56 
4.2. Main Substances ............................................................................................................................................................. 57 
Primary Substance .......................................................................................................................................................... 57 
Secondary Substance ...................................................................................................................................................... 57 
4.3. Cohort Characteristics ..................................................................................................................................................... 58 
Accommodation Status ................................................................................................................................................... 58 
Employment Status ......................................................................................................................................................... 59 
Parental Status ................................................................................................................................................................ 60 
Disabilities or Chronic Conditions ................................................................................................................................... 61 
4.4. Geographic Profile .......................................................................................................................................................... 62 
Local Authority of residence ........................................................................................................................................... 62 
Postcode District of Residence ....................................................................................................................................... 63 
Location Maps ................................................................................................................................................................. 64 
4.5. Needle and Syringe Exchange Transactions .................................................................................................................... 65 
4.6. NSP New Individuals ....................................................................................................................................................... 66 
NSP Individuals by year of first presentation .................................................................................................................. 66 
New Individuals only - By Age and Gender ..................................................................................................................... 67 
Proportion of New individuals by age group .................................................................................................................. 68 
4.7. Annual Client Numbers ................................................................................................................................................... 69 
Prevalence Estimates ...................................................................................................................................................... 70 
5. Brief Intervention: Drugs or Alcohol (non-injecting clients) ..................................................................................... 71 
5.1. Demographic Profile ....................................................................................................................................................... 71 
Age and Gender .............................................................................................................................................................. 71 
Ethnicity .......................................................................................................................................................................... 72 
5.2. Main Substances ............................................................................................................................................................. 73 
Primary Substance .......................................................................................................................................................... 73 
Secondary Substance ...................................................................................................................................................... 74 
5.3. Cohort Characteristics ..................................................................................................................................................... 75 
Accommodation Status ................................................................................................................................................... 75 
Employment Status ......................................................................................................................................................... 76 
Parental Status ................................................................................................................................................................ 78 
Disabilities or Chronic Conditions ................................................................................................................................... 79 
5.4. Geographic profile .......................................................................................................................................................... 80 
Local Authority of residence ........................................................................................................................................... 80 
Postcode District of Residence ....................................................................................................................................... 81 
Location Maps ................................................................................................................................................................. 82 
5.5. Annual Client Numbers ................................................................................................................................................... 83 
Prevalence Estimates ...................................................................................................................................................... 84 
5.6. Affected Others - support services for family or friends affected by substance use ...................................................... 85 
6. Integrated Monitoring System - Activity (all clients) ............................................................................................... 87 
6.1. Interventions ................................................................................................................................................................... 87 
6  Integrated Monitoring System Annual Report 2016-17 
6.2. Referrals .......................................................................................................................................................................... 89 
Referral source / Inward referrals .................................................................................................................................. 89 
Onward referrals ............................................................................................................................................................. 90 
6.3. Wellbeing ........................................................................................................................................................................ 91 
Overview of wellbeing .................................................................................................................................................... 91 
Wellbeing reviews ........................................................................................................................................................... 91 
Wellbeing change ........................................................................................................................................................... 92 
7. Novel Psychoactive Substances (NPS) & Club Drugs ................................................................................................ 93 
8. Drug Related Deaths ............................................................................................................................................... 94 
Discussion and conclusion .................................................................................................................................................... 95 
Recommendations based on IMS Data ......................................................................................................................................... 99 
Appendixes ......................................................................................................................................................................... 101 
A. Agency based NSP services .................................................................................................................................... 101 
A.1. NSP Agency Only - All Individuals by Cohort ................................................................................................................. 101 
A.2. NSP Agency Only - New Individuals by Cohort.............................................................................................................. 102 
B. Pharmacy based NSP services ............................................................................................................................... 103 
B.1. NSP Pharmacy Only - All Individuals by Cohort............................................................................................................. 103 
B.2. NSP Pharmacy Only - New Individuals by Cohort ......................................................................................................... 104 
C. Detailed breakdown by service ............................................................................................................................. 105 
C.1. Detail by Service provider - IMS All Individuals............................................................................................................. 105 
C.2. Detail by Service provider - IMS All Activity .................................................................................................................. 109 
References .......................................................................................................................................................................... 113 
Data methodology .............................................................................................................................................................. 115 
 
  
Integrated Monitoring System Annual Report 2016-17  7 
LIST OF TABLES 
Table 1 - All IMS individuals by cohort and local authority, 2016-17 ............................................................................................... 28 
Table 2 - All IMS individuals, annual client numbers 2013-14 to 2016-17, ....................................................................................... 31 
Table 3 - Number of IMS, CJD, and NDTMS individuals by Local Authority, 2016-17 ....................................................................... 34 
Table 4 - Estimated combined client group by Local Authority, 2016-17 ......................................................................................... 34 
Table 5 - Percentage change by client group, compared with 2015-16 ........................................................................................... 34 
Table 6 - Number of IMS individuals matching to NDTMS, by age and gender ................................................................................ 35 
Table 7 - Proportion of IMS individuals by age and gender who match to NDTMS .......................................................................... 35 
Table 8 - Number of IMS individuals matching to NDTMS, by Local Authority and cohort group ................................................... 35 
Table 9 - Proportion of IMS individuals by Local Authority and cohort group who match to NDTMS ............................................. 35 
Table 10 - Number of IMS individuals matching to CJD, by age and gender .................................................................................... 36 
Table 11 - Proportion of IMS individuals by age and gender who match to CJD .............................................................................. 36 
Table 12 - Number of IMS individuals matching to CJD, by Local Authority and cohort group ........................................................ 36 
Table 13 - Proportion of IMS individuals by Local Authority and cohort group who match to CJD ................................................. 36 
Table 14 - Psychoactive drugs cohort by age and gender, 2016-17 ................................................................................................. 37 
Table 15 - Psychoactive drugs cohort, percentage split by ethnicity, 2016-17  ................................................................................ 39 
Table 16 - Psychoactive drugs cohort by primary substance and local authority, 2016-17 ............................................................. 40 
Table 17 - Psychoactive drugs cohort by primary and secondary substance, 2016-17 .................................................................... 41 
Table 18 - Psychoactive drugs cohort by accommodation status, 2016-17 ...................................................................................... 42 
Table 19 - Psychoactive drugs cohort by employment status, 2016-17 ........................................................................................... 43 
Table 20 - Psychoactive drugs cohort by parental status, 2016-17 .................................................................................................. 44 
Table 21 - Psychoactive drugs cohort, individuals stating any disability or chronic condition, 2016-17 .......................................... 45 
Table 22 - Psychoactive drugs cohort, individuals by local authority of residence and local authority of service provider, 2016-17
 .......................................................................................................................................................................................................... 46 
Table 23 - Psychoactive drugs cohort, individuals by postcode district of residence, 2016-17 ........................................................ 47 
Table 24 - Psychoactive drugs cohort, total needle exchange visits and equipment issued, 2016-17 ............................................. 49 
Table 25 - Psychoactive drugs cohort, mean averages for needle exchange visits and equipment issued, 2016-17 ....................... 49 
Table 26 - Psychoactive drugs cohort, all individuals 2016-17, by year of first presentation........................................................... 50 
Table 27 - Psychoactive drugs cohort, new individuals 2016-17, by age and gender....................................................................... 51 
Table 28 - Psychoactive drugs cohort, new individuals 2016-17, as a proportion of total individuals, by age group ...................... 52 
Table 29 - Psychoactive drugs cohort, annual client numbers 2013-14 to 2016-17 ......................................................................... 54 
Table 30 - Psychoactive drugs cohort, annual prevalence estimates by local authority, 2013-14 to 2016-17 ................................ 54 
Table 31 - Steroid and IPEDs cohort by age and gender, 2016-17 .................................................................................................... 55 
Table 32 - Steroid and IPEDs cohort, percentage split by ethnicity, 2016-17  .................................................................................. 56 
Table 33 - Steroid and IPEDs cohort by primary substance and local authority, 2016-17 ................................................................ 57 
Table 34 - Steroid and IPEDs cohort by primary and secondary substance, 2016-17 ...................................................................... 57 
Table 35 - Steroid and IPEDs cohort by accommodation status, 2016-17 ........................................................................................ 58 
Table 36 - Steroid and IPEDs cohort by employment status, 2016-17 ............................................................................................. 59 
Table 37 - Steroid and IPEDs cohort by parental status, 2016-17 .................................................................................................... 60 
Table 38 - Steroid and IPEDs cohort, individuals stating any disability or chronic condition, 2016-17 ............................................ 61 
Table 39 - Steroid and IPEDs cohort, individuals by local authority of residence and local authority of service provider, 2016-17 62 
Table 40 - Steroid and IPEDs cohort, individuals by postcode district of residence, 2016-17 .......................................................... 63 
Table 41 - Steroid and IPEDs cohort, total needle exchange visits and equipment issued, 2016-17 ............................................... 65 
Table 42 - Steroid and IPEDs cohort, mean averages for needle exchange visits and equipment issued, 2016-17 ......................... 65 
Table 43 - Steroid and IPEDs cohort, all individuals 2016-17, by year of first presentation ............................................................. 66 
Table 44 - Steroid and IPEDs cohort, new individuals 2016-17, by age and gender ......................................................................... 67 
Table 45- Steroid and IPEDs cohort, new individuals 2016-17, as a proportion of total individuals, by age group ......................... 68 
Table 46 - Steroid and IPEDs cohort, annual client numbers by local authority, 2013-14 to 2016-17 ............................................. 70 
Table 47 - Steroid and IPEDs cohort, annual prevalence estimates by local authority, 2013-14 to 2016-17 ................................... 70 
Table 48 - Drugs or alcohol (non-injecting) cohort by age and gender, 2016-17 ............................................................................. 71 
8  Integrated Monitoring System Annual Report 2016-17 
Table 49 - Drugs or alcohol (non-injecting) cohort, percentage split by ethnicity, 2016-17  ........................................................... 72 
Table 50 - Drugs or alcohol (non-injecting) cohort by primary substance and local authority, 2016-17 ......................................... 73 
Table 51 - Drugs or alcohol (non-injecting) cohort by primary and secondary substance, 2016-17 ................................................ 74 
Table 52 - Drugs or alcohol (non-injecting) cohort by accommodation status, 2016-17 ................................................................. 75 
Table 53 - Drugs or alcohol (non-injecting) cohort by employment status, 2016-17 ....................................................................... 76 
Table 54 - Drugs or alcohol (non-injecting) cohort by parental status, 2016-17 .............................................................................. 78 
Table 55 - Drugs or alcohol (non-injecting) cohort, individuals stating any disability or chronic condition, 2016-17 ...................... 79 
Table 56 - Drugs or alcohol (non-injecting) cohort, individuals by local authority of residence and local authority of service 
provider, 2016-17 ............................................................................................................................................................................. 80 
Table 57 - Drugs or alcohol (non-injecting) cohort, individuals by postcode district of residence, 2016-17 ................................... 81 
Table 58 - Drugs or alcohol (non-injecting) cohort, annual client numbers by local authority, 2013-14 to 2016-17 ....................... 84 
Table 59 - Drugs or alcohol (non-injecting) cohort, annual prevalence estimates by local authority, 2013-14 to 2016-17 ............ 84 
Table 60 - Drugs or alcohol (non-injecting) cohort, individuals with no recorded substance, 2016-17 ........................................... 85 
Table 61 - Drugs or alcohol (non-injecting) cohort, individuals with no recorded substance, by age and gender, 2016-17 ........... 86 
Table 62 - All IMS individuals, interventions delivered, 2016-17 ...................................................................................................... 87 
Table 63 - All IMS individuals, intervention categories recorded, 2016-17 ...................................................................................... 87 
Table 64 - All IMS individuals, intervention types recorded, 2016-17 .............................................................................................. 88 
Table 65 - All IMS individuals, inward referrals, by referral category, 2016-17 ................................................................................ 89 
Table 66 - All IMS individuals, inward referrals, by referral type or organisation, 2016-17 ............................................................. 89 
Table 67 - All IMS individuals, onward referrals, by referral category, 2016-17 .............................................................................. 90 
Table 68 - All IMS individuals, onward referrals, by referral type or organisation, 2016-17 ............................................................ 90 
Table 69 - Novel Psychoactive Substances (NPS) & 'Club Drugs' ...................................................................................................... 93 
Table 70 - Number of individuals using NSP services by Local Authority, 2007-2017 ...................................................................... 96 
Table 71 - Number of individuals using agency based NSP service, by cohort group ..................................................................... 101 
Table 72 - Proportion of individuals by cohort group who used agency based NSP services ......................................................... 101 
Table 73 - Number of new individuals using agency based NSP service, by cohort group ............................................................. 102 
Table 74 - Proportion of individuals using agency based NSP services who are new during the 2016-17 year ............................. 102 
Table 75 - Number of individuals using pharmacy based NSP service, by cohort group ................................................................ 103 
Table 76 - Proportion of individuals by cohort group who used pharmacy based NSP services .................................................... 103 
Table 77 - Number of new individuals using pharmacy based NSP service, by cohort group ........................................................ 104 
Table 78 - Proportion of individuals using pharmacy based NSP services who are new during the 2016-17 year ........................ 104 
 
  
Integrated Monitoring System Annual Report 2016-17  9 
LIST OF FIGURES 
Figure 1 - Definitions for the three new IMS client cohort groups ................................................................................................... 15 
Figure 2- All IMS individuals by local authority, 2016-17 .................................................................................................................. 28 
Figure 3 - All IMS individuals, percentage split by cohort group, 2016-17 ....................................................................................... 29 
Figure 4 - IDU individuals, percentage split by cohort group, 2016-17 ............................................................................................ 29 
Figure 5 - Annual client numbers 2013-14 to 2016-17, all IMS individuals ...................................................................................... 30 
Figure 6 - Annual client numbers 2013-14 to 2016-17, all IMS individuals, by local authority ........................................................ 30 
Figure 7 - Annual client numbers 2013-14 to 2016-17, client cohort group split ............................................................................. 32 
Figure 8 - Annual client numbers 2013-14 to 2016-17, client cohort group split, by local authority ............................................... 32 
Figure 9 - Estimated combined client group Cheshire and Merseyside, 2016-17 ............................................................................ 33 
Figure 10 - Psychoactive drugs cohort, percentage split by age group, 2016-17 ............................................................................. 38 
Figure 11 - Psychoactive drugs cohort by accommodation status (excludes status 'not known'), 2016-17 .................................... 42 
Figure 12 - Psychoactive drugs cohort by employment status (excludes status 'not known'), 2016-17 .......................................... 43 
Figure 13 - Psychoactive drugs cohort by parental status, only clients who stated they have children under 18, 2016-17 ............ 44 
Figure 14 - Psychoactive drugs cohort, split by residence within the local authority of service provider (excludes 'not stated'), 
2016-17 ............................................................................................................................................................................................. 46 
Figure 15 - Psychoactive drugs cohort, individuals by Local Authority area, 2016-17...................................................................... 48 
Figure 16 - Psychoactive drugs cohort, prevalence (per 1,000 population) by Local Authority area, 2016-17 ................................ 48 
Figure 17 - Psychoactive drugs cohort, individuals by postcode district of residence, 2016-17 ...................................................... 48 
Figure 18 - Annual client numbers 2013-14 to 2016-17, psychoactive drugs cohort ....................................................................... 53 
Figure 19 - Annual client numbers 2013-14 to 2016-17, psychoactive drugs cohort, by local authority ......................................... 53 
Figure 20 - Annual prevalence estimates 2013-14 to 2016-17, psychoactive drugs cohort, by local authority ............................... 54 
Figure 21 - Steroid and IPEDs cohort by accommodation status (excludes status 'not known'), 2016-17 ....................................... 58 
Figure 22 - Steroid and IPEDs cohort by employment status (excludes status 'not known'), 2016-17 ............................................ 59 
Figure 23 - Steroid and IPEDs cohort by parental status, only clients who stated they have children under 18, 2016-17 .............. 60 
Figure 24 - Steroid and IPEDs cohort, split by residence within the local authority of service provider (excludes 'not stated'), 
2016-17 ............................................................................................................................................................................................. 62 
Figure 25 - Steroid and IPEDs cohort, individuals by Local Authority area, 2016-17 ........................................................................ 64 
Figure 26 - Steroid and IPEDs cohort, prevalence (per 1,000 population) by Local Authority area, 2016-17 .................................. 64 
Figure 27 - Steroid and IPEDs cohort, individuals by postcode district of residence, 2016-17 ......................................................... 64 
Figure 28 - Steroid and IPEDs cohort, annual client numbers 2013-14 to 2016-17 .......................................................................... 69 
Figure 29 - Steroid and IPEDs cohort, annual client numbers by local authority, 2013-14 to 2016-17 ............................................ 69 
Figure 30 - Annual prevalence estimates 2013-14 to 2016-17, steroid and IPEDs cohort, by local authority ................................. 70 
Figure 31 - Drugs or alcohol (non-injecting) cohort by accommodation status (excludes status 'not known'), 2016-17 ................ 75 
Figure 32 - Drugs or alcohol (non-injecting) cohort by employment status (excludes status 'not known'), 2016-17 ...................... 76 
Figure 33 - Drugs or alcohol (non-injecting) cohort by parental status, only clients who stated they have children under 18, 2016-
17 ...................................................................................................................................................................................................... 78 
Figure 34 - Drugs or alcohol (non-injecting) cohort, split by residence within the local authority of service provider (excludes 'not 
stated'), 2016-17 ............................................................................................................................................................................... 80 
Figure 35 - Drugs or alcohol (non-injecting) cohort, individuals by Local Authority area, 2016-17 ................................................. 82 
Figure 36 - Drugs or alcohol (non-injecting) cohort, prevalence (per 1,000 population) by Local Authority area, 2016-17 ............ 82 
Figure 37 - Drugs or alcohol (non-injecting) cohort, individuals by postcode district of residence, 2016-17 .................................. 82 
Figure 38 - Drugs or alcohol (non-injecting) cohort, annual client numbers 2013-14 to 2016-17 ................................................... 83 
Figure 39 - Drugs or alcohol (non-injecting) cohort, annual client numbers by local authority 2013-14 to 2016-17 ...................... 83 
Figure 40 - Annual prevalence estimates 2013-14 to 2016-17, drugs or alcohol (non-injecting) cohort, by local authority ........... 84 
Figure 41 - Split of scores recorded at latest Wellbeing review, shown by main substance group  ................................................. 91 
Figure 42 - Change in wellbeing score between first and latest review ........................................................................................... 92 
Figure 43 - Direction of change in wellbeing score, by main substance group ................................................................................. 92 
Figure 44 - Imputation of NSP activity, 1991-2017 ........................................................................................................................... 95 
Figure 45 - NSP activity (number of individuals) 2007-2017 ............................................................................................................. 96 
10  Integrated Monitoring System Annual Report 2016-17 
Figure 46 - Number of NSP visits, 2013-2017 ................................................................................................................................... 97 
Figure 47 - Number of psychoactive/IPED individuals by cohort, pre imputation ........................................................................... 97 
Figure 48 - Number of psychoactive/IPED individuals by cohort, post imputation .......................................................................... 97 
Figure 50 - Proportion of individuals in NSP cohorts aged 40 years or over .................................................................................... 98 
 
 
  
Integrated Monitoring System Annual Report 2016-17  11 
EXECUTIVE SUMMARY 
This publication is the fourth IMS (Integrated Monitoring System) annual report. This system collates information on both 
Needle and Syringe Programme (NSP) activity and the delivery of brief interventions related to drug and alcohol use across 
Cheshire and Merseyside.  This is presented alongside a summary of local and national publications relating to drug and alcohol 
use for the year, and an overview of PHI’s work related to drug and alcohol use.  
During 2016-17, a total of 43 drug and alcohol services, including 20 services offering Needle and Syringe Programmes (NSPs), 
and 91 pharmacies reported attributable information (i.e. individuals’ initials, date of birth and gender) to IMS. Data was 
received from a total 134 different sites (a small increase from 131 sites in 2015-16). While the number of individuals reported 
to the system has dropped slightly from 2015-16, the number of NSP transactions was similar to the previous year. However 
following three consecutive years of increases, the number of brief interventions and Identification & Brief Advice (IBA) 
interventions recorded via IMS decreased to 36,888. This decrease is partly accounted for by methodological changes and 
services changing the way they record data about the delivery of these interventions. Using the new definition of one 
interaction per person per day, overall during the year, 143,721 interventions, NSP transactions or referrals to other agencies 
were delivered to 25,024 individuals, which represents a 4.5% decrease in the individuals compared to 2015-16.  
For the first time in this year’s annual report, IMS is reporting figures using three separate cohorts as show below; individuals 
with NSP activity for either 1) psychoactive drugs or 2) steroid/image and performance enhancing drugs (IPED), and 3) 
individuals receiving brief interventions from IMS reporting services. The cohorts have been used in quarterly IMS reports since 
April 2017 in response to requests from commissioners of services throughout the region to stratify the data in order to provide 
them with an overview of key groups of service users. Where the primary substance is not known for an individual, this is 
imputed1 using various characteristics including the number of an individual’s NSP transactions, their age/gender profile and the 
types of NSP equipment they have taken out. The imputation provides a clearer picture of those using NPS services, particularly 
for those areas with high numbers of individuals who do not state a primary substance. 
 
 
 
 
 
 
 
 
 
CROSS MATCHING IMS WITH OTHER DATA SOURCES 
 
When data was cross matched with data from the National Drug Treatment Monitoring System (NDTMS) and Criminal Justice 
Dataset (CJD, including Drug Intervention Programme (DIP) for those areas who provide it) the estimated combined client group 
in contact with services during 2016-17 totalled 40,645 individuals, representing a 4% decrease on 2015-16. This figure reflects a 
mixture of some areas having increased IMS numbers while nearly all areas had fewer individuals reporting to NDTMS and all 
areas reporting to the CJD had fewer individuals than in the previous year. An average of 21% of individuals reported to IMS also 
appeared in the NDTMS dataset, a decrease from 30% in 2015-16.  For those identifying steroids or an IPED as their primary 
substance, this number varied by local authority between 2% in Halton and 9% in Cheshire East.  For those identifying a 
psychoactive drug such as heroin as their primary substance, the proportions in both datasets was considerably higher, ranging 
                                                                
1 Imputation is the process of replacing missing data with substituted values. 
Injecting Drug Use: IDU 
Individuals with NSP activity recorded within the year, or an 
injecting status of ‘current’ on their last assessment. 
 
Substance at client’s latest assessment where the main 
substance is either steroids or other drugs (but not alcohol).  
Where a substance is not recorded the cohort group is 
imputed using the client attributes and activity. 
Steroid and IPEDs 
cohort 
Non-Injectors: BI 
Individuals with Brief Interventions, 
referrals and well-being only. 
 
Psychoactive drugs 
cohort 
Drugs or alcohol  
(non-injecting) cohort 
The main substance (drugs or 
alcohol) as recorded in client’s 
last assessment 
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from 13% in Liverpool to 40% in Wirral.  Across all local authority areas, the proportion of those injecting psychoactive drugs not 
in structured treatment within the past year was 80%. 
 
INJECTING DRUG USE: PSYCHOACTIVE DRUGS COHORT 
The profile of the psychoactive IDU cohort (those injecting opiates, crack cocaine or other psychoactive substances) shows an 
increasingly older population, with 70% aged 40 years or over across all areas, the highest proportion recorded for this group to 
date. At a local level, Knowsley and Wirral have the oldest profiles with 27% and 25% of individuals respectively being aged over 
50 years.  Four in five (81%) individuals in the psychoactive IDU cohort are male. Of those who identify a substance within this 
cohort, heroin is the most commonly named primary substance, ranging from 83% in Sefton to 98 % in Warrington. Crack 
cocaine is the second most commonly identified substance with 4% of individuals in Liverpool and 7% of individuals in Sefton 
stating it as their primary substance. The number of individuals with some form of housing problem is 12%. 46% of individuals 
are unemployed and seeking work while 35% are long term sick or disabled. Where an individual states that they are a parent of 
at least one child under 18, 84% do not have any children living with them. Where the field has been completed, 41% state that 
they have a chronic condition or disability. Over 1.25 million needles and syringes were distributed across Cheshire and 
Merseyside during 2016/17 to people who inject psychoactive drugs, with the average number of needles given on each visit 
ranging from 11 in St Helens to 34 in Halton.  
INJECTING DRUG USE: STEROID/IPED COHORT 
The profile of the steroid/IPED IDU cohort shows a considerably younger population than the psychoactive IDU cohort, with only 
13% across all areas being aged 40 years or over, compared to the figure of 70% for the psychoactive IDU cohort. At a local level, 
the areas with the highest proportion of people who inject steroid and IPEDs aged 50 or over are Halton (19%), Warrington and 
Wirral (18% each), while Cheshire East has the highest number for steroid and IPED IDU under the age of 25 (21%).  98.1% of 
individuals in this cohort are male compared to 81% of the psychoactive IDU cohort.  Accommodation appears to be a far less 
significant issue for the IMS steroid and IPED IDU cohort than their psychoactive IDU counterparts, with all areas reporting 
housing issues at under 5%, compared to 12% for psychoactive IDU. Very high levels of regular employment are recorded across 
each local authority area, and only 2% of individuals identified as being long term sick or disabled. Where an individual states 
that they are a parent of at least one child under 18, a majority of people who inject steroid/IPEDs have at least one child living 
with them in every area, and in all areas other than Halton and Wirral the majority have all of their children living with them.  
Over 660,000 needles and syringes were distributed across Cheshire and Merseyside during 2016/17 to people who inject 
steroid and IPEDs, with the number of needles given on each visit ranging from 19 in St Helens to 52 in Halton.  
BRIEF INTERVENTIONS ONLY 
Individuals who appear in the IMS dataset but have no NSP transactions attached to them are included in the Brief Intervention 
(BI) cohort. BIs delivered by drug and alcohol services are recorded variably across different local authority areas and so cohorts 
are not directly comparable in the same way that NSP based cohorts are. However most individuals receiving BIs (66%) are aged 
40 or over. Brief interventions have historically been used most extensively for individuals presenting with issues around their 
alcohol use and over 7 in 10 (72%) receiving BIs in 2016-17 identified alcohol as their main problem substance, followed by 
heroin (9%), cocaine (7%) and cannabis (6%).  For individuals receiving BIs, 18% cited a housing a problem, just over a third (38%) 
of individuals receiving a BI are unemployed and seeking work, with a further quarter (24%) long term sick or disabled. Just 
under one in five (18%) are in regular employment.  
INTERVENTIONS, REFERRALS AND WELLBEING REVIEWS 
Interventions were delivered on 36,888 separate occasions to a total of 9,179 individuals, an average of 4 interventions per 
person; the main interventions noted were “Health and wellbeing” (15,179 interventions), recovery support and relapse 
prevention (9,139 interventions) and “creative session or other activities” (9,138 interventions). A total of 877 outward referrals 
were recorded by service providers across five local authority areas, seven in ten of which were to another service provider 
(71%). Where a specific organisation was named, the main services individuals were referred on to were The Brink (n=248), 
Liverpool Community Alcohol Service (LCAS) (n=86) and Action on Addiction - SHARP (n=64). During 2016-17, wellbeing reviews 
were completed for 1,489 individuals. A cohort of 320 individuals had completed WEMWBS on two separate occasions. For all 
individuals with multiple wellbeing reviews just over half (51%) showed a positive change in score between their first and latest 
review, while 8% had no change and 41% recorded a negative change.  
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NOVEL PSYCHOACTIVE SUBSTANCES (NPS)  
Recording of information on NPS via IMS has been sporadic and while 11 agencies across Liverpool, Warrington and Wirral have 
reported NPS use, the data has so far been mainly collected from one young persons (YP) service based in St Helens. The data 
shows that males were more likely to use both NPS and club drugs than females although with the exception of cocaine, the 
ratio male to female was around 2:1, when this ratio is at least 3:1 for structured and standard low threshold services.  
Unsurprisingly given the age group the main reporting service catered for, most individuals (55%) were aged under 30 with very 
little use (3%) by individuals aged over 49 years. Cocaine and ‘NPS – predominantly cannabis’ were the most commonly reported 
substances. 
DRUG RELATED DEATHS 
IMS monitors drug related deaths for five local authorities using a dedicated module which reflects best practice in a number of 
areas as recommended by Public Health England (PHE), collating information from an array of sources including treatment 
services, the local coroner, NSP and low threshold and social services. A report is then compiled collating information on 
individual cases which goes out to DRD panels for discussion on a quarterly basis. Chaired by PHI, membership of the panel 
includes representation from drug services, local authority leads and social services, as well as the lead prescriber from 
treatment services. To date up until November 2017, 187 deaths have been reported via the system and a number of actions 
have resulted from panel discussions and reflection on cases including improving the process for notification when an individual 
fails to pick up a script, examining the process of handover following recommissioning, improvement of links and pathways with 
primary care, regular COPD screening and a focus on the management of physical health. 
DISCUSSION 
IMS data from 2016-17 demonstrate the importance of continuing to monitor low threshold interventions and NSP activity at a 
time when numbers using such services remain high. The data suggests that the number of individuals using a psychoactive 
substance and presenting to NSP services who are not in structured drug treatment is rising – for 2016/17 this figure is 81%. 
There have been substantial increases over the last 10 years in the number of individuals presenting to NSP services, although 
numbers appear to have levelled off in the most recent years.  Most of this change has been driven by large increases in the 
number of people using steroid and IPED presenting to NSPs since 2007-08, although the number of people injecting 
psychoactive IDU drugs has also increased in a majority of local authority areas. 
Local drug related death monitoring systems have frequently found that individuals whose NDTMS record states that they have 
not injected drugs have a number of NSP transactions recorded in IMS, indicating that they have injected. This would suggest 
that when using NDTMS the injecting status should be used with caution. 
Although the authenticity of attributors given by clients using NPS services is sometimes queried, work undertaken by PHI during 
the summer of 2017 found that over two thirds of agencies or pharmacies reporting to IMS believed that individuals using their 
service used the same consistent attributors on each visit.  Moreover, as part of the drug related death monitoring process, a 
substantial majority of individuals whose personal details are confirmed to be correct by both the treatment service and the 
coroner have matching IMS records. Together these indicate that the use of genuine details is the norm and not the exception, 
and suggest that the numbers in IMS are broadly accurate.   
RECOMMENDATIONS 
It is recommended that local authorities should continue to monitor lower threshold activity, the use of screening and 
assessment tools should be expanded, agency based NSP services should make better links with pharmacies, smoking cessation 
interventions should be routinely recorded, housing should be a key area for drug services at all tiers of provision and recording 
of data on steroid and PIED use should continue.  It is also recommended that IMS data should be used for the purposes of local 
drug related death reviews, use of the Novel Psychoactive Substance module should be expanded, IMS should be used across 
local authority areas by any relevant organisation and new harm reduction initiatives should be explored where the evidence is 
substantive.  
 
  
14  Integrated Monitoring System Annual Report 2016-17 
INTRODUCTION 
This publication presents the most recent data from the Integrated Monitoring System (IMS) which records data on the delivery 
of needles and syringe programmes (NSPs) and brief interventions across Cheshire and Merseyside. Data from the IMS for the 
2016-17 financial year is presented alongside an overview of recent research findings and significant developments related to 
policy in the drugs and alcohol fields. For the first time we have split the report into sections reflecting the three cohort groups 
which IMS now uses when reporting data. These are described in Figure 1 below: psychoactive injecting drug use (IDU), steroid 
and image & performance enhancing IDU and non-injecting individuals receiving brief interventions. Where an individual has not 
stated a main substance, this was imputed by a number of characteristics relating to their presenting to the NSP service: their 
gender, age profile, type of equipment taken and the number of visits they have made to the service over the course of a year. 
This was based upon a number of elements: 
- Although individuals using NSP services are usually male by a factor of around four to one, they are almost unanimously 
male in the case of people using IPED (Bates, McVeigh, 2015; Dunn et al 2014) 
- People injecting psychoactive substance are older on average than people who inject IPED  by around 12 years 
(Whitfield et al, 2016). 
- While data shows that all types of equipment are taken by both people who inject psychoactive substances and people 
who inject IPED, the latter group are more likely to take longer needles and larger barrels for the purposes of muscular 
injection (Exchange Supplies, 2017). 
- People injecting IPED make less frequent visits to NSP services than those injecting psychoactive substances, although 
they sometimes take out larger volumes of equipment (McVeigh et al, 2003) 
Using the principles above and running the imputation for individuals for whom a primary substance was known showed that 
the model was accurate in 85% of cases. Accordingly it has been possible to allocate individuals who previously did not state a 
primary substance to one of these two groups and this allows us to look at data in more depth historically, the results of which 
are discussed towards the end of this report. 
PHE have again been able to match IMS figures with National Drug Treatment Monitoring System (NDTMS) data in order to 
ascertain the total numbers of presenting individuals by local authority. This is a valuable tool for local authorities in estimating 
prevalence of substance use across their areas, and for the first time we have included prevalence estimated for each local 
authority area in this report. The estimated cross-matched figures show the significant contribution IMS data makes to the 
overall picture of drug and alcohol use across the region, the numbers uniquely reporting to IMS in some areas exceeding the 
total numbers presenting to structured treatment and illustrating the importance of delivering and monitoring interventions to 
individuals presenting at all levels of need.  
There have been small variations in the number of agencies (low threshold services for people using drugs or alcohol) and 
pharmacies reporting to IMS although the total figure remains comparable to previous years. However IMS as a system has seen 
provisional expansion into other areas, offering a solution particularly to voluntary and third sector organisations to evidence 
the work that they do while also providing a robust, quality data source for PHI that can be utilised for further analysis. 
The quarterly IMS report has now been split into two separate reports focussing on data quality and monitoring and aimed at 
services and commissioners respectively. A dedicated data quality officer within the team has worked closely with IMS reporting 
services in order to improve both data accuracy and completion rates, and has begun to work with pharmacies in some areas. 
The ongoing move to electronic reporting by pharmacies in many areas continues apace with only one local authority area 
reporting Needle and Syringe Programme (NSP) data via paper forms remaining. 
For the third year we have included a small section on wellbeing which while not showing clear results for the overall 
population, shows improvements for individuals citing alcohol as their primary substance. In addition, a positive change in 
wellbeing is shown for those individuals receiving support related to someone else’s drug or alcohol use. We have also included 
for the first time a section on drug related deaths, since PHI is commissioned to monitor this for five local authority areas, and at 
a time when deaths are both locally and nationally at record levels, IMS continues to provide key local intelligence on multiple 
factors where deaths occur. 
Integrated Monitoring System Annual Report 2016-17  15 
 
 
 
 
 
 
 
 
 
Figure 1 - Definitions for the three new IMS client cohort groups 
 
  
Injecting Drug Use: IDU 
Individuals with NSP activity recorded within the year, or an 
injecting status of ‘current’ on their last assessment. 
 
Substance at client’s latest assessment where the main 
substance is either steroids or other drugs (but not alcohol).  
Where a substance is not recorded the cohort group is 
imputed using the client attributes and activity. 
Steroid and IPEDs 
cohort 
Non-Injectors: BI 
Individuals with Brief Interventions, 
referrals and well-being only. 
 
Psychoactive drugs 
cohort 
Drugs or alcohol (non-injecting) 
cohort 
The main substance (drugs or 
alcohol) as recorded in client’s 
last assessment 
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1. LITERATURE AND CURRENT RESEARCH 
SETTING THE SCENE - ALCOHOL 
Alcohol misuse is a key public health concern. The Department of Health (2016a) has recommended that there should be greater 
clarity about guidelines around alcohol consumption, not simply limits and units. Public Health England (2016b) have also 
outlined the importance of creating alcohol treatment plans for adults, which include national, regional and local setups that 
help those who need it to enter treatment. It is also important to consider how and why this misuse may occur with research 
highlighting the impact of alcohol use in adolescence (Gatta et al., 2016) and aspects of psychosocial influence (Lammers et 
al.,2015) upon drinking behaviours.  
Since 1980, sales of alcohol in England and Wales have increased by 42%, from around 400 million litres with a peak high of 567 
million litres in 2008 (Public Health England, 2016a). There has been a shift in the way in which alcohol has been sold and 
consumed. There are numerous reasons why alcohol consumption has increased, while the amount of litres consumed has 
declined. These include increased consumption by women, a shift to higher strength drinks, increased affordability of alcohol 
and more alcohol being bought from shops and consumed at home (Public Health England, 2016a). Figures from the Home 
Office (2016) illustrate that in 2016, the number of alcohol licensees for club premises decreased by 700, which represents a five 
percent decrease compared to 2014 figure (15,500). In comparison, the number of personal licences increased by 63,000, which 
represents an 11% increase compared to 2014 (583,500).  
 
In England, alcohol is widely available and consumed by a large proportion of the adult population. Figures from the Health and 
Social Care Information Centre (HSCIC 2016) suggest that 58% of adults (28.9 million people in Great Britain) reported drinking 
alcohol in the previous week. In most cases drinking takes place with no adverse effects. In some cases, however, alcohol can 
lead to significant health issues (Public Health England, 2016b). Alcohol is considered a Grade 1 carcinogen (the most 
carcinogenic) and can have acute and chronic effects that make up over two-hundred disease conditions. These include cirrhosis 
of the liver, links to obesity, poorer mental health and acute cases of accidents, injuries or poisoning (APMS, 2016a).  
Alcohol related hospital admissions have increased by 32% compared to 2004/05 figures, with an estimated 333,000 admissions 
relating to alcohol misuse in 2016 (HSCIC, 2016). In 2015, there were 8,758 alcohol-related deaths in the UK (14.2 deaths per 
100,000 people in the population). On the whole, alcohol-related death rates in the UK have not changed in recent years, but 
the rate in 2015 was a record high (Office For National Statistics, 2017a).  
There has been a reduction in the number of secondary school children who reported drinking within the previous week (HSCIC, 
2016). In 2014, 38% of secondary school students reported having drunk in the previous week, compared to 62% when the 
survey began in 2003 (HSCIC, 2016). 
SOME FACTS AND FIGURES ABOUT ALCOHOL USE, ALCOHOL-RELATED CONSEQUENCES AND TREATMENT 
 In England, more than 10 million people (24% of the population) drink at levels that increase their risk of health conditions 
(Public Health England, 2016b). 
 From 2011-2014, 25.7% of adults in England were cited to regularly drink over 14 units per week (current health guidelines) 
compared to 15.5% of adults in England who abstained from drinking alcohol over the same period (Public Health England, 
2016b).  
 There were 1.3 licenced premises per km2 in England in 2015-16 (Public Health England, 2016a). 
 The economic burden of alcohol is substantial, with estimates placing the annual cost to be between 1.3% and 2.7% of 
annual Gross Domestic Product (GDP) (Public Health England, 2017). GDP for 2016 was just below £2 billion (Statista, 2017), 
meaning the additional financial burden of alcohol could be between £26 million and £54 million. 
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SETTING THE SCENE - DRUGS 
Drug misuse, including intravenous (IV) drug use and the use of image and performance enhancing drugs (IPEDs) and 
psychoactive substances are considered a continuously developing issue (APMS, 2016b). Drug misuse is defined by the World 
Health Organisation (WHO) as the use of a substance not congruent with the medical or legal guidelines, for example the non-
medical use of prescription medications or the recreational use of illegal drugs (APMS, 2016b).  
As with excessive/long-term alcohol consumption, the use of drugs also has health and wellbeing implications for individuals. 
This harm can be physical, relating to organ damage, increased risk of cancers and damage to skin and veins (Public Health 
England, 2015b). It can also impact upon mental health and wellbeing; with drugs affecting psychological abilities and drug use 
being associated with poorer mental health, increased anxiety, drug dependence and depression (Public Health England, 2015b).  
Drug misuse and dependence can be harmful to individuals, their families, friends and wider communities, but it is important to 
note that there are ways to help alleviate these issues. Public Health England (2016c) outline that vital to helping reduce the 
significance of this issue is prevention, treatment and recovery. It is believed that this will also have a positive effect upon 
reducing other negative aspects of drug use such as crime, anti-social behaviour and other associated issues. This is why 
planning to inform and prevent, aid treatment of and allow for a fully supported recovery is vital. This is only possible with the 
right planning and support from governmental, regional and local community partners and groups (Public Health England, 
2016c). 
Research suggests cannabis is the most popular drug of choice, and that its use can lead to problematic drug effects such as 
dependence on cannabis or the use of other drugs (APMS, 2016b). Dependence is commonly but not solely associated with 
opioid use (such as heroin, codeine and morphine). Approximately 300,000 people are dependent on heroin and/or crack in 
England (Public Health England, 2016c). Figures are also increasing for other drugs such as cannabis, psychoactive substances 
and image/performance enhancing substances (Public Health England, 2016c). There is also concern that levels of dependence 
are increasing for over-the-counter and prescribed medicines (Public Health England, 2016c). 
The creation and distribution of new substances is also an issue. A report from the European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA, 2016) highlighted that Novel Psychoactive Substances (NPS) are developing at an alarming rate. 
Figures suggest that over recent years there has been a yearly increase of new NPS identified, which allows for further 
unidentified substances (Shapiro, 2016). It is also suggested that this trend of new NPS is not set to decline and 
medical/pharmaceutical examination of the drugs cannot be carried out quickly enough (EMCDDA, 2016; Shapiro, 2016).  
  
Image and Performance Enhancing Drugs (IPEDs) are a classification of drugs that are used specifically to alter or modify one’s 
appearance or performance. These include steroids and gym drugs; nootropics (smart drugs – used to enhance brain function, 
commonly used by people wishing to do continuous work without rest); weight loss tablets, botox, tanning and filler drugs 
(Lifeline Project, 2017). These drugs have previously been separated from what has been considered conventional drug use as 
they are largely prevalent in sporting contexts. However, IPEDs are becoming more and more common across the general 
populations, particularly in England and Wales (Bates and McVeigh, 2016).  
Hazards associated with the use of IPEDs include syringe cross contamination (leading to infections and diseases like HIV and 
hepatitis) (Public Health England, 2016d); personal physical harm (to skin or organs due to self-dosage) (Public Health England, 
2015b); and in circumstances where other drugs and alcohol are mixed with IPEDs, accidental death (Lifeline Project, 2017). 
Public Health England (2015a) highlight that many users of IPEDs have complex needs; this relates to any physical damage that 
may have occurred but also psychological harm. Often there are side effects of using IPEDs (particularly anabolic steroids) such 
as anxiety, paranoia and dependency (Bates and McVeigh, 2016). Although accurate prevalence figures for the UK are difficult to 
obtain, Public Health England knowledges that in many parts of the country IPED users make up a significant proportion of 
people using needle and syringe programmes, and many have complex health needs highlighting the importance of providing 
appropriate services for IPED users (Public Health England, 2015a).  
 
When considering a wider public health context, it is important to look at the information relating to treatment and secure 
setting facilities for these drug misuse issues. The Department of Health (2016b) provides some statistics on adults (people 18 
years or older) accessing treatment services in the UK. A total of 288,843 people were in contact with an alcohol or drug related 
service in the 2015-16 period. The number of people who commenced their treatment during this year was 138,081, with 97% 
of these people waiting three weeks or less to start treatment.  
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The reasons for treatment were split into four classifications: opiate (149,807, 52%), non-opiate only (25,814, 9%), non-opiate 
and alcohol (28,187, 10%), and alcohol only (85,035, 29%). As these figures show, opiate use was the largest reason for 
treatment followed by alcohol only (The Department of Health, 2016b). There was a 2% decrease in people accessing treatment 
during this period and these individuals were largely opiate clients (The Department of Health, 2016b). 
 
The Department of Health (2017) also published a similar report that looked at young people (18 years or younger) who were in 
treatment/secure settings. These include Youth Offending Institute (1,067, 69%), Secure Children’s Homes (247, 16%), Secure 
Training Centres (187, 12%) and Welfare Only Homes (40, 3%). When asked what substance there were being treated for, 
cannabis was the most cited substance with 91% (1396) of young people reporting it. A further 51% (793) reported that they 
have problems with their alcohol use. Several other substances were also cited; NPS (121, 8%), cocaine (296, 19%) and nicotine 
(297, 19%).  
  
 
SOME FACTS AND FIGURES ABOUT DRUG USE, DRUG-RELATED CONSEQUENCES AND TREATMENT 
 There were 15,074 hospital admissions with a primary diagnosis of poisoning by illicit drugs in 2015-16. This is 6% more than 
2014-15 and 51% more than 2005/06 (NHS Digital, 2017).  
 People in receipt of Employment and Support Allowance (ESA) were more likely to report signs of drug dependence than 
people who do not receive this benefit. Some of these people will have been eligible for ESA due to their drug dependence 
and associated physical and mental poor health (APMS, 2016b). 
 Approximately one in 200 people who have injected psychoactive drugs is currently living with the hepatitis B infection 
(Public Health England, 2016d). Levels are similar to that of recent years, which is showing a stability of the infection, 
suggesting that the number of infections is not becoming more serious.  
 According to the 2015-16 Crime Survey for England and Wales, use of any class A drug was around 10 times higher among 
people who had visited a nightclub at least four times in the past month (18%) compared with those who had not visited a 
nightclub in the past month (2%). A similar pattern was found for those visiting pubs and bars more frequently (National 
Institute for Health and Care Excellence, 2017c).  
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NATIONAL, REGIONAL, AND LOCAL LITERATURE 
The literature included in this section covers the period from 1st April 2016 to 31st March 2017 and should be used in conjunction 
with literature reported upon in previous Integrated Monitoring System reports. 
 
ALCOHOL 
 
STATISTICS ON ALCOHOL, ENGLAND, HEALTH AND SOCIAL CARE INFORMATION CENTRE (HSCIC, JUNE 2016) 
This 2016 report seeks to bring together some of the alcohol related statistics that directly link to hospital and health functions. 
It reports on issues such as:  
 General information about alcohol and why alcohol is consumed.  
 The prevalence of hospital admissions related to alcohol, including nationwide and local area 
figures that are compared to the previous year, with demographics about individuals and 
local areas.  
 Information about the drinking habits of adults and children. These include frequency of 
drinking, drunkenness, and preference about drink type. These statistics also look at 
differences by gender and local area. 
 Statistics about the affordability of alcohol in relation to household income.  
 The health risks associated with alcohol and how well understood these risks are among 
adults and children.  
Available from: http://content.digital.nhs.uk/catalogue/PUB20999/alc-eng-2016-rep.pdf 
 
RESEARCH AND STATISTICAL BULLETIN 8/2017 - VIEWS ON ALCOHOL AND DRUG RELATED ISSUES: FINDINGS FROM THE 
OCTOBER 2016 NORTHERN IRELAND OMNIBUS SURVEY (DEPARTMENT OF JUSTICE (NORTHERN IRELAND) AND NORTHERN 
IRELAND STATISTICS AND RESEARCH AGENCY, 2017) 
Several times a year the Northern Ireland Statistics and Research Agency conduct the Northern Ireland Omnibus Survey. The aim 
of the report is to collect and use the information on alcohol and drug use to help reinforce and adapt to policies within 
Northern Ireland. These focus on developing community safety and understanding of alcohol and drug use for future policy. The 
report is designed to build upon the previous September 2015 report. Findings include:  
 Results from the October 2016 Northern Ireland Omnibus Survey (NIOS) found that 43.3% of 
respondents agreed or strongly agreed with the statement ‘I am concerned about alcohol 
related issues in my local area’. This compares to 40.3% of respondents who disagreed or 
strongly disagreed with the statement. 
 When participants were asked to select five issues that concerned them from least to most 
important, the most cited reasons given for those reporting concern about alcohol related 
issues in the local area was ‘underage drinking’ (59.1%) and ‘drinking in public places’ 
(33.1%). For drug related issues, 55.0% of respondents stated ‘drug use/abuse’ was the 
primary drug related issue in the local area. The secondary issue for respondents in relation 
to drugs was ‘drug dealing’ (43.6%). 
 Eight out of ten respondents (82.4%) stated there was no change in the level of alcohol 
related issues in their local area in the last 12 months. A similar proportion of respondents 
(80.0%) stated there was no change in the level of drug related issues in their local area in 
the last 12 months. 
 Nearly one in 10 respondents (8.8%) had heard of the Northern Ireland Assembly’s New Strategic Direction for Alcohol and 
Drugs Phase 2, 2011-16. This suggests that the findings of the report are not commonly well known.  
 Available from: https://www.justice-ni.gov.uk/publications/research-and-statistical-bulletin-82017-views-alcohol-and-drug-
related-issues-findings-october-2016 
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THE PUBLIC HEALTH BURDEN OF ALCOHOL AND THE EFFECTIVENESS AND COST-EFFECTIVENESS OF ALCOHOL CONTROL 
POLICIES AN EVIDENCE REVIEW (PUBLIC HEALTH ENGLAND, 2016A) 
This evidence review aims to look at the risks and influences of alcohol and the effectiveness and costing of control policy 
surrounding policy. The main points from the review include:  
 There are over 10 million people drinking at levels that increase their risk of health harm. 
Among those aged 15 to 49 in England, alcohol is now the leading risk factor for ill-health, 
early mortality and disability. 
 In England, the average age at death of those dying from an alcohol-specific cause is 54.3 
years. This compared to the average age of death from all causes of 77.6 years.  
 An individual may die by suicide following a single bout of heavy drinking or as a result of 
suicidal ideation attributable to chronic heavy drinking. In England in 2014-15, there were 
5,800 hospital admissions for intentional self-harm and a further 170 admissions for events 
of undetermined intent, accounting for less than 1% of all alcohol-related hospital 
admissions. Among men aged 25 to 34 years, intentional self-harm was the leading cause of 
alcohol-related death and for women in this age group it was the second. 
Available from: https://www.gov.uk/government/publications/the-public-health-burden-of-
alcohol-evidence-review 
 
 
ALCOHOL-RELATED DEATHS IN THE UK: REGISTERED IN 2015 (OFFICE FOR NATIONAL STATISTICS, 2017) 
The statistical bulletin from the Office for National Statistics includes statistics on alcohol related deaths. These seek to 
understand the mortality rate and demographic information of these deaths.  
 In 2015, there were 8,758 alcohol-related deaths in the UK, an age-standardised rate of 14.2 
deaths per 100,000 population. 
 For the UK as a whole, alcohol-related death rates have not changed in recent years, but the 
rate in 2015 is still higher than that observed in 1994. 
 The majority of alcohol-related deaths (65%) in the UK in 2015 were among males. In the 
same year, rates of alcohol-related death in males and females were highest in those aged 55 
to 64 years in 2015. 
 Scotland remains the UK country with the highest rate of alcohol-related deaths in 2015 (31 deaths per 100,000 population.) 
Scotland has also seen the largest decrease in its rates since they peaked in the early 2000’s (46 deaths per 100,000 
population). 
Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/causesofdeath/bulletins/ 
alcoholrelateddeathsintheunitedkingdom/registeredin2015 
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STATISTICS FROM THE ADULT PSYCHIATRIC MORBIDITY SURVEY (APMS) 2014 CHAPTER 10 ON ALCOHOL DEPENDENCE 
(DRUMMOND ET AL., 2016) 
This chapter from a much broader survey aims to provide some statistical and demographical insight into rates of alcohol 
dependence in England. Some of the leading statistics are:  
 In 2014, 16.6% of adults drank at hazardous levels, 1.9% were harmful or mildly dependent 
drinkers and 1.2% were highlighted as probably being dependent drinkers. As in previous 
years, men were more likely than women to drink at hazardous levels and above. Most adults 
drank at lower risk levels (57.5%) or did not drink at all (22.8%). 
 Levels of hazardous drinking have declined in men aged 16-74 years over the past fifteen 
years (36.8% in 2000; 32.4% in 2007; 27.9% in 2014). These levels have remained stable in 
women with 13.4% of women drinking at a hazardous level in 2014. 
 White British men and women were more likely to drink at hazardous, harmful or dependent 
levels than their counterparts in other ethnic groups. 
Available from: http://content.digital.nhs.uk/catalogue/PUB21748 
  
 
HOW TO KEEP HEALTH RISKS FROM DRINKING ALCOHOL TO A LOW LEVEL: GOVERNMENT RESPONSE TO THE PUBLIC 
CONSULTATION (DEPARTMENT OF HEALTH, 2016A).  
This update from the Department of Health is a response to a public consolation with the Government. The UK Chief Medical 
Officer (CMO) worked with local government to help develop plans to keep alcohol related health risks low. The original plans 
date back to 2012 and have been progressed through to publication. Some of the updates include:  
 Aiming to provide a clear guide and understanding to people so they can make informed 
decisions about drinking alcohol.  
 Considerations around the inclusion of a single occasion unit limit for drinking alcohol, i.e., 
how many units maximum should be drunk in one session.  
 Discussion around providing greater clarity about alcohol consumption guidelines, not simply 
limits and units. The use of language and terminology in coverage of alcohol misuse is 
important.  
 Agreement that information regarding pregnancy and drinking is clear and understandable.  
Available from: https://www.gov.uk/government/consultations/health-risks-from-alcohol-new-
guidelines 
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DRUGS 
 
STATISTICS ON DRUG MISUSE. ENGLAND 2017 (NHS DIGITAL [FORMALLY HSCIC], 2017)  
This 2017 report seeks to bring together some of the drug misuse related statistics that directly link to hospital and health 
functions. These include statistics such as:  
 In 2015-16 drug use for adults aged 16-59 (8.4% of people surveyed) was similar to the 2014-15 figures (8.6%).  
 The prevalence of drug use for children (11-16 years old) increased with age. 6% of 11 year 
olds said they had tried drugs at least once, compared with 24% of 15 year olds 
 The prevalence of hospital admissions related to drug use in England. These also include 
demographic information about individuals and local areas.  
 Information about the drug misuse habits of adults and children. These include frequency of 
drug use, selection of drugs and likelihood to use illicit drugs. These statistics also look at 
gender and local area differences. 
 There is special consideration asking children about their knowledge of drugs, particularly 
legal highs.  
Available from: http://www.content.digital.nhs.uk/catalogue/PUB23442 
 
 
STATISTICS FROM THE ADULT PSYCHIATRIC MORBIDITY SURVEY (APMS) 2014. CHAPTER 11 ON DRUG USE AND DEPENDENCE 
(ROBERTS ET AL., 2016 
This chapter from a much broader survey aims to provide some statistical and demographical insight into rates of drug use and 
dependence in England. Some of the leading statistics are:  
 Cannabis was the most commonly used drug in the past year. Among those 16–24 year olds 
who had completed the survey, 23.7% of men and 16.2% of women had used it in the past 
year, followed by ecstasy, cocaine, ketamine and mephedrone. Ketamine and mephedrone 
use was rarely reported by people in older age-groups. 
 Overall, 3.1% of adults who completed the survey recognised they showed signs of 
dependence on drugs (based upon daily use, inability to abstain and withdrawal symptoms) – 
2.3% showed signs of dependence on cannabis only and 0.8% with signs of dependence on 
other drugs (with or without cannabis dependence as well). After increases in the 1990’s, the 
overall rate of perceived dependence has remained stable since 2000. 
 Half (50.1%) of people with signs of dependence on drugs other than cannabis were in receipt 
of mental health treatment at the time of taking part in the survey. In contrast, those with 
signs of dependence on cannabis only (12.6%) had similar mental health treatment rates to 
the rest of the population in the survey (11.2%). 
Available from: http://content.digital.nhs.uk/catalogue/PUB21748 
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DRUG MISUSE: FINDINGS FROM THE 2015/16 CRIME SURVEY FOR ENGLAND AND WALES. SECOND EDITION, STATISTICAL 
BULLETIN 07/16 (HOME OFFICE, 2016B).  
This release covers the extent and trends of drug use for adults and children while looking at frequency of drug use in 
households, area characteristics and lifestyle factors. It also considers the use of new psychoactive substances and perceived 
accessibility to and ease of obtaining illicit drugs. Key findings include: 
 Around 1 in 12 (8.4%) adults surveyed who were aged 16 to 59 had taken a drug in the last 
year. This equated to around 2.7 million people in England and Wales.  
 Less than five percent (4.3%) of adults surveyed who were aged 16 to 59 had taken a drug in 
the last month, compared to nearly 1 in 10 (9.1%) young adults aged 16 to 24 who had. 
 The majority of last year NPS users had also used another drug in the last year. Among adults 
aged 16 to 59 who had used an NPS, 84.9% had used another drug in the last year. This 
proportion was similar for young adults aged 16 to 24 (85.2%). 
 Herbal smoking mixtures were the most commonly used NPS in the last year. More than half 
(52%) of those surveyed who were aged 16 to 59 years old had taken such a substance on the 
last occasion that they used NPS. 
 Younger people were shown to be more likely to take drugs than older people, while men are 
more likely to take drugs than women. Urban areas were more associated with drug use 
(including NSP) than rural areas as were visits to the pub, bars and nightclubs compared to 
staying at home.  
Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/564760/drug-misuse-1516.pdf 
 
 
ADULTS – DRUGS JSNA SUPPORT PACK 2017-18: COMMISSIONING PROMPTS; PLANNING FOR DRUG PREVENTION, 
TREATMENT AND RECOVERY IN ADULTS (PUBLIC HEALTH ENGLAND, 2016C). 
This report aimed to outline ways in which drug prevention and treatment could be implemented in 2017/18. There is a large 
focus on understanding the current status of drugs, how they are used and how national and regional support links may be used 
effectively. Key points include:  
 Early intervention and identification to prevent drug misuse and dependence. This is 
underpinned by numerous policies and using evidence-based programmes to add further 
support.  
 Establishing strong community-connected links that promote information sharing and 
encourage individuals to make the best use of the available prevention and intervention 
services. 
 Putting more interventions in place to increase knowledge about the harm to health drug use 
can have is necessary from local/national authorities. This information needs to be aimed at 
those who use drugs and those who do not. For example, many drug users are not aware of 
the health risks with injecting drugs.  
 The need for treatment provision that is goal orientated, effective, high-quality and 
productive. There needs to be a shared information base from all health partners to help 
facilitate recovery from drug misuse. Recovery should also focus on providing support from peers and others in the local 
community. Patriotically it is argued that facilitators of recovery should ensure they work with partners to produce the best 
recovery solutions.  
Available from: http://www.nta.nhs.uk/healthcare-JSNA.aspx 
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DRUG MISUSE PREVENTION: TARGETED INTERVENTIONS. NICE (NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE) 
GUIDELINES (NICE, 2017)  
NICE have compiled a large amount of information that is targeted at professionals and people who work with drug users and 
people who take drugs. The document aims to help increase awareness and aid prevention of drug taking. Some of the key 
points of the guideline include: 
 Use of any ‘Class A’ drug was around 10 times higher among people who had visited a 
nightclub at least four times in the past month (18%) compared with those who had not visited 
a nightclub in the past month (2%). A similar pattern was found for those visiting pubs and 
bars more frequently. 
 The report noted that the literature review for cost-effectiveness evidence did not find any 
studies that were directly relevant to drug misuse prevention in the UK. Health economic 
modelling was undertaken to provide cost-effectiveness evidence for this guideline. This was 
done to help shape the future design of drug misuse services.  
 Recommendations that drug misuse prevention interventions should be delivered through a 
range of existing services for people in groups at risk, rather than setting up dedicated 
services. These services include primary and secondary health services, specialist services, 
community-based criminal justice groups and emergency services. 
Available from: https://www.nice.org.uk/guidance/ng64 
 
 
SHOOTING UP. INFECTIONS AMONG PEOPLE WHO INJECTED DRUGS IN THE UK, 2015. AN UPDATE: NOVEMBER 2016 (PUBLIC 
HEALTH ENGLAND, 2016D).  
 
 In 2015 in England, Wales and Northern Ireland, 1.0% of the people who inject psychoactive 
drugs surveyed were HIV positive. Among those attending needle and syringe programmes in 
Scotland during 2015-16, 1.9% were HIV positive. 
 Approximately nine out of ten hepatitis C infections diagnosed in the UK are thought to have 
been acquired through injecting drug use. Across the UK, nearly 13,000 positive test results for 
hepatitis C were reported during 2015.  
 The proportion of people who inject psychoactive drugs ever infected with hepatitis B in 
England, Wales and Northern Ireland has halved over the past 10 years, falling from 28% in 
2006 to 13% in 2015. In 2015, only 0.41% had a current hepatitis B infection, similar to the 
level seen in recent years. It is suggested that this is due to the increased update of the 
hepatitis B vaccine. The proportion of individuals receiving at least one dose of the vaccine 
have increased from 59% in 2005 to 75% in 2015. Figures have remained stable in recent years 
across England, Wales and Northern Ireland. 
 There has been a slight decrease over the last ten years in those injecting psychoactive drugs in England, Wales and Northern 
who reported that they had experienced an abscess, sore or open wound during the past year (33%, 2015; 35%, 2006). These 
symptoms appear to be slightly more prevalent in women (38%) compared to men (31%). The reason for this difference is 
unclear.  
Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/567231/ 
Shooting_Up_2016_Update.pdf 
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NEEDLE AND SYRINGE PROGRAMMES OVERVIEW (NICE, 2017B) 
NICE needle and syringe programmes overview considers the functioning of current programmes and the development of new 
programmes. Some of the key points include:  
 The importance of ensuring needle and syringe programmes are taking place and that they 
effectively reach out to the community. The overview highlighted that more needs to be done 
to work with people from different demographic areas who may need help.  
 Improvements need to be made in the collection and analysis of data on injecting drug use. 
The purpose of this is to help increase awareness of the prevalence of infections and diseases. 
This includes ensuring the up-to-date recording of drug type in line with the ever-changing 
drug landscape.  
 The identified need for the development of policy specific to young people. This is due to a 
high drug use prevalence in this age group and increased access/ease of access. Such policy 
should include understanding the difficulties young people face and attempting to understand 
their drug use/injecting habits. 
NICE guidance available from: https://www.nice.org.uk/guidance/ph52 
Updated overview and pathway charts: https://pathways.nice.org.uk/pathways/needle-and-syringe-programmes 
https://pathways.nice.org.uk/pathways/needle-and-syringe-programmes/needle-and-syringe-programmes-overview.pdf 
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EXAMPLES OF RESEARCH WITHIN THE PUBLIC HE ALTH INSTITUTE 
Below are examples of research conducted and completed at the LJMU Public Health Institute, during the period from 1st April 
2016 to 31st March 2017, alongside research that is currently taking place. 
NATIONAL IPED INFO SURVEY 
The use of image and performance enhancing drugs (IPEDs) including anabolic steroids and other drugs used to increase 
muscularity and enhance appearance has increased over the past decade and become an area of increasing public health 
significance amongst the general population. Individuals who use IPEDs differ from those who use other substances such as illicit 
psychoactive drugs and present a range of specific challenges for those commissioning and providing health services. 
The Public Health Institute in collaboration with Public Health Wales undertook the largest survey of people who use IPEDs in 
2015. The survey examined use amongst a sample of 663 individuals recruited from needle and syringe programmes and gym 
and sporting settings across England, Wales and Scotland, exploring participants’ experiences relating to their IPED use. Another 
large survey of this group was undertaken in 2016, with an increased emphasis on recruiting participants outside of health 
service settings. This survey closed in December 2016, and its findings will be available on PHI’s website. 
 
HEALTH RESPONSES TO NEW PSYCHOACTIVE SUBSTANCES (NPS)  
The emergence of Novel Psychoactive Substances (NPS) over the last decade poses an important challenge to drug policy. While 
prevalence levels of NPS use remain low in the general European population, there are important concerns with more 
problematic forms of use and harms in particular risk groups across different health and social settings. Important public health 
issues have arisen as a consequence of their use, although the real extent of these harms across Europe remains unknown. 
Initial responses to NPS in Europe have largely been regulatory, focusing on their supply using legislative tools but, as the 
phenomenon evolves, it has increasingly become a priority to formulate and implement effective public health responses. While 
information and our understanding on the availability and use of NPS has increased, there are still considerable knowledge gaps 
on current practices and even on the challenges and needs of European health professionals who are responding to use and 
harms caused by these novel substances.  
To address this lack of evidence and information, a rapid review of the literature was conducted for the European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA) following a two-day consultation with a range of European experts working in a 
number of settings across Europe. A settings-based approach was taken to draw attention to specific issues faced by a number 
of high risk groups and health professionals, and the health and intervention responses that are available in these settings. High 
risk user groups identified include ‘partygoers’/ nightlife attendees; individuals presenting to emergency departments; people in 
prison; existing problematic users and people who inject drugs (PWIDs); and men who have sex with men (MSM).  
The report provides an overview of: 
 the current situation in terms of NPS use and harms across Europe;  
 the challenges posed to European health professionals by an increasingly diverse and dynamic drug market; and  
 available health and drug-related interventions to reduce and prevent use and potential harms of New Psychoactive 
Substances (NPS) including acute care in emergency settings, drug treatment, harm reduction and prevention activities 
delivered over the internet and in various interventions settings (schools, specialist treatment centres, low-threshold, 
nightlife, sexual health and custodial settings). 
 
The report was published by the EMCDDA in June 2016. Drawing on the research, an online NPS module aimed at professionals 
was also developed and is available via the EMCDDA website. The report can be found here: 
http://www.emcdda.europa.eu/topics/pods/health-responses-to-nps 
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EVALUATION OF THE NORTH YORKSHIRE HORIZONS DRUG AND ALCOHOL TREATMENT AND RECOVERY SERVICE 
The Public Health Institute was commissioned by North Yorkshire County Council to undertake a two-year evaluation of the 
newly commissioned integrated treatment and recovery services in North Yorkshire.  
The aim of the evaluation was to explore issues relating to service use, completions, re-representations, relapses, outcomes and 
cost-effectiveness. Qualitative interviews were carried out with commissioners, staff who worked at the services and other key 
stakeholders as well as service users. Analysis of treatment and recovery data for the service users has also been carried and 
compared to national averages in addition to a cost-effectiveness exercise.  
This evaluation was to be completed by the end of August 2016 and is currently being written up.  
 
AN EXPLORATION OF THE ROLE OF ALCOHOL IN THE LIFE EXPERIENCES OF THE HOMELESS POPULATION IN 
MERSEYSIDE 
This research was funded by Alcohol Research UK. The main objective of this research was to explore the impact that alcohol 
consumption can have on the homeless population. Merseyside was used as a case study for this research and local services that 
provide care and advice for those who are homeless assisted with the recruitment of participants.  
A novel multi-method approach combining life history calendars was used alongside a participatory photography exercise. The 
life history calendar approach was used with 15 participants and provided a structured approach to creating a framework and 
cues to trigger recall through the use of significant events to use as reference points to link changes in their alcohol 
consumption. Five participants were invited to take part in the participatory photography, which involved producing images that 
reflect their experiences of being homeless and how their alcohol consumption had changed.  
This research was published in March 2017.  
Full report available here: http://alcoholresearchuk.org/alcohol-insights/an-exploration-of-the-role-of-alcohol-in-the-life-
experiences-of-the-homeless-population-in-merseyside-uk 
 
ALCOHOL’S HARM TO OTHERS: THE HARMS FROM OTHER PEOPLE’S ALCOHOL CONSUMPTION IN WALES 
Internationally, there is growing recognition of the harms that an individual’s alcohol consumption can cause to those around 
them (referred to as alcohol’s harms to others). Consequently, research into this issue has started to emerge highlighting the 
nature, extent and costs of alcohol’s harms to others across various populations. This report looks at the harms from other 
people’s alcohol consumption in Wales. 
 
This study provides an initial overview of the experience of alcohol’s harms to others amongst adults in Wales. Whilst further 
research is needed, the prevalence of alcohol’s harms to others identified should act as a catalyst for policymakers, practitioners 
and the public, to both consider and work towards addressing the wide ranging effects of alcohol use.  
The full report is available from: http://www.cph.org.uk/wp-content/uploads/2016/09/PHW-Harms-to-Others-Report-E7.pdf  
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2. INTEGRATED MONITORING SYSTEM - SUMMARY 
2.1.  IMS COHORT SUMMARY:  
During the 2016-17 year 25,024 individuals in total reported to the IMS, a slight decrease of 4.4% on the previous year but this is 
mainly accounted for by a dip in the number of individuals who have received a brief intervention. The largest group of 
individuals in the IMS dataset reside in Liverpool (43.8%) with other areas reporting between 5.3% (Cheshire East) and 10.5% 
(Sefton) of the total.  
 
 
Figure 2- All IMS individuals by local authority, 2016-17 
 
For the first year, the IMS client group has been broken down into 3 cohorts representing Injecting Drug Use (IDU) of 
Psychoactive Drugs, IDU of steroids and IPEDs, and non-injecting individuals in receipt of a brief intervention. Proportionally, 
Liverpool has the highest percentage of psychoactive IDU (46.3%) and Cheshire East the highest percentage of steroid/IPED IDU 
(61.8%). Knowsley has the highest percentage of those receiving brief interventions only (53.2%). 
Local Authority 
IDU: Psychoactive 
Drugs 
IDU: Steroid & 
IPEDs 
BI: Drug  
or Alcohol 
All IMS 
Individuals 
Cheshire East 511 825 0 1,336 
Cheshire West & Chester 862 1,174 2 2,038 
Halton 127 539 503 1,169 
Knowsley 300 427 826 1,553 
Liverpool 5,080 2,940 2,941 10,961 
Sefton 957 595 1,073 2,625 
St. Helens 950 922 390 2,262 
Warrington 578 775 252 1,605 
Wirral 835 943 276 2,054 
Cheshire & Merseyside2 9,913 9,022 6,089 25,024 
Table 1 - All IMS individuals by cohort and local authority, 2016-17 
 
                                                                
2 Some individuals may have presented in more than one area, therefore this figure will be less than a sum of the separate local authority totals. 
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Figure 3 - All IMS individuals, percentage split by cohort group, 2016-17 
 
Looking at IDU only, Liverpool again has the highest level proportionally of psychoactive drug injectors (63.1%) while Halton has 
the largest proportion of steroid/IPED injectors (81.4%). The average proportion of psychoactive IDU across the nine local 
authority areas is 52.2%. 
 
Figure 4 - IDU individuals, percentage split by cohort group, 2016-17 
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2.2.  ANNUAL IMS FIGURES 2013-14 TO 2016-17 
ANNUAL NUMBERS RECORDED, FOR ALL IMS INDIVIDUALS 
The number of individuals reporting to IMS has stayed fairly static over the last four years, with the exception of 2014-15 which 
saw a 21.2% rise on the previous year due to an increase in the number of individuals using NSP services. The overall slight 
decrease in 2016-17 from the previous year is mainly accounted for by decreases in some of the larger areas as opposed to 
smaller areas such as Cheshire West and Chester and Knowsley which saw an increase in their numbers. 
 
Figure 5 - Annual client numbers 2013-14 to 2016-17, all IMS individuals 
 
 
Figure 6 - Annual client numbers 2013-14 to 2016-17, all IMS individuals, by local authority 
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All IMS Individuals 2013-14 2014-15 2015-16 2016-17 
Cheshire East 1,293 1,425 1,374 1,336 
Cheshire West & Chester 1,713 1,954 1,417 2,038 
Halton 608 845 874 1,169 
Knowsley 583 783 1,170 1,553 
Liverpool 10,579 12,658 11,804 10,961 
Sefton 2,234 3,762 3,103 2,625 
St. Helens 2,092 3,744 2,783 2,262 
Warrington 1,531 1,996 1,730 1,605 
Wirral 4,102 4,720 2,570 2,054 
Cheshire & Merseyside 25,760 31,246 26,197 25,024 
Table 2 - All IMS individuals, annual client numbers 2013-14 to 2016-17,  
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ANNUAL NUMBERS RECORDED, BY COHORT GROUPS 
While the number of individuals receiving brief interventions has declined over the last three years and the number for the 
psychoactive IDU cohort has decreased slightly, the number for the steroid and IPED IDU cohort has increased by 12.6% since 
2015-16. Cheshire West and Chester, Liverpool, Sefton and Wirral have all seen an increase in the number of individuals using 
NSP services since 2015-16. 
 
Figure 7 - Annual client numbers 2013-14 to 2016-17, client cohort group split 
 
 
 
Figure 8 - Annual client numbers 2013-14 to 2016-17, client cohort group split, by local authority 
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2.3.  CROSS MATCHING - IMS, NDTMS, AND CRIMINAL JUSTICE DATASETS 
COMBINED CLIENT GROUP - CHESHIRE AND MERSEYSIDE 
This section looks at the combined data from the Integrated Monitoring System (IMS), the Criminal Justice Dataset (CJD which 
includes DIP for four local authority areas) and the National Drugs Treatment Monitoring System (NDTMS), inclusive of every 
individual in contact with any drug or alcohol treatment/low threshold service or syringe-exchange in each local authority. 
Individual attributor data from IMS was cross matched by PHE for all individuals in treatment between 1st April 2016 and 31st 
March 2017 within any of the nine local authority areas in Cheshire and Merseyside, and the result of this data cross match 
exercise combined with publicly available NDTMS 2016-17 data have been used to produce estimations of the combined client 
group. 
The estimated combined client group in contact with services during 2016-17 totalled 40,645 individuals, representing a 4.0% 
decrease on 2015-16. 
 
 
Figure 9 - Estimated combined client group Cheshire and Merseyside, 2016-17 
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COMBINED CLIENT GROUP - LOCAL AUTHORITY AREAS 
 
Tables 3 and 4 shows the number of individuals appearing in the three datasets, broken down by cohort and then by combined 
client group. While Table 5 shows an overall 4.0% decline in overall numbers for the combined client group, this figure reflects a 
mixture of some areas having increased IMS numbers while nearly all areas had fewer individuals reported to NDTMS, and all 
areas reporting to the CJD had fewer individuals than the previous year. 
 
Local Authority 
IDU: 
Psychoactive 
Drugs 
IDU: Steroid 
& IPEDs 
BI: Drug or 
Alcohol 
All IMS 
individuals 
total 
All CJD 
individuals 
total 
All NDTMS 
individuals 
total3 
Cheshire East 511 825 0 1,336 - 1,209 
Cheshire West & Chester 862 1,174 2 2,038 - 1,540 
Halton 127 539 503 1,169 - 900 
Knowsley 300 427 826 1,553 113 1,250 
Liverpool 5,080 2,940 2,941 10,961 902 5,611 
Sefton 957 595 1,073 2,625 321 2,716 
St. Helens 950 922 390 2,262 197 1,474 
Warrington 578 775 252 1,605 - 1,381 
Wirral 835 943 276 2,054 598 3,474 
Cheshire & Merseyside 9,913 9,022 6,089 25,024 1,931 19,555 
Table 3 - Number of IMS, CJD, and NDTMS individuals by Local Authority, 2016-17 
Local Authority All IMS Individuals 
CJD clients  
matching to IMS 
NDTMS clients matching to IMS 
Combined  
Client group4 
Cheshire East 1,336 - 244 2,301 
Cheshire West & Chester 2,038  - 301 3,277 
Halton 1,169 - 469 1,600 
Knowsley 1,553 69 659 2,188 
Liverpool 10,961 263 1,637 15,574 
Sefton 2,625 132 1,296 4,234 
St. Helens 2,262 90 409 3,434 
Warrington 1,605  - 154 2,832 
Wirral 2,054 158 439 5,529 
Cheshire & Merseyside  25,024 617 5,248 40,645 
Table 4 - Estimated combined client group by Local Authority, 2016-17 
Local Authority IMS 
Criminal Justice 
Data 
NDTMS 
Combined  
Client group 
Cheshire East -2.8% - -15.6% -7.1% 
Cheshire West & Chester 43.8% - -15.1% 11.9% 
Halton 33.8% - -16.5% -8.5% 
Knowsley 32.7% -34.3% -19.0% -10.5% 
Liverpool -7.1% -51.0% -10.1% -10.5% 
Sefton -15.4% -37.1% -8.9% -3.0% 
St. Helens -18.7% -40.1% 10.2% -8.4% 
Warrington -7.2% - 1.8% -0.9% 
Wirral -20.1% -7.0% -4.5% -5.2% 
Cheshire & Merseyside  -4.5% -44.7% -8.7% -4.0% 
Table 5 - Percentage change by client group, compared with 2015-16 
                                                                
3 NDTMS Monthly 'Number in Treatment' YTD figures. Data source: https://www.ndtms.net/Reports.aspx Accessed: 9th Nov 2017 
4 The combined client group is an estimate of the total number of clients based on data cross matching between IMS and CJIP, and IMS and NDTMS data. We are 
unable to cross match data between Criminal Justice Data and NDTMS.  
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IMS INDIVIDUALS MATCHING TO NDTMS 
 
Table 9 shows that an average of 21.0% of individuals reporting to IMS also appeared in the NDTMS dataset, a decrease from 
30.3% in 2015-16.  For those identifying steroids or an IPED as their primary substance, this number varied by local authority 
between 2.0% in Halton and 8.7% in Cheshire East.  For those identifying a psychoactive drug such as heroin as their primary 
substance, the proportions in both datasets was considerably higher, ranging from 13.0% in Liverpool to 37.8% in Halton.  Across 
all local authority areas, the proportion of psychoactive substance injectors not in structured treatment within the past year was 
80.1%. 
 
 
0 - 18 19 - 29 30 - 39 40 - 49 50 - 59 60+ Total 
Female 18 155 446 553 257 89 1,518 
Male 23 318 969 1,544 722 154 3,730 
All IMS  41 473 1,415 2,097 979 243 5,248 
Table 6 - Number of IMS individuals matching to NDTMS, by age and gender 
 
0 - 18 19 - 29 30 - 39 40 - 49 50 - 59 60+ Total 
Female 15.9% 27.6% 35.8% 39.8% 38.6% 22.3% 34.7% 
Male 13.1% 7.5% 14.8% 24.2% 29.3% 18.1% 18.1% 
All IMS  14.2% 9.9% 18.2% 27.0% 31.3% 19.4% 21.0% 
Table 7 - Proportion of IMS individuals by age and gender who match to NDTMS 
Local Authority 
IDU: Psychoactive 
Drugs 
IDU: Steroid & 
IPEDs 
BI: Drug  
or Alcohol 
All IMS Individuals 
Cheshire East 172 72 0 244 
Cheshire West & Chester 220 81 0 301 
Halton 48 11 410 469 
Knowsley 81 15 563 659 
Liverpool 660 73 904 1,637 
Sefton 258 17 1,021 1,296 
St. Helens 268 54 87 409 
Warrington 122 27 5 154 
Wirral 337 47 55 439 
Cheshire & Merseyside 1,969 384 2,895 5,248 
Table 8 - Number of IMS individuals matching to NDTMS, by Local Authority and cohort group 
Local Authority 
IDU: Psychoactive 
Drugs 
IDU: Steroid & 
IPEDs 
BI: Drug  
or Alcohol 
All IMS Individuals 
Cheshire East 33.7% 8.7% - 18.3% 
Cheshire West & Chester 25.5% 6.9% - 14.8% 
Halton 37.8% 2.0% 81.5% 40.1% 
Knowsley 27.0% 3.5% 68.2% 42.4% 
Liverpool 13.0% 2.5% 30.7% 14.9% 
Sefton 27.0% 2.9% 95.2% 49.4% 
St. Helens 28.2% 5.9% 22.3% 18.1% 
Warrington 21.1% 3.5% 2.0% 9.6% 
Wirral 40.4% 5.0% 19.9% 21.4% 
Cheshire & Merseyside 19.9% 4.3% 47.5% 21.0% 
Table 9 - Proportion of IMS individuals by Local Authority and cohort group who match to NDTMS 
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IMS INDIVIDUALS MATCHING TO CRIMINAL JUSTICE DATA  
 
The number of individuals recorded in IMS who also appeared in the criminal justice dataset ranged from 2.4% in Liverpool to 
7.7% in Wirral, although it should be noted that only five of the nine local authorities reporting to the CJD dataset. 
 
 
0 - 18 19 - 29 30 - 39 40 - 49 50 - 59 60+ Total 
Female 0 17 51 43 10 0 121 
Male 0 91 162 191 46 6 496 
All IMS  0 108 213 234 56 6 617 
Table 10 - Number of IMS individuals matching to CJD, by age and gender 
 
0 - 18 19 - 29 30 - 39 40 - 49 50 - 59 60+ Total 
Female 0.0% 3.0% 4.1% 3.1% 1.5% 0.0% 2.8% 
Male 0.0% 2.1% 2.5% 3.0% 1.9% 0.7% 2.4% 
All IMS  0.0% 2.3% 2.7% 3.0% 1.8% 0.5% 2.5% 
Table 11 - Proportion of IMS individuals by age and gender who match to CJD 
Local Authority 
IDU: Psychoactive 
Drugs 
IDU: Steroid & 
IPEDs 
BI: Drug  
or Alcohol 
All IMS Individuals 
Cheshire East - - - - 
Cheshire West & Chester - - - - 
Halton - - - - 
Knowsley 14 1 54 69 
Liverpool 175 15 73 263 
Sefton 52 4 76 132 
St. Helens 51 17 22 90 
Warrington - - - - 
Wirral 116 22 20 158 
Cheshire & Merseyside 356 56 205 617 
Table 12 - Number of IMS individuals matching to CJD, by Local Authority and cohort group 
Local Authority 
IDU: Psychoactive 
Drugs 
IDU: Steroid & 
IPEDs 
BI: Drug  
or Alcohol 
All IMS Individuals 
Cheshire East - - - - 
Cheshire West & Chester - - - - 
Halton - - - - 
Knowsley 4.7% 0.2% 6.5% 4.4% 
Liverpool 3.4% 0.5% 2.5% 2.4% 
Sefton 5.4% 0.7% 7.1% 5.0% 
St. Helens 5.4% 1.8% 5.6% 4.0% 
Warrington - - - - 
Wirral 13.9% 2.3% 7.2% 7.7% 
Cheshire & Merseyside 3.6% 0.6% 3.4% 2.5% 
Table 13 - Proportion of IMS individuals by Local Authority and cohort group who match to CJD 
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3. NSP CLIENTS - IDU: PSYCHOACTIVE DRUGS 
3.1.  DEMOGRAPHIC PROFILE  
The profile of psychoactive IDU (injecting drug use for opiates, crack cocaine or other psychoactive substances) shows an 
increasingly ageing population, with 70.4% across all areas aged 40 years or over. At a local level, Knowsley and Wirral have the 
oldest profiles with 27% and 25% of individuals respectively being aged 50 years or over. This contrasts with Halton (12% of 
individuals aged 50 years or over) and Warrington (10% of individuals aged 50 years or over). Warrington has the highest 
proportion of young people (aged under 30) in the psychoactive IDU cohort (11%) while Knowsley has the highest proportion 
aged 60 years or over (7%). 80.7% of individuals in the psychoactive IDU cohort are male compared to 98.1% of the steroid and 
IPED IDU cohort. 
AGE AND GENDER 
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Cheshire East 
Female 0.0% 0.0% 2.8% 4.8% 21.4% 29.0% 22.1% 13.1% 4.1% 1.4% 1.4% 0.0% 145 
Male 0.0% 0.0% 0.8% 0.8% 3.0% 4.4% 43.2% 25.7% 17.2% 2.7% 1.6% 0.5% 366 
Total 0.0% 0.0% 1.4% 2.0% 8.2% 11.4% 37.2% 22.1% 13.5% 2.3% 1.6% 0.4% 511 
Cheshire West 
& Chester 
Female 0.0% 0.0% 1.8% 13.2% 19.8% 15.0% 21.6% 11.4% 10.2% 6.0% 0.0% 1.2% 167 
Male 0.0% 0.0% 1.0% 1.6% 3.6% 4.3% 40.4% 25.3% 15.4% 6.0% 1.6% 0.7% 695 
Total 0.0% 0.0% 1.2% 3.8% 6.7% 6.4% 36.8% 22.6% 14.4% 6.0% 1.3% 0.8% 862 
Halton 
Female 0.0% 0.0% 6.9% 0.0% 24.1% 24.1% 24.1% 13.8% 3.4% 3.4% 0.0% 0.0% 29 
Male 0.0% 0.0% 0.0% 3.1% 5.1% 14.3% 35.7% 28.6% 9.2% 3.1% 1.0% 0.0% 98 
Total 0.0% 0.0% 1.6% 2.4% 9.4% 16.5% 33.1% 25.2% 7.9% 3.1% 0.8% 0.0% 127 
Knowsley 
Female 0.0% 0.0% 0.0% 25.0% 11.5% 13.5% 13.5% 11.5% 11.5% 1.9% 3.8% 7.7% 52 
Male 0.0% 0.0% 0.8% 2.4% 4.0% 5.6% 34.3% 25.4% 15.3% 5.6% 1.6% 4.8% 248 
Total 0.0% 0.0% 0.7% 6.3% 5.3% 7.0% 30.7% 23.0% 14.7% 5.0% 2.0% 5.3% 300 
Liverpool 
Female 0.1% 0.0% 2.8% 8.6% 12.2% 23.7% 22.9% 19.3% 6.8% 1.7% 0.9% 0.9% 988 
Male 0.0% 0.4% 1.4% 5.3% 8.7% 12.4% 26.5% 25.5% 12.9% 4.3% 1.3% 1.4% 4,092 
Total 0.1% 0.3% 1.7% 5.9% 9.4% 14.6% 25.8% 24.3% 11.7% 3.8% 1.3% 1.3% 5,080 
Sefton 
Female 0.0% 0.0% 5.6% 11.1% 19.8% 17.9% 16.7% 19.8% 6.2% 1.2% 1.2% 0.6% 162 
Male 0.1% 0.4% 2.5% 5.5% 11.2% 15.5% 21.4% 25.4% 11.9% 3.5% 1.1% 1.4% 795 
Total 0.1% 0.3% 3.0% 6.5% 12.6% 15.9% 20.6% 24.5% 11.0% 3.1% 1.1% 1.3% 957 
St. Helens 
Female 0.0% 0.0% 3.8% 14.6% 22.2% 22.2% 12.3% 15.6% 7.1% 1.4% 0.0% 0.9% 212 
Male 0.0% 0.1% 1.5% 2.3% 4.3% 5.8% 34.3% 33.1% 11.7% 5.6% 0.8% 0.5% 738 
Total 0.0% 0.1% 2.0% 5.1% 8.3% 9.5% 29.4% 29.2% 10.6% 4.6% 0.6% 0.6% 950 
Warrington 
Female 1.4% 0.0% 5.4% 4.1% 12.2% 35.1% 27.0% 5.4% 8.1% 0.0% 1.4% 0.0% 74 
Male 0.0% 0.0% 2.8% 8.3% 12.3% 14.7% 31.3% 20.4% 8.5% 0.8% 0.6% 0.2% 504 
Total 0.2% 0.0% 3.1% 7.8% 12.3% 17.3% 30.8% 18.5% 8.5% 0.7% 0.7% 0.2% 578 
Wirral 
Female 0.0% 0.8% 2.4% 8.9% 13.7% 25.0% 17.7% 16.9% 12.1% 2.4% 0.0% 0.0% 124 
Male 0.0% 0.1% 1.1% 4.5% 7.3% 11.5% 23.6% 25.2% 17.9% 4.1% 3.1% 1.5% 711 
Total 0.0% 0.2% 1.3% 5.1% 8.3% 13.5% 22.8% 24.0% 17.0% 3.8% 2.6% 1.3% 835 
NSP Pysch 
cohort - All 
individuals 
Female 0.1% 0.1% 3.0% 9.8% 15.5% 22.9% 20.8% 16.7% 7.3% 2.0% 0.8% 0.9% 19.3% 
Male 0.0% 0.3% 1.4% 4.3% 7.6% 10.6% 29.3% 25.9% 13.5% 4.2% 1.5% 1.3% 80.7% 
Total 0.1% 0.2% 1.8% 5.4% 9.2% 13.0% 27.6% 24.2% 12.3% 3.8% 1.3% 1.2% 9,913 
Table 14 - Psychoactive drugs cohort by age and gender, 2016-17 
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Figure 10 - Psychoactive drugs cohort, percentage split by age group, 2016-17 
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ETHNICITY 
The ethnicity of psychoactive IDUs who have an ethnicity recorded is overwhelmingly in the main White British, ranging from 
96.0% in Sefton to 98.8% in Cheshire West and Chester. Of those whose ethnicity is not recorded as White British, only Other 
White and White Irish are recorded at 0.7% or above. 
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White British 98.6% 98.8% 98.3% 98.5% 94.8% 96.0% 97.1% 97.6% 97.7% 96.7% 
Other White 0.0% 0.0% 0.0% 0.0% 1.2% 1.7% 0.0% 1.2% 1.3% 1.0% 
White Irish 0.0% 0.0% 0.0% 0.0% 1.2% 1.2% 0.6% 0.0% 0.6% 0.7% 
White and Black 
Caribbean 
0.0% 0.0% 1.7% 0.8% 0.5% 0.0% 0.0% 0.0% 0.1% 0.3% 
Other Mixed 0.0% 0.0% 0.0% 0.8% 0.4% 0.3% 0.3% 0.0% 0.0% 0.2% 
Other Black 0.0% 0.0% 0.0% 0.0% 0.5% 0.3% 0.3% 1.2% 0.0% 0.2% 
Other White - Polish 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 1.5% 0.0% 0.0% 0.2% 
Other 0.0% 0.0% 0.0% 0.0% 0.5% 0.6% 0.0% 0.0% 0.0% 0.2% 
White and Black 
African 
0.0% 0.0% 0.0% 0.0% 0.3% 0.0% 0.0% 0.0% 0.1% 0.1% 
Other White - Czech 1.4% 0.0% 0.0% 0.0% 0.1% 0.0% 0.0% 0.0% 0.0% 0.1% 
African 0.0% 0.0% 0.0% 0.0% 0.1% 0.0% 0.3% 0.0% 0.0% 0.1% 
Other Asian 0.0% 0.0% 0.0% 0.0% 0.1% 0.0% 0.0% 0.0% 0.0% 0.0% 
Caribbean 0.0% 0.0% 0.0% 0.0% 0.1% 0.0% 0.0% 0.0% 0.0% 0.0% 
Chinese 0.0% 1.2% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Other - Arab 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.0% 
White and Asian 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Indian 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Pakistani 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Bangladeshi 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Other Black - Nigerian 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Other - Gypsy 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Table 15 - Psychoactive drugs cohort, percentage split by ethnicity, 2016-17 5 
 
  
                                                                
5 Percentage split is calculated as the proportion of only those clients who stated an ethnicity. 
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3.2.  MAIN SUBSTANCES 
PRIMARY SUBSTANCE 
For the first year, we have imputed primary substance for those individuals who do not have this information recorded, as 
described in the introduction of this report. Collection of this figure varies considerably across local authorities, ranging from 
completion rates of 13.3% in Cheshire East to over 80% in Sefton, Warrington and Wirral. The overall completion rate across 
Cheshire and Merseyside is 58.5%. Of those who identify a substance within this cohort, heroin is the most commonly named 
primary substance, ranging from 82.7% in Sefton to 98.2% in Warrington. Crack cocaine is the second most commonly identified 
substance with 3.5% of individuals in Liverpool and 7.4% of individuals in Sefton stating it as their primary substance.  
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Amphetamines (excl 
Ecstasy) 
** ** 0 0 0 10 7 ** 17 39 
4.4% 1.0% 0.0% 0.0% 0.0% 1.3% 2.4% 0.2% 2.5% 0.7% 
Benzodiazepines 
** ** 0 0 0 8 0 0 0 10 
2.9% 0.5% 0.0% 0.0% 0.0% 1.0% 0.0% 0.0% 0.0% 0.2% 
Cocaine (excl Crack) 
** ** ** ** 6 38 8 ** 14 75 
1.5% 1.5% 3.3% 3.7% 0.2% 4.9% 2.8% 0.6% 2.1% 1.3% 
Crack Cocaine 
** ** 0 ** 118 57 ** 0 11 189 
2.9% 0.5% 0.0% 1.9% 3.5% 7.4% 0.7% 0.0% 1.6% 3.3% 
Ecstasy 
0 0 0 ** 0 0 0 0 0 ** 
0.0% 0.0% 0.0% 0.9% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Heroin 
57 191 53 97 2,828 635 249 484 594 4,938 
83.8% 93.2% 88.3% 90.7% 82.9% 82.7% 86.5% 98.2% 88.1% 85.1% 
Methadone 
** ** ** 0 6 10 0 ** 24 47 
2.9% 1.0% 5.0% 0.0% 0.2% 1.3% 0.0% 0.2% 3.6% 0.8% 
Novel Psychoactive 
Substances 
0 0 0 0 0 0 ** 0 ** 5 
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.7% 0.0% 0.4% 0.1% 
Other Drugs 
0 5 0 ** 449 7 12 ** ** 467 
0.0% 2.4% 0.0% 2.8% 13.2% 0.9% 4.2% 0.4% 0.1% 8.1% 
Other Opiates 
** 0 ** 0 ** ** ** 0 ** 14 
1.5% 0.0% 3.3% 0.0% 0.1% 0.4% 1.4% 0.0% 0.3% 0.2% 
Prescription Drugs 
0 0 0 0 ** 0 ** ** 8 16 
0.0% 0.0% 0.0% 0.0% 0.1% 0.0% 1.4% 0.4% 1.2% 0.3% 
           
Not Stated 6, 7 
443 657 67 193 1,668 189 662 85 161 4,112 
86.7% 76.2% 52.8% 64.3% 32.8% 19.7% 69.7% 14.7% 19.3% 41.5% 
Total Individuals 511 862 127 300 5,080 957 950 578 835 9,913 
Table 16 - Psychoactive drugs cohort by primary substance and local authority, 2016-17 
  
                                                                
6 Percentages shown by substance excludes those individuals where the substance was not stated. Percentages shown for ‘Not stated’ is the percentage of all 
individuals. 
7 ‘Not Stated’ these are individuals who do not have a primary substance recorded, but have been imputed as using a psychoactive substance based on their 
activity recorded within IMS, such as the client characteristics and type of injecting equipment obtained. 
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SECONDARY SUBSTANCE 
Very small numbers of individuals stating they inject a psychoactive substance named a secondary substance, other than for 
people who inject heroin, 87.3% of which identified crack cocaine as their secondary substance. Conversely, 76.9% of crack 
cocaine injectors named heroin as their secondary substance. While other substance groups did have reasonably large 
proportions naming secondary substance types, these percentages are based on low numbers. 
Primary Substance 
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Amphetamines (excl 
Ecstasy) 
0 ** 0 0 ** ** ** 0 0 ** 0 0  ** 31 
0.0% 14.3% 0.0% 0.0% 14.3% 14.3% 14.3% 0.0% 0.0% 42.9% 0.0% 0.0%  - 79.5% 
Benzodiazepines 
0 0 0 0 ** ** ** 0 0 ** 0 0  0 5 
0.0% 0.0% 0.0% 0.0% 20.0% 20.0% 40.0% 0.0% 0.0% 20.0% 0.0% 0.0%  - 50.0% 
Cocaine (excl Crack) 
** ** ** ** 0 ** 22 0 0 0 0 **  0 45 
6.7% 3.3% 3.3% 3.3% 0.0% 6.7% 73.3% 0.0% 0.0% 0.0% 0.0% 3.3%  - 60.0% 
Crack Cocaine 
** ** ** 0 ** ** 50 ** ** 0 0 **  0 124 
1.5% 1.5% 3.1% 0.0% 4.6% 6.2% 76.9% 1.5% 1.5% 0.0% 0.0% 3.1%  - 65.6% 
Ecstasy 
0 0 0 0 0 ** 0 0 0 0 0 0  0 0 
0.0% 0.0% 0.0% 0.0% 0.0% 100% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%  - 0.0% 
Heroin 
** ** 21 ** 25 1,269 45 11 47 ** ** 20  5 3,480 
0.2% 0.3% 1.4% 0.2% 1.7% 87.3% 3.1% 0.8% 3.2% 0.1% 0.3% 1.4%  - 70.5% 
Methadone 
0 0 0 ** 0 0 6 0 ** 0 0 **  0 37 
0.0% 0.0% 0.0% 10.0% 0.0% 0.0% 60.0% 0.0% 10.0% 0.0% 0.0% 20.0%  - 78.7% 
Novel Psychoactive 
Substances 
0 0 0 0 0 0 0 0 0 0 0 0  0 5 
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%  - 100% 
Other Drugs 
0 0 0 0 0 ** ** 0 29 ** 0 **  0 428 
0.0% 0.0% 0.0% 0.0% 0.0% 10.3% 2.6% 0.0% 74.4% 2.6% 0.0% 10.3%  - 91.6% 
Other Opiates 
0 0 0 0 ** 0 0 0 0 0 0 0  0 13 
0.0% 0.0% 0.0% 0.0% 100% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%  - 92.9% 
Prescription Drugs 
0 0 0 0 0 0 0 0 0 0 0 0  0 16 
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%  - 100% 
Total  
6 7 24 5 31 1,282 127 12 76 6 ** 29  6 8,296 
0.4% 0.4% 1.5% 0.3% 1.9% 79.6% 7.9% 0.7% 4.8% 0.4% 0.2% 1.8%  - 83.7% 
Table 17 - Psychoactive drugs cohort by primary and secondary substance, 2016-17 
 
 
  
                                                                
8 Percentages shown by substance excludes those individuals with no secondary substance or where the substance was not stated. Percentages shown for ‘Not 
Stated’ is the percentage of all individuals. 
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3.3.  COHORT CHARACTERISTICS 
ACCOMMODATION STATUS 
Accommodation status is somewhat complicated within the IMS dataset due to its collection via two separate methods, the IMS 
field around accommodation status and the postcode field used by different contributing systems, particularly pharmacies, 
which sometimes includes the status “NFA” (no fixed abode). Using just the IMS data item around accommodation, the number 
of individuals with some form of housing problem ranges from around 2% or less in Cheshire East, Liverpool and Warrington to 
around 16% in Cheshire West & Chester and Knowsley and 26% in Halton. However once the NFA status from the postcode field 
is included, areas such as Liverpool and Sefton show much higher numbers (10.8% and 46.8% respectively).  
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NFA - Urgent Housing 
Problem 
** 16 6 9 59 23 65 ** 24 175 
1.4% 9.8% 13.0% 8.7% 1.6% 37.1% 7.7% 0.4% 3.6% 2.6% 
Housing Problem 
** 8 6 10 15 6 6 ** 6 55 
0.7% 4.9% 13.0% 9.6% 0.4% 9.7% 0.7% 0.4% 0.9% 0.8% 
No Housing Problem 
8 9 29 50 37 33 13 5 76 236 
2.9% 5.5% 63.0% 48.1% 1.0% 53.2% 1.5% 1.9% 11.4% 3.6% 
*Not Stated 9 (NFA) 
** ** ** 0 321 (259)8 9 ** 5 572 
0.7% 1.8% 2.2% 0.0% 8.8% See footnote 1.1% 1.5% 0.8% 8.6% 
*Not Stated  
(Has Address) 
261 127 ** 35 3,220 (575)8 746 249 553 5,585 
94.2% 77.9% 8.7% 33.7% 88.2% See footnote 88.9% 95.8% 83.3% 84.3% 
           
Not Known 10 
234 699 81 196 1,428 61 111 318 171 3,290 
45.8% 81.1% 63.8% 65.3% 28.1% 6.4% 11.7% 55.0% 20.5% 33.2% 
Total 511 862 127 300 5,080 957 950 578 835 9,913 
Table 18 - Psychoactive drugs cohort by accommodation status, 2016-17 
 
Figure 11 - Psychoactive drugs cohort by accommodation status (excludes status 'not known'), 2016-17 
                                                                
9 The majority of pharmacy NSP do not state client accommodation status. These figures are derived from where either ‘NFA’ or a postcode of residence is 
recorded. They should be treated with caution where used to interfere the client’s accommodation status, and for this reason they are excluded from total 
percentages shown for Sefton LA. 
10 Percentages shown by accommodation status excludes those individuals where the accommodation status is not known. Percentages shown for ‘not known’ 
are the percentage of all individuals. 
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EMPLOYMENT STATUS 
The levels of collection of the employment status field are still relatively poor from most areas, although Halton and Knowsley 
have the highest completion rates at 33.1% and 25.3% respectively. Looking at data from areas where completion rates are 
above 5%, Sefton and St. Helens have the highest proportion of long term sick or disabled psychoactive IDUs (37.1% and 39.1% 
respectively), while Knowsley and Halton both have over 60% of individuals unemployed and seeking work. St. Helens has the 
largest proportion in regular employment (20.9%). 
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Regular Employment 
** 5 ** 15 10 11 24 ** 18 73 
20.0% 13.2% 4.8% 19.7% 5.0% 8.9% 20.9% 33.3% 12.8% 11.8% 
Pupil / Student 
0 0 0 0 0 0 0 0 ** ** 
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.7% 0.2% 
Long term sick or 
disabled 
** 21 8 10 81 46 45 ** 40 217 
40.0% 55.3% 19.0% 13.2% 40.7% 37.1% 39.1% 50.0% 28.4% 35.2% 
Unemployed and 
seeking work 
** 11 28 46 85 60 36 ** 79 282 
40.0% 28.9% 66.7% 60.5% 42.7% 48.4% 31.3% 16.7% 56.0% 45.7% 
Not receiving 
benefits 
0 ** ** ** 10 ** 10 0 0 25 
0.0% 2.6% 4.8% 3.9% 5.0% 2.4% 8.7% 0.0% 0.0% 4.1% 
Other 
0 0 ** ** 13 ** 0 0 ** 19 
0.0% 0.0% 4.8% 2.6% 6.5% 3.2% 0.0% 0.0% 2.1% 3.1% 
           
Not Known 11 
506 824 85 224 4,881 833 835 572 694 9,296 
99.0% 95.6% 66.9% 74.7% 96.1% 87.0% 87.9% 99.0% 83.1% 93.8% 
Total 511 862 127 300 5,080 957 950 578 835 9,913 
Table 19 - Psychoactive drugs cohort by employment status, 2016-17 
 
Figure 12 - Psychoactive drugs cohort by employment status (excludes status 'not known'), 2016-17 
                                                                
11 Percentages shown by employment status excludes those individuals where the employment status is not known. Percentages shown for ‘not known’ are the 
percentage of all individuals. 
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PARENTAL STATUS 
Similarly, the levels of collection of the parental status field are also relatively poor from most areas, although Halton and 
Knowsley have the highest completion rates at 25.2% and 27.0% respectively. Where an individual states that they are a parent 
of at least one child under 18, Sefton has the highest proportion (94.6%) where none live with the parent, while Wirral has the 
lowest proportion where none live with the parent (71.9%). 
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All of the children 
live with client 
** ** ** ** 6 ** ** ** 11 23 
20.0% 3.0% 6.3% 4.9% 4.1% 0.7% 1.4% 16.7% 9.0% 4.4% 
Some of the children 
live with client 
0 0 ** ** ** ** ** 0 7 13 
0.0% 0.0% 3.1% 1.2% 2.0% 1.4% 1.4% 0.0% 5.7% 2.5% 
None of the children 
live with client 
** 13 19 22 56 53 14 ** 46 191 
40.0% 39.4% 59.4% 27.2% 38.1% 38.1% 19.7% 33.3% 37.7% 36.7% 
Not a parent of 
children under 18 
** 17 9 54 74 73 50 ** 57 269 
40.0% 51.5% 28.1% 66.7% 50.3% 52.5% 70.4% 50.0% 46.7% 51.7% 
Client declined to 
answer 
0 ** ** 0 8 10 5 0 ** 24 
0.0% 6.1% 3.1% 0.0% 5.4% 7.2% 7.0% 0.0% 0.8% 4.6% 
           
Not Known 12 
506 829 95 219 4,933 818 879 572 713 9,393 
99.0% 96.2% 74.8% 73.0% 97.1% 85.5% 92.5% 99.0% 85.4% 94.8% 
Total 511 862 127 300 5,080 957 950 578 835 9,913 
Table 20 - Psychoactive drugs cohort by parental status, 2016-17 
 
Figure 13 - Psychoactive drugs cohort by parental status, only clients who stated they have children under 18, 2016-17 
  
                                                                
12 Percentages shown by parental status excludes those individuals where the parental status is recorded. Percentages shown for ‘not known’ are the 
percentage of all individuals. 
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DISABILITIES OR CHRONIC CONDITIONS 
The disabilities or chronic conditions field is sporadically completed but does give some indication as to recurring issues where 
this data is collected. Where the field has been completed, St. Helens has the highest proportion for psychoactive IDU who 
indicated they have a chronic condition or disability (51.9%). Variations of mental health including depression are the most 
frequently cited condition, but COPD and mobility issues are also noted.  
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Individuals with chronic 
condition or disability 
** 7 ** 5 31 15 41 ** 63 147 
60.0% 20.0% 36.4% 15.2% 39.2% 32.6% 51.9% 33.3% 48.5% 40.8% 
No chronic conditions or 
disabilities 
** 28 7 28 48 31 38 ** 67 213 
40.0% 80.0% 63.6% 84.8% 60.8% 67.4% 48.1% 66.7% 51.5% 59.2% 
           
Not Stated 13 
506 827 116 267 5,001 911 871 575 705 9,553 
99.0% 95.9% 91.3% 89.0% 98.4% 95.2% 91.7% 99.5% 84.4% 96.4% 
Total 511 862 127 300 5,080 957 950 578 835 9,913 
           
Recorded conditions:           
Arthritis 0 0 0 ** 0 ** 0 0 ** ** 
Asthma 0 ** 0 0 ** 0 0 0 ** ** 
Chronic Pain 0 0 0 0 0 ** 0 0 0 ** 
COPD Chronic Obstructive 
Pulmonary disease  
0 0 ** ** ** ** ** 0 8 15 
Depression 0 ** 0 0 ** 0 ** 0 9 12 
Diabetes 0 0 0 0 0 0 0 0 ** ** 
Epilepsy 0 0 0 0 ** 0 0 ** ** ** 
Hearing impairment 0 0 0 0 0 ** 0 0 ** ** 
Liver disease / Cirrhosis 0 ** 0 0 0 ** 0 0 ** ** 
Mental health 0 0 ** ** 5 ** 8 0 5 21 
Mental ill health ** 0 ** ** 8 ** 27 0 6 36 
Mobility issues ** ** 0 0 ** 0 ** 0 11 14 
Specific learning difficulties 
(e.g. Dyslexia) 
0 0 0 0 ** 0 ** 0 0 ** 
Visual impairment 0 0 0 0 ** 0 0 0 ** ** 
Other 0 ** ** ** 6 ** ** 0 14 27 
Table 21 - Psychoactive drugs cohort, individuals stating any disability or chronic condition, 2016-17 
 
 
 
 
 
                                                                
13 Percentages shown is for those clients where a disability or chronic condition record was completed. Percentages shown for ‘not known’ are the percentage 
of all individuals. 
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3.4.  GEOGRAPHIC PROFILE 
LOCAL AUTHORITY OF RESIDENCE 
Most individuals who provide a postcode reside in the Local Authority area in which the IMS reporting service is based. However 
both Cheshire East and Knowsley see over 25% of their psychoactive IDU client base from surrounding areas, while this figure is 
less than 5% for Warrington and Wirral services. 
 Local Authority of IMS reporting service  
Local Authority of 
residence 
 C
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Cheshire East 214 ** 0 0 ** 0 ** ** 0 215 
Cheshire West and 
Chester 
5 244 ** 0 12 0 ** ** ** 252 
Halton ** 0 54 0 9 0 ** ** 0 63 
Knowsley 0 0 ** 82 77 6 9 ** 0 142 
Liverpool ** 8 ** 20 3,370 36 18 7 13 3,382 
Sefton ** ** 0 ** 108 797 ** ** 8 873 
St. Helens 0 ** 0 ** 23 ** 808 ** ** 821 
Warrington ** ** 0 0 6 ** 13 541 0 556 
Wirral 0 6 0 ** 46 15 ** ** 728 758 
West Lancashire 0 0 0 0 0 52 ** 0 0 53 
Newcastle-under-Lyme 24 0 0 0 0 0 0 0 0 24 
Staffordshire Moorlands 22 0 0 0 0 0 0 0 0 22 
Flintshire 0 19 0 0 0 ** 0 0 5 24 
Manchester 17 ** 0 0 0 0 ** 0 0 18 
Salford 0 0 0 0 ** 0 ** 0 0 ** 
Wigan 0 0 0 0 0 0 ** ** 0 ** 
Stockport 5 0 0 0 ** 0 0 0 0 7 
Others ** 0 ** ** 12 ** ** 0 ** 20 
Not Stated 216 578 67 190 1,412 42 83 17 74 2,676 
Total 511 862 127 300 5,080 957 950 578 835 9,913 
Table 22 - Psychoactive drugs cohort, individuals by local authority of residence and local authority of service provider, 2016-17 
 
 
Figure 14 - Psychoactive drugs cohort, split by residence within the local authority of service provider (excludes 'not stated'), 2016-17 
 
72.5%
85.9% 90.0%
74.5%
91.9% 87.1% 93.2% 96.4% 95.7%
27.5%
14.1% 10.0%
25.5% 8.1%
12.9% 6.8% 3.6% 4.3%
0%
20%
40%
60%
80%
100%
Cheshire East Cheshire West
& Chester
Halton Knowsley Liverpool Sefton St. Helens Warrington Wirral
Resident within LA of treatment Resident outside LA of treatment
Integrated Monitoring System Annual Report 2016-17  47 
POSTCODE DISTRICT OF RESIDENCE 
 
Postcode 
district 
Number of 
Individuals 
Percentage 14 
 
Postcode 
district 
Number of 
Individuals 
Percentage 
L6 668 10.6% 
 
L2 31 0.5% 
L4 470 7.5% 
 
CW12 30 0.5% 
WA9 341 5.4% 
 
WA12 29 0.5% 
WA10 276 4.4% 
 
L32 28 0.4% 
CH41 272 4.3% 
 
CH46 25 0.4% 
L13 256 4.1% 
 
WA7 24 0.4% 
L3 245 3.9% 
 
CW2 22 0.4% 
L8 238 3.8% 
 
L35 21 0.3% 
L5 224 3.6% 
 
CH45 18 0.3% 
L7 214 3.4% 
 
CH49 18 0.3% 
L20 196 3.1% 
 
CH66 18 0.3% 
CH42 187 3.0% 
 
CH3 17 0.3% 
PR8 168 2.7% 
 
L33 16 0.3% 
PR9 120 1.9% 
 
L18 16 0.3% 
CH44 111 1.8% 
 
WA5 14 0.2% 
L1 103 1.6% 
 
CW8 14 0.2% 
WA2 100 1.6% 
 
ST7 14 0.2% 
WA11 97 1.5% 
 
CW10 14 0.2% 
L11 92 1.5% 
 
L28 13 0.2% 
WA4 91 1.5% 
 
L27 13 0.2% 
SK11 87 1.4% 
 
L10 12 0.2% 
L21 82 1.3% 
 
CW7 12 0.2% 
L17 73 1.2% 
 
L31 10 0.2% 
L9 72 1.1% 
 
L16 8 0.1% 
L15 70 1.1% 
 
CW11 8 0.1% 
L12 68 1.1% 
 
L26 7 0.1% 
L30 64 1.0% 
 
CH61 7 0.1% 
WA1 64 1.0% 
 
CH62 6 0.1% 
SK10 53 0.8% 
 
L34 6 0.1% 
L14 51 0.8% 
 
WA3 6 0.1% 
L24 50 0.8% 
 
CH48 6 0.1% 
CH4 48 0.8% 
 
CH2 5 0.1% 
CW1 44 0.7% 
 
CH60 5 0.1% 
L25 43 0.7% 
 
SK1 5 0.1% 
L22 43 0.7% 
 
Other Postcodes 110 1.8% 
CH65 41 0.7% 
 
   
CW9 41 0.7% 
 
   
CH1 40 0.6% 
 
   
CH43 35 0.6% 
 
   
WA8 33 0.5% 
 
   
L19 33 0.5% 
 
   
L36 31 0.5% 
 
Not Stated 3,639 - 
L23 31 0.5% 
 
Total 9,913  
Table 23 - Psychoactive drugs cohort, individuals by postcode district of residence, 2016-17 
 
  
Key: CHE CHW HAL KNW LIV SEF SHL WAR WIR 
 
                                                                
14 Percentage of those individuals who stated a valid postcode 
48  Integrated Monitoring System Annual Report 2016-17 
LOCATION MAPS 
 
 
 
 
 
 
 
 
 
 
  
Figure 15 - Psychoactive drugs cohort, individuals by Local 
Authority area, 2016-17 
Figure 16 - Psychoactive drugs cohort, prevalence (per 1,000 
population) by Local Authority area, 2016-17 
Figure 17 - Psychoactive drugs cohort, individuals by postcode district of residence, 2016-17 
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3.5.  NEEDLE AND SYRINGE EXCHANGE TRANSACTIONS 
Over 1.25 million needles and syringes were distributed to people who inject psychoactive drugs across Cheshire and 
Merseyside during 2016-17, with the average number of needles and syringes given on each visit ranging from 12 in St. Helens 
to 34 in both Halton and Knowsley. This figure is almost double the amount of equipment distributed for IPED/Steroid IDU 
(664,538 needles and syringes in 2016-17). The average number of needles given per person over the course of the year ranged 
from 95 in Liverpool to 256 in Cheshire East, with an average of 126 per person across the all the local authority areas combined. 
 
Individuals 
Needle and 
syringe 
exchange visits 
Total equipment issued out 
 Needles & 
syringes 
Barrels 
Other 
paraphernalia 
Cheshire East 511 4,187 131,012 52,569 235,803 
Cheshire West & 
Chester 
862 6,523 142,955 65,030 247,651 
Halton 127 338 11,635 5,277 17,261 
Knowsley 300 994 33,340 12,325 62,676 
Liverpool 5,080 21,059 481,081 140,432 1,008,977 
Sefton 957 6,846 126,460 48,587 249,342 
St. Helens 950 12,925 148,514 105,013 434,892 
Warrington 578 2,732 51,909 17,487 71,701 
Wirral 835 7,360 124,206 73,852 325,889 
NSP Pysch cohort  
All individuals 
9,913 62,964 1,251,112 520,572 2,654,192 
Table 24 - Psychoactive drugs cohort, total needle exchange visits and equipment issued, 2016-17 
 
Individuals 
Average 
exchange 
visits 
Average per visit Average per person 
 Needles & 
syringes 
Barrels 
Parapher-
nalia 
Needles & 
syringes 
Barrels 
Parapher-
nalia 
Cheshire East 511 8.2 31.3 12.6 56.3 256.4 102.9 461.5 
Cheshire West  
& Chester 
862 7.6 21.9 10.0 38.0 165.8 75.4 287.3 
Halton 127 2.7 34.4 15.6 51.1 91.6 41.6 135.9 
Knowsley 300 3.3 33.5 12.4 63.1 111.1 41.1 208.9 
Liverpool 5,080 4.1 22.8 6.7 47.9 94.7 27.6 198.6 
Sefton 957 7.2 18.5 7.1 36.4 132.1 50.8 260.5 
St. Helens 950 13.6 11.5 8.1 33.6 156.3 110.5 457.8 
Warrington 578 4.7 19.0 6.4 26.2 89.8 30.3 124.1 
Wirral 835 8.8 16.9 10.0 44.3 148.7 88.4 390.3 
NSP Pysch cohort 
All individuals 
9,913 6.4 19.9 8.3 42.2 126.2 52.5 267.7 
Table 25 - Psychoactive drugs cohort, mean averages for needle exchange visits and equipment issued, 2016-17 
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3.6.  NSP NEW INDIVIDUALS: 2016-17 
NSP INDIVIDUALS BY YEAR OF FIRST PRESENTATION 
Almost two thirds (63.4%) of psychoactive IDU individuals presenting to IMS did so for the first time in the most recent financial 
year, although this figure ranged from two in five (40.1%) individuals in Cheshire East to 72.0% in Liverpool, suggesting that new 
psychoactive injectors made up the majority of the NSP clientele. However, in some areas, including Cheshire West & Chester, 
St. Helens and Warrington, over 10% of individuals had presented to an NSP service before 2011. The reliability of these 
numbers is discussed at the end of this report. 
 Year of first presentation NSP Pysch 
cohort - All 
individuals 
2016-17 
 2010 or 
earlier 
2011-12 2012-13 2013-14 2014-15 2015-16 2016-17 
Cheshire East 
37 96 27 40 41 65 205 
511 
7.2% 18.8% 5.3% 7.8% 8.0% 12.7% 40.1% 
Cheshire West & 
Chester 
94 56 26 66 71 113 436 
862 
10.9% 6.5% 3.0% 7.7% 8.2% 13.1% 50.6% 
Halton 
0 11 ** ** 10 20 78 
127 
0.0% 8.7% 3.1% 3.1% 7.9% 15.7% 61.4% 
Knowsley 
27 ** 10 22 29 47 161 
300 
9.0% 1.3% 3.3% 7.3% 9.7% 15.7% 53.7% 
Liverpool 
39 7 9 13 31 1,322 3,659 
5,080 
0.8% 0.1% 0.2% 0.3% 0.6% 26.0% 72.0% 
Sefton 
51 ** ** 5 22 325 549 
957 
5.3% 0.1% 0.4% 0.5% 2.3% 34.0% 57.4% 
St. Helens 
111 32 69 56 73 105 504 
950 
11.7% 3.4% 7.3% 5.9% 7.7% 11.1% 53.1% 
Warrington 
90 7 18 21 36 48 358 
578 
15.6% 1.2% 3.1% 3.6% 6.2% 8.3% 61.9% 
Wirral 
** ** ** 62 128 224 415 
835 
0.2% 0.1% 0.4% 7.4% 15.3% 26.8% 49.7% 
NSP Pysch cohort - 
All individuals 
413 204 156 269 408 2,176 6,287 
9,913 
4.2% 2.1% 1.6% 2.7% 4.1% 22.0% 63.4% 
Table 26 - Psychoactive drugs cohort, all individuals 2016-17, by year of first presentation 
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NEW INDIVIDUALS ONLY - BY AGE AND GENDER 
The main group of newly presenting psychoactive injectors are aged between 40 and 49 years, with the 40-44 year age band 
being the main age band for all areas other than Sefton. The number of new female injectors is substantially lower than the 
number of new male injectors: 54% of females are under the age of 40 while this figure for males is only 25%. This is the case 
across all local authority areas to differing degrees. 
    
0
 -
 1
7
 
1
8
 -
 1
9
 
2
0
 -
 2
4
 
2
5
 -
 2
9
 
3
0
 -
 3
4
 
3
5
 -
 3
9
 
4
0
 -
 4
4
 
4
5
 -
 4
9
 
5
0
 -
 5
4
 
5
5
 -
 5
9
 
6
0
 -
 6
4
 
6
5
 +
 
To
ta
l 
Cheshire East 
Female 0% 0% 3% 7% 20% 30% 26% 8% 3% 2% 2% 0% 61 
Male 0% 0% 1% 1% 0% 2% 44% 24% 22% 3% 2% 1% 144 
Total 0% 0% 1% 2% 6% 10% 39% 20% 17% 2% 2% 0% 205 
Cheshire West 
& Chester 
Female 0% 0% 4% 17% 17% 16% 18% 11% 12% 5% 0% 1% 83 
Male 0% 0% 1% 1% 1% 2% 46% 26% 14% 7% 2% 1% 353 
Total 0% 0% 1% 4% 4% 5% 41% 23% 13% 6% 1% 1% 436 
Halton 
Female 0% 0% 12% 0% 24% 24% 24% 12% 6% 0% 0% 0% 17 
Male 0% 0% 0% 0% 0% 11% 39% 33% 11% 3% 2% 0% 61 
Total 0% 0% 3% 0% 5% 14% 36% 28% 10% 3% 1% 0% 78 
Knowsley 
Female 0% 0% 0% 35% 8% 12% 15% 8% 8% 0% 8% 8% 26 
Male 0% 0% 1% 1% 4% 3% 35% 27% 16% 7% 1% 4% 135 
Total 0% 0% 1% 7% 5% 4% 32% 24% 14% 6% 2% 5% 161 
Liverpool 
Female 0% 0% 3% 10% 12% 25% 21% 19% 6% 2% 1% 1% 752 
Male 0% 1% 1% 5% 9% 12% 27% 25% 13% 4% 1% 2% 2,907 
Total 0% 0% 2% 6% 9% 15% 26% 24% 11% 4% 1% 2% 3,659 
Sefton 
Female 0% 0% 8% 13% 18% 21% 14% 18% 5% 2% 2% 0% 101 
Male 0% 1% 4% 6% 13% 15% 19% 24% 12% 3% 2% 1% 448 
Total 0% 1% 5% 7% 14% 16% 18% 23% 11% 3% 2% 1% 549 
St. Helens 
Female 0% 0% 2% 16% 24% 18% 14% 15% 8% 3% 0% 2% 114 
Male 0% 0% 2% 1% 2% 2% 36% 35% 12% 8% 1% 1% 390 
Total 0% 0% 2% 5% 7% 5% 31% 30% 11% 7% 1% 1% 504 
Warrington 
Female 2% 0% 8% 4% 17% 33% 21% 2% 10% 0% 2% 0% 48 
Male 0% 0% 3% 9% 15% 12% 31% 19% 9% 1% 0% 0% 310 
Total 0% 0% 4% 9% 15% 15% 30% 17% 9% 1% 1% 0% 358 
Wirral 
Female 0% 2% 5% 11% 14% 29% 14% 15% 11% 2% 0% 0% 66 
Male 0% 0% 1% 5% 8% 8% 26% 23% 19% 4% 4% 2% 349 
Total 0% 0% 2% 6% 9% 12% 24% 21% 18% 4% 3% 1% 415 
New Pysch 
Cohort IMS 
individuals 
Female 0% 0% 4% 11% 15% 24% 19% 16% 7% 2% 1% 1% 1,255 
Male 0% 0% 2% 5% 8% 10% 29% 25% 13% 4% 1% 1% 5,032 
Total 0% 0% 2% 6% 9% 13% 27% 24% 12% 4% 1% 1% 6,287 
Table 27 - Psychoactive drugs cohort, new individuals 2016-17, by age and gender 
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PROPORTION OF NEW INDIVIDUALS BY AGE GROUP 
The chart below shows the proportion of new psychoactive substance injectors for each local authority area by age group. 
Unsurprisingly this overall proportion reduces the older the cohorts become, as people attending become more likely to have 
presented previously, although there is some variation within different areas. Cheshire East has the lowest number of new 
psychoactive substance injectors overall (40.1%), while Liverpool has the highest at 72.0%. 
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Cheshire East - - 42.9% 50.0% 28.6% 36.2% 42.1% 35.4% 49.3% 41.7% 50.0% 50.0% 40.1% 
Cheshire West & 
Chester 
- - 60.0% 51.5% 31.0% 36.4% 56.2% 51.3% 46.8% 51.9% 54.5% 85.7% 50.6% 
Halton - - 100% - 33.3% 52.4% 66.7% 68.8% 80.0% 50.0% 100% - 61.4% 
Knowsley - - 50.0% 57.9% 50.0% 33.3% 55.4% 56.5% 52.3% 66.7% 50.0% 50.0% 53.7% 
Liverpool 66.7% 100% 74.4% 77.7% 72.5% 71.9% 71.6% 70.6% 70.6% 72.8% 68.8% 84.8% 72.0% 
Sefton 100% 100% 86.2% 62.9% 63.6% 57.9% 51.3% 53.4% 56.2% 50.0% 90.9% 50.0% 57.4% 
St. Helens - 100% 52.6% 47.9% 45.6% 28.9% 56.6% 54.9% 55.4% 79.5% 50.0% 66.7% 53.1% 
Warrington 100% - 72.2% 68.9% 77.5% 54.0% 59.6% 56.1% 67.3% 75.0% 50.0% - 61.9% 
Wirral - 100% 63.6% 55.8% 53.6% 42.5% 51.6% 44.5% 52.8% 46.9% 63.6% 54.5% 49.7% 
NSP Pysch cohort 
All individuals 
80.0% 100% 72.4% 69.9% 63.7% 61.7% 63.0% 61.8% 62.4% 66.2% 65.4% 71.7% 63.4% 
Table 28 - Psychoactive drugs cohort, new individuals 2016-17, as a proportion of total individuals, by age group 
 
Colour 
Key: 
7.0%  6.0%  5.0%  4.0%  3.0%  2.0%  1.0%  
Highest << Proportion of new 
individuals 
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3.7.  ANNUAL CLIENT NUMBERS 
There was a 7.2% drop in the number of people who inject psychoactive drugs from 2015-16, although areas varied widely with 
some local authorities including Cheshire East (-29.1%) and Warrington (-28.1%) seeing large drops while others such as 
Cheshire West & Chester (+8.8%) and Halton (+58.8%) seeing rises in their numbers. It should be noted that the total number for 
people who inject psychoactive drugs is still 9% higher than the number who inject steroid and IPEDs.  
 
Figure 18 - Annual client numbers 2013-14 to 2016-17, psychoactive drugs cohort 
 
 
Figure 19 - Annual client numbers 2013-14 to 2016-17, psychoactive drugs cohort, by local authority 
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IDU: Psychoactive Drugs 2013-14 2014-15 2015-16 2016-17 
Cheshire East 495 343 721 511 
Cheshire West & Chester 793 794 792 862 
Halton 84 88 80 127 
Knowsley 272 345 384 300 
Liverpool 3,427 4,510 5,246 5,080 
Sefton 1,104 1,690 838 957 
St. Helens 1,069 1,873 1,245 950 
Warrington 678 783 804 578 
Wirral 992 1,318 815 835 
Cheshire & Merseyside 10,200 11,276 10,679 9,913 
Table 29 - Psychoactive drugs cohort, annual client numbers 2013-14 to 2016-17 
 
PREVALENCE ESTIMATES 15 
Liverpool has the highest prevalence of people who inject psychoactive drugs with a rate of just over 1%, or 10.48 per 1,000 
population in 2016-17, although since 2013-14 prevalence has increased in both Cheshire areas, Halton and Knowsley, while 
decreasing in Sefton, St. Helens, Warrington and Wirral. Overall prevalence is down slightly from 4.21 in 2013-14 to 4.04 in 
2016-17. 
IDU: Psychoactive Drugs 2013-14 2014-15 2015-16 2016-17 
Cheshire East 1.33 0.92 1.92 1.36 
Cheshire West & Chester 2.40 2.39 2.37 2.57 
Halton 0.67 0.70 0.63 1.00 
Knowsley 1.86 2.36 2.61 2.03 
Liverpool 7.28 9.53 10.96 10.48 
Sefton 4.04 6.18 3.06 3.49 
St. Helens 6.07 10.57 7.01 5.32 
Warrington 3.31 3.79 3.87 2.77 
Wirral 3.10 4.11 2.54 2.60 
Cheshire & Merseyside 4.21 4.64 4.37 4.04 
Table 30 - Psychoactive drugs cohort, annual prevalence estimates by local authority, 2013-14 to 2016-17  
 
Figure 20 - Annual prevalence estimates 2013-14 to 2016-17, psychoactive drugs cohort, by local authority  
                                                                
15 Prevalence (per 1,000 population) is based on the ONS mid-year population estimates for each local authority area. 
https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/populationestimatesforukenglandandwalessc
otlandandnorthernireland 
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4. NSP CLIENTS - IDU: STEROID AND IPEDS 
4.1.  DEMOGRAPHIC PROFILE 
The profile of the steroid and IPED IDU cohort shows a much younger population than the psychoactive IDU cohort, with only 
13.2% across all areas being aged 40 years or over, compared to the figure of 70.4% for the psychoactive IDU cohort. Almost two 
in five (38.2%) people who inject steroid and IPEDs are aged under 30 years. At a local level, the areas with the highest 
proportion of steroid and IPED IDU aged 40 or over are Warrington (18.9%) and Halton (18.8%), while Cheshire East has the 
highest number of steroid and IPED IDU under the age of 25 (21.4%). 98.1% of individuals in this cohort are male compared to 
80.7% of the psychoactive IDU cohort. 
AGE AND GENDER 
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Cheshire East 
Female 14.3% 28.6% 0.0% 42.9% 0.0% 14.3% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 7 
Male 0.2% 2.4% 18.5% 25.9% 22.1% 24.3% 3.3% 2.0% 0.4% 0.7% 0.1% 0.0% 818 
Total 0.4% 2.7% 18.3% 26.1% 21.9% 24.2% 3.3% 1.9% 0.4% 0.7% 0.1% 0.0% 825 
Cheshire West 
& Chester 
Female 0.0% 33.3% 0.0% 11.1% 22.2% 22.2% 11.1% 0.0% 0.0% 0.0% 0.0% 0.0% 9 
Male 0.2% 1.2% 13.6% 25.9% 28.8% 24.2% 3.3% 2.0% 0.5% 0.3% 0.1% 0.0% 1,165 
Total 0.2% 1.4% 13.5% 25.8% 28.7% 24.2% 3.4% 2.0% 0.5% 0.3% 0.1% 0.0% 1,174 
Halton 
Female 0.0% 0.0% 11.1% 44.4% 22.2% 0.0% 0.0% 0.0% 11.1% 11.1% 0.0% 0.0% 9 
Male 0.0% 1.7% 11.9% 23.0% 25.7% 19.1% 8.3% 6.2% 2.3% 1.5% 0.4% 0.0% 530 
Total 0.0% 1.7% 11.9% 23.4% 25.6% 18.7% 8.2% 6.1% 2.4% 1.7% 0.4% 0.0% 539 
Knowsley 
Female 0.0% 10.0% 0.0% 40.0% 10.0% 0.0% 30.0% 0.0% 0.0% 10.0% 0.0% 0.0% 10 
Male 0.2% 0.5% 10.3% 26.6% 27.6% 24.5% 5.3% 3.1% 1.0% 1.0% 0.0% 0.0% 417 
Total 0.2% 0.7% 10.1% 26.9% 27.2% 23.9% 5.9% 3.0% 0.9% 1.2% 0.0% 0.0% 427 
Liverpool 
Female 1.4% 2.9% 17.4% 18.8% 23.2% 14.5% 8.7% 2.9% 2.9% 4.3% 2.9% 0.0% 69 
Male 0.1% 0.8% 10.1% 22.3% 25.0% 27.4% 6.1% 4.4% 2.2% 1.1% 0.3% 0.3% 2,871 
Total 0.1% 0.8% 10.3% 22.2% 25.0% 27.1% 6.2% 4.3% 2.2% 1.2% 0.4% 0.3% 2,940 
Sefton 
Female 5.3% 5.3% 5.3% 10.5% 10.5% 15.8% 21.1% 10.5% 15.8% 0.0% 0.0% 0.0% 19 
Male 0.3% 1.2% 8.2% 22.6% 28.3% 22.2% 7.8% 5.6% 2.1% 1.0% 0.3% 0.3% 576 
Total 0.5% 1.3% 8.1% 22.2% 27.7% 22.0% 8.2% 5.7% 2.5% 1.0% 0.3% 0.3% 595 
St. Helens 
Female 0.0% 16.7% 0.0% 33.3% 33.3% 8.3% 0.0% 0.0% 0.0% 0.0% 0.0% 8.3% 12 
Male 0.0% 2.1% 14.6% 27.0% 20.8% 27.8% 3.6% 2.4% 1.1% 0.3% 0.2% 0.0% 910 
Total 0.0% 2.3% 14.4% 27.1% 20.9% 27.5% 3.6% 2.4% 1.1% 0.3% 0.2% 0.1% 922 
Warrington 
Female 0.0% 0.0% 6.3% 12.5% 37.5% 12.5% 12.5% 12.5% 0.0% 6.3% 0.0% 0.0% 16 
Male 0.1% 0.4% 11.7% 26.5% 25.7% 16.9% 9.7% 5.8% 1.8% 0.9% 0.1% 0.3% 759 
Total 0.1% 0.4% 11.6% 26.2% 25.9% 16.8% 9.8% 5.9% 1.8% 1.0% 0.1% 0.3% 775 
Wirral 
Female 0.0% 0.0% 13.3% 26.7% 26.7% 20.0% 6.7% 0.0% 0.0% 6.7% 0.0% 0.0% 15 
Male 0.0% 1.3% 13.7% 25.4% 23.7% 17.6% 9.3% 5.1% 2.6% 0.9% 0.3% 0.2% 928 
Total 0.0% 1.3% 13.7% 25.5% 23.8% 17.6% 9.2% 5.0% 2.5% 1.0% 0.3% 0.2% 943 
NSP Steroid 
cohort - All 
individuals 
Female 1.8% 6.7% 10.4% 22.6% 21.3% 13.4% 10.4% 3.7% 3.7% 4.3% 1.2% 0.6% 1.9% 
Male 0.1% 1.2% 12.4% 24.4% 25.0% 24.0% 6.0% 4.0% 1.6% 0.8% 0.2% 0.2% 98.1% 
Total 0.2% 1.3% 12.3% 24.4% 25.0% 23.8% 6.1% 4.0% 1.7% 0.9% 0.3% 0.2% 9,022 
Table 31 - Steroid and IPEDs cohort by age and gender, 2016-17 
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ETHNICITY 
The ethnicity of people who inject steroids and IPEDs who have this recorded is overwhelmingly White British, ranging from 
88.7% in Cheshire East to 99.3% in both Knowsley and Sefton. Of those whose ethnicity is not recorded as White British, only 
Other White is recorded at 0.8% or above. 
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White British 88.7% 97.4% 98.0% 99.3% 94.4% 99.3% 97.9% 95.3% 98.8% 97.0% 
Other White 5.4% 1.3% 0.7% 0.0% 1.0% 0.7% 0.0% 0.7% 0.3% 0.8% 
Other Black 0.5% 0.0% 0.2% 0.3% 1.7% 0.0% 0.0% 0.3% 0.3% 0.4% 
Other Mixed 0.9% 0.6% 0.4% 0.3% 0.5% 0.0% 0.3% 0.0% 0.1% 0.3% 
Other White - Polish 1.4% 0.0% 0.0% 0.0% 0.7% 0.0% 0.0% 1.0% 0.0% 0.3% 
White Irish 0.9% 0.0% 0.2% 0.0% 0.0% 0.0% 0.5% 0.0% 0.2% 0.2% 
Other 0.9% 0.6% 0.0% 0.0% 0.2% 0.0% 0.3% 0.3% 0.0% 0.2% 
White and Black 
Caribbean 
0.9% 0.0% 0.0% 0.0% 0.2% 0.0% 0.0% 0.3% 0.0% 0.1% 
White and Black 
African 
0.0% 0.0% 0.0% 0.0% 0.5% 0.0% 0.3% 0.3% 0.0% 0.1% 
Indian 0.0% 0.0% 0.0% 0.0% 0.2% 0.0% 0.0% 1.0% 0.0% 0.1% 
White and Asian 0.5% 0.0% 0.4% 0.0% 0.0% 0.0% 0.3% 0.0% 0.0% 0.1% 
Chinese 0.0% 0.0% 0.0% 0.0% 0.5% 0.0% 0.0% 0.0% 0.0% 0.1% 
Other - Gypsy 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.5% 0.0% 0.0% 0.1% 
Pakistani 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.3% 0.0% 0.0% 
Bangladeshi 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.0% 
Other Asian 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.0% 
African 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.3% 0.0% 0.0% 
Other White - Czech 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Caribbean 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Other Black - Nigerian 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Other - Arab 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Table 32 - Steroid and IPEDs cohort, percentage split by ethnicity, 2016-17 16 
  
                                                                
16 Percentage split is calculated as the proportion of only those clients who stated an ethnicity. 
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4.2.  MAIN SUBSTANCES 
PRIMARY SUBSTANCE 
For the first year, we have imputed primary substance for those individuals who do not have this information recorded, as 
described in the introduction of this report. Collection of this figure varies considerably across local authorities, ranging from 
completion rates of less than 40% in both Cheshire areas and St. Helens to over 70% in Halton, Warrington and Wirral. The 
overall completion rate is 56.4%. Of those who identify a secondary substance, the vast majority identified another steroid or 
IPED.  
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Steroids & IPEDs 
293 402 379 228 1,834 392 296 605 752 5,085 
35.5% 34.2% 70.3% 53.4% 62.4% 65.9% 32.1% 78.1% 79.7% 56.4% 
Not Stated 17 
532 772 160 199 1,106 203 626 170 191 3,937 
64.5% 65.8% 29.7% 46.6% 37.6% 34.1% 67.9% 21.9% 20.3% 43.6% 
Total Individuals 825 1,174 539 427 2,940 595 922 775 943 9,022 
Table 33 - Steroid and IPEDs cohort by primary substance and local authority, 2016-17 
SECONDARY SUBSTANCE 
 
 
Secondary Substance 18    
Primary Substance 
 A
lc
o
h
o
l 
A
m
p
h
e
ta
m
in
e
s 
(e
xc
l E
cs
ta
sy
) 
B
e
n
zo
d
ia
ze
p
in
e
s 
C
an
n
ab
is
 
C
o
ca
in
e
 (
e
xc
l 
C
ra
ck
) 
C
ra
ck
 C
o
ca
in
e
 
H
e
ro
in
 
O
th
e
r 
D
ru
gs
 
St
e
ro
id
s 
&
 I
P
ED
s 
 N
o
 S
e
co
n
d
ar
y 
Su
b
st
an
ce
 
N
o
t 
St
at
e
d
 
Steroids & IPEDs 
8 ** ** 6 ** 12 ** 17 353  26 4,655 
2.0% 0.2% 0.2% 1.5% 0.7% 3.0% 0.7% 4.2% 87.4%  - 91.5% 
Not Stated 
           3,937 
- - - - - - - - -  - 100.0% 
Total 
8 ** ** 6 ** 12 ** 17 353  26 8,592 
2.0% 0.2% 0.2% 1.5% 0.7% 3.0% 0.7% 4.2% 87.4%  - 95.2% 
Table 34 - Steroid and IPEDs cohort by primary and secondary substance, 2016-17 
 
  
                                                                
17 ‘Not Stated’ these are individuals who do not have a primary substance recorded, but have been imputed as using a Steroid or IPED based on their activity 
recorded within IMS, such as the client characteristics and type of injecting equipment obtained. 
18 Percentages shown by substance excludes those individuals with no secondary substance or where the substance was not stated. Percentages shown for ‘Not 
Stated’ is the percentage of all individuals. 
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4.3.  COHORT CHARACTERISTICS 
ACCOMMODATION STATUS 
Accommodation status is somewhat complicated within the IMS dataset due to its collection via two separate methods, the IMS 
field around accommodation status and the postcode field used by different contributing systems, particularly pharmacies, 
which sometimes includes the status “NFA” (no fixed abode). Accommodation appears to be a far less significant issue for the 
IMS steroid and IPED IDU cohort than their psychoactive IDU counterparts, with all areas reporting housing issues at under 5%, 
compared to 12.1% for the psychoactive IDU cohort. 
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NFA - Urgent Housing 
Problem 
0 ** 0 ** 5 0 5 0 ** 14 
0.0% 0.8% 0.0% 1.0% 0.3% 0.0% 0.7% 0.0% 0.3% 0.3% 
Housing Problem 
5 ** ** ** ** ** ** 5 ** 28 
1.8% 1.6% 2.3% 0.5% 0.2% 1.3% 0.5% 0.9% 0.6% 0.6% 
No Housing Problem 
82 64 127 176 136 79 145 146 471 1,405 
29.4% 50.8% 95.5% 88.0% 6.9% 98.8% 19.8% 27.3% 72.6% 27.8% 
*Not Stated 19 (NFA) 
0 0 0 ** 87 (176)18 ** 0 ** 261 
0.0% 0.0% 0.0% 1.0% 4.4% See footnote 0.5% 0.0% 0.2% 5.2% 
*Not Stated  
(Has Address) 
192 59 ** 19 1,747 (267)18 573 383 171 3,348 
68.8% 46.8% 2.3% 9.5% 88.3% See footnote 78.4% 71.7% 26.3% 66.2% 
           
Not Known 20 
546 1,048 406 227 961 72 191 241 294 3,966 
66.2% 89.3% 75.3% 53.2% 32.7% 12.1% 20.7% 31.1% 31.2% 44.0% 
Total 825 1,174 539 427 2,940 595 922 775 943 9,022 
Table 35 - Steroid and IPEDs cohort by accommodation status, 2016-17 
 
 
Figure 21 - Steroid and IPEDs cohort by accommodation status (excludes status 'not known'), 2016-17 
                                                                
19 The majority of pharmacy NSP do not state client accommodation status. These figures are derived from where either ‘NFA’ or a postcode of residence is 
recorded. They should be treated with caution where used to interfere the client’s accommodation status, and for this reason they are excluded from total 
percentages shown for Sefton LA. 
20 Percentages shown by accommodation status excludes those individuals where the accommodation status is not known. Percentages shown for ‘not known’ 
are the percentage of all individuals. 
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EMPLOYMENT STATUS 
Collection of the employment status field is still relatively poor from most areas, although Knowsley and Wirral have completion 
rates for the field of 37.7% and 44.5% respectively. Despite the variable rates of completion, very high levels of regular 
employment are recorded across each local authority area, ranging from 75.8% in Knowsley to 95.0% in Sefton. Only 2.0% of 
individuals identified as being long term sick or disabled, which compares to 35.2% for the psychoactive IDU cohort.  
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Regular 
Employment 
** 58 97 122 90 38 24 30 334 776 
100.0% 89.2% 88.2% 75.8% 84.9% 95.0% 70.6% 76.9% 79.5% 81.9% 
Pupil / Student 
0 0 0 ** 0 ** 0 ** ** 9 
0.0% 0.0% 0.0% 1.2% 0.0% 2.5% 0.0% 5.1% 1.0% 0.9% 
Long term sick or 
disabled 
0 0 0 ** 0 0 5 ** 12 19 
0.0% 0.0% 0.0% 0.6% 0.0% 0.0% 14.7% 2.6% 2.9% 2.0% 
Unemployed and 
seeking work 
0 5 12 34 14 0 5 ** 61 124 
0.0% 7.7% 10.9% 21.1% 13.2% 0.0% 14.7% 5.1% 14.5% 13.1% 
Not receiving 
benefits 
0 ** 0 0 0 0 0 ** ** 7 
0.0% 3.1% 0.0% 0.0% 0.0% 0.0% 0.0% 7.7% 0.5% 0.7% 
Other 
0 0 ** ** ** ** 0 ** 7 13 
0.0% 0.0% 0.9% 1.2% 1.9% 2.5% 0.0% 2.6% 1.7% 1.4% 
           
Not Known 21 
823 1,109 429 266 2,834 555 888 736 523 8,074 
99.8% 94.5% 79.6% 62.3% 96.4% 93.3% 96.3% 95.0% 55.5% 89.5% 
Total 825 1,174 539 427 2,940 595 922 775 943 9,022 
Table 36 - Steroid and IPEDs cohort by employment status, 2016-17 
 
Figure 22 - Steroid and IPEDs cohort by employment status (excludes status 'not known'), 2016-17 
  
                                                                
21 Percentages shown by employment status excludes those individuals where the employment status is not known. Percentages shown for ‘not known’ are the 
percentage of all individuals. 
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PARENTAL STATUS 
Similarly, collection of the parental status field is relatively poor for most areas, although Wirral has a completion rate of over 
40%. Where an individual states that they are a parent of at least one child under 18, a majority of people who inject 
steroid/IPEDs have at least one child living with them in every area, and a majority in all areas other than Halton and Wirral have 
all of their children living with them. This compares with psychoactive IDU wherein every area a substantial majority of 
individuals have none of their children under 18 living with them. 
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All of the children 
live with client 
** 19 ** 23 9 11 ** 5 67 136 
50.0% 29.2% 5.3% 26.1% 18.0% 25.0% 11.1% 14.7% 17.1% 19.5% 
Some of the children 
live with client 
0 ** ** 8 8 ** 0 ** 39 60 
0.0% 1.5% 15.8% 9.1% 16.0% 4.5% 0.0% 2.9% 10.0% 8.6% 
None of the children 
live with client 
0 7 ** ** ** ** ** 0 86 101 
0.0% 10.8% 5.3% 2.3% 2.0% 6.8% 11.1% 0.0% 22.0% 14.5% 
Not a parent of 
children under 18 
** 31 11 53 25 17 18 20 195 355 
50.0% 47.7% 57.9% 60.2% 50.0% 38.6% 66.7% 58.8% 49.9% 50.9% 
Client declined to 
answer 
0 7 ** ** 7 11 ** 8 ** 45 
0.0% 10.8% 15.8% 2.3% 14.0% 25.0% 11.1% 23.5% 1.0% 6.5% 
           
Not Known 22 
823 1,109 520 339 2,890 551 895 741 552 8,325 
99.8% 94.5% 96.5% 79.4% 98.3% 92.6% 97.1% 95.6% 58.5% 92.3% 
Total 825 1,174 539 427 2,940 595 922 775 943 9,022 
Table 37 - Steroid and IPEDs cohort by parental status, 2016-17 
 
 
Figure 23 - Steroid and IPEDs cohort by parental status, only clients who stated they have children under 18, 2016-17 
                                                                
22 Percentages shown by parental status excludes those individuals where the parental status is recorded. Percentages shown for ‘not known’ are the 
percentage of all individuals. 
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DISABILITIES OR CHRONIC CONDITIONS 
The disabilities or chronic conditions field is poorly completed but where it has been, 92.3% of the steroid/IPED IDU cohort state 
that they have no chronic conditions or disabilities compared to 59.2% in the psychoactive IDU cohort. Mental health is again 
one of the main reported conditions, along with hearing impairment, arthritis and asthma.  
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Individuals with chronic 
condition or disability 
6 ** 0 ** ** ** 9 ** 38 62 
37.5% 3.3% 0.0% 1.1% 2.1% 7.0% 26.5% 2.3% 9.3% 7.7% 
No chronic conditions or 
disabilities 
10 58 32 93 95 40 25 43 369 744 
62.5% 96.7% 100.0% 98.9% 97.9% 93.0% 73.5% 97.7% 90.7% 92.3% 
           
Not Stated 23 
809 1,114 507 333 2,843 552 888 731 536 8,216 
98.1% 94.9% 94.1% 78.0% 96.7% 92.8% 96.3% 94.3% 56.8% 91.1% 
Total 825 1,174 539 427 2,940 595 922 775 943 9,022 
           
Recorded conditions:           
Arthritis ** 0 0 0 ** ** 0 0 ** 5 
Asthma ** 0 0 0 0 ** 0 0 ** 5 
Chronic Pain 0 0 0 0 0 0 0 0 0 0 
COPD Chronic Obstructive 
Pulmonary disease 
0 0 0 0 0 ** 0 0 ** ** 
Depression 0 0 0 0 0 0 0 0 ** ** 
Diabetes 0 0 0 0 0 0 0 0 ** ** 
Epilepsy 0 0 0 0 0 0 0 0 ** ** 
Hearing impairment 0 0 0 0 0 0 0 ** 5 6 
Liver disease / Cirrhosis 0 0 0 0 0 0 0 0 0 0 
Mental health 0 0 0 0 0 0 ** 0 ** ** 
Mental ill health 0 0 0 0 0 0 ** 0 ** 7 
Mobility issues 0 0 0 ** 0 0 0 0 ** ** 
Specific learning difficulties 
(e.g. Dyslexia) 
0 0 0 0 0 0 ** 0 0 ** 
Visual impairment 0 0 0 0 0 0 ** 0 0 ** 
Other ** ** 0 0 ** 0 ** 0 18 24 
Table 38 - Steroid and IPEDs cohort, individuals stating any disability or chronic condition, 2016-17 
 
 
  
                                                                
23 Percentages shown is for those clients where a disability or chronic condition record was completed. Percentages shown for ‘not known’ are the percentage 
of all individuals 
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4.4.  GEOGRAPHIC PROFILE 
LOCAL AUTHORITY OF RESIDENCE 
Most individuals who provide a postcode reside in the Local Authority area in which the IMS reporting service is based. Similar to 
the psychoactive IDU cohort, both Cheshire East and Knowsley see the largest number (around 20%) of their steroid and IPED 
IDU client base from surrounding areas, although Warrington has substantially more people who inject steroid and IPEDs from 
out of the area than psychoactive IDU (14.4% compared to 3.6%). 
 Local Authority of service provider  
Local Authority of 
residence 
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Cheshire East 381 ** ** 0 0 0 ** ** ** 384 
Cheshire West and 
Chester 
11 441 ** ** ** 0 ** 21 24 494 
Halton ** ** 362 ** 7 0 6 ** 0 379 
Knowsley 0 0 ** 186 99 14 18 ** 0 304 
Liverpool ** ** 8 35 1,789 22 7 ** 6 1,841 
Sefton 0 0 0 ** 98 452 ** ** 0 544 
St. Helens ** 0 ** ** 6 ** 644 55 ** 707 
Warrington ** ** ** ** ** 0 58 630 ** 692 
Wirral 0 ** ** ** 13 7 0 ** 790 806 
West Lancashire 0 0 0 0 ** 45 35 ** 0 84 
Newcastle-under-Lyme 44 0 0 0 0 0 0 0 0 44 
Staffordshire Moorlands 31 0 0 0 0 0 0 0 0 31 
Flintshire 0 5 0 0 ** ** ** 0 10 21 
Manchester 5 0 0 0 0 0 0 0 0 5 
Salford 0 0 0 0 ** 0 0 12 0 15 
Wigan 0 0 0 0 ** ** 7 ** 0 11 
Stockport ** 0 0 0 0 0 0 0 0 ** 
Others 0 ** 0 0 9 5 ** ** ** 22 
Not Stated 344 715 158 194 903 47 138 39 106 2,637 
Total 825 1,174 539 427 2,940 595 922 775 943 9,022 
Table 39 - Steroid and IPEDs cohort, individuals by local authority of residence and local authority of service provider, 2016-17 
 
Figure 24 - Steroid and IPEDs cohort, split by residence within the local authority of service provider (excludes 'not stated'), 2016-17 
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POSTCODE DISTRICT OF RESIDENCE 
 
Postcode 
district 
Number of 
Individuals 
Percentage 24 
 
Postcode 
district 
Number of 
Individuals 
Percentage 
WA9 316 5.8% 
 
CH62 53 1.0% 
WA4 200 3.7% 
 
L30 46 0.8% 
WA8 173 3.2% 
 
CH49 46 0.8% 
WA10 170 3.1% 
 
L22 45 0.8% 
WA7 158 2.9% 
 
CW12 44 0.8% 
L13 144 2.6% 
 
L18 44 0.8% 
WA2 139 2.5% 
 
WA12 41 0.8% 
L6 137 2.5% 
 
CH46 40 0.7% 
L8 135 2.5% 
 
CH45 40 0.7% 
CH42 135 2.5% 
 
L23 32 0.6% 
L4 132 2.4% 
 
CW7 32 0.6% 
L19 126 2.3% 
 
WA3 32 0.6% 
L36 124 2.3% 
 
L10 29 0.5% 
WA11 114 2.1% 
 
L32 26 0.5% 
CW1 114 2.1% 
 
CW8 26 0.5% 
CH41 104 1.9% 
 
L31 26 0.5% 
L11 97 1.8% 
 
L34 26 0.5% 
CH43 97 1.8% 
 
L33 25 0.5% 
L12 95 1.7% 
 
L16 25 0.5% 
L3 94 1.7% 
 
CH63 25 0.5% 
WA5 91 1.7% 
 
CH1 23 0.4% 
L24 90 1.6% 
 
L2 23 0.4% 
L15 89 1.6% 
 
L26 21 0.4% 
L7 85 1.6% 
 
ST7 20 0.4% 
WA1 84 1.5% 
 
CW11 19 0.3% 
CH4 81 1.5% 
 
CW5 19 0.3% 
L20 77 1.4% 
 
CH66 17 0.3% 
SK11 76 1.4% 
 
L27 17 0.3% 
L1 74 1.4% 
 
SK10 15 0.3% 
CH44 73 1.3% 
 
CH6 15 0.3% 
L25 70 1.3% 
 
CW10 13 0.2% 
CH65 68 1.2% 
 
CH64 13 0.2% 
CW2 68 1.2% 
 
CH61 11 0.2% 
L17 66 1.2% 
 
CH3 10 0.2% 
PR9 63 1.2% 
 
CH47 10 0.2% 
L9 62 1.1% 
 
CH48 9 0.2% 
PR8 58 1.1% 
 
CH2 9 0.2% 
L21 58 1.1% 
 
L39 9 0.2% 
L14 58 1.1% 
 
L28 6 0.1% 
CW9 55 1.0% 
 
CH60 6 0.1% 
L35 55 1.0% 
 
SK1 6 0.1% 
L5 54 1.0% 
 
L37 6 0.1% 
   
 
Other Postcodes 97 1.8% 
   
 
   
   
 
Not Stated 3,566 - 
   
 
Total 9,022  
Table 40 - Steroid and IPEDs cohort, individuals by postcode district of residence, 2016-17 
Key: CHE CHW HAL KNW LIV SEF SHL WAR WIR 
  
                                                                
24 Percentage of those individuals who stated a valid postcode 
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LOCATION MAPS 
 
 
 
 
 
 
 
 
 
 
  
Figure 27 - Steroid and IPEDs cohort, individuals by postcode district of residence, 2016-17 
Figure 25 - Steroid and IPEDs cohort, individuals by Local Authority 
area, 2016-17 
Figure 26 - Steroid and IPEDs cohort, prevalence (per 1,000 
population) by Local Authority area, 2016-17 
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4.5.  NEEDLE AND SYRINGE EXCHANGE TRANSACTIONS 
Over 660,000 needles and syringes were distributed to people who inject steroid and IPEDs across Cheshire and Merseyside 
during 2016-17, with the average number of needles and syringes given on each visit ranging from 19 in St. Helens to 52 in 
Halton, and on average 62% more than equipment given to people who inject psychoactive drugs. The average number of 
needles given per person over the course of the year ranged from 49 in Liverpool to 140 in Cheshire East, with an average of 74 
per person across all the different local authority areas combined. 
 
Individuals 
Needle and 
syringe 
exchange visits 
Total equipment issued out 
 Needles & 
syringes 
Barrels 
Other 
paraphernalia 
Cheshire East 825 3,444 115,817 48,435 145,808 
Cheshire West 
& Chester 
1,174 2,982 84,932 39,346 72,558 
Halton 539 937 49,099 21,901 14,555 
Knowsley 427 709 29,241 12,460 29,786 
Liverpool 2,940 5,088 145,265 49,278 161,748 
Sefton 595 1,033 38,311 16,240 24,359 
St. Helens 922 3,216 61,137 35,717 91,940 
Warrington 775 1,752 61,516 25,314 50,588 
Wirral 943 1,846 79,220 38,065 42,613 
NSP Steroid 
cohort - All 
individuals 
9,022 21,007 664,538 286,756 633,955 
Table 41 - Steroid and IPEDs cohort, total needle exchange visits and equipment issued, 2016-17 
 
Individuals 
Average 
exchange 
visits 
Average per visit Average per person 
 Needles & 
syringes 
Barrels 
Parapher-
nalia 
Needles & 
syringes 
Barrels 
Parapher-
nalia 
Cheshire East 511 4.2 33.6 14.1 42.3 140.4 58.7 176.7 
Cheshire West  
& Chester 
862 2.5 28.5 13.2 24.3 72.3 33.5 61.8 
Halton 127 1.7 52.4 23.4 15.5 91.1 40.6 27.0 
Knowsley 300 1.7 41.2 17.6 42.0 68.5 29.2 69.8 
Liverpool 5,080 1.7 28.6 9.7 31.8 49.4 16.8 55.0 
Sefton 957 1.7 37.1 15.7 23.6 64.4 27.3 40.9 
St. Helens 950 3.5 19.0 11.1 28.6 66.3 38.7 99.7 
Warrington 578 2.3 35.1 14.4 28.9 79.4 32.7 65.3 
Wirral 835 2.0 42.9 20.6 23.1 84.0 40.4 45.2 
NSP Steroid 
cohort - All 
individuals 
9,913 2.3 31.6 13.7 30.2 73.7 31.8 70.3 
Table 42 - Steroid and IPEDs cohort, mean averages for needle exchange visits and equipment issued, 2016-17 
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4.6.  NSP NEW INDIVIDUALS 
NSP INDIVIDUALS BY YEAR OF FIRST PRESENTATION 
Just under three in five (57.2%) steroid and IPED IDU individuals presenting to IMS did so for the first time in the most recent 
financial year, although this figure ranged from two in five (40.8%) individuals in Halton to 72.5% in Liverpool, suggesting that 
new steroid and IPED injectors made up the majority of the NSP clientele. Warrington and Cheshire East had the highest 
proportions (21.6% and 19.4% respectively) of individuals who presented to an NSP service before 2011-12. The reliability of 
these numbers is discussed at the end of this report. 
 Year of first presentation NSP Steroid 
cohort - All 
individuals 
2016-17 
 2010 or 
earlier 
2011-12 2012-13 2013-14 2014-15 2015-16 2016-17 
Cheshire East 
80 80 70 60 73 98 364 
825 
9.7% 9.7% 8.5% 7.3% 8.8% 11.9% 44.1% 
Cheshire West 
& Chester 
102 60 55 83 143 104 627 
1,174 
8.7% 5.1% 4.7% 7.1% 12.2% 8.9% 53.4% 
Halton 
** 27 102 42 78 68 220 
539 
0.4% 5.0% 18.9% 7.8% 14.5% 12.6% 40.8% 
Knowsley 
31 16 5 34 48 80 213 
427 
7.3% 3.7% 1.2% 8.0% 11.2% 18.7% 49.9% 
Liverpool 
36 10 6 14 21 721 2,132 
2,940 
1.2% 0.3% 0.2% 0.5% 0.7% 24.5% 72.5% 
Sefton 
45 0 6 17 20 125 382 
595 
7.6% 0.0% 1.0% 2.9% 3.4% 21.0% 64.2% 
St. Helens 
27 25 102 82 101 113 472 
922 
2.9% 2.7% 11.1% 8.9% 11.0% 12.3% 51.2% 
Warrington 
129 39 47 49 66 86 359 
775 
16.6% 5.0% 6.1% 6.3% 8.5% 11.1% 46.3% 
Wirral 
** 0 0 255 92 162 433 
943 
0.1% 0.0% 0.0% 27.0% 9.8% 17.2% 45.9% 
NSP Steroid 
cohort - All 
individuals 
447 253 387 630 624 1,524 5,157 
9,022 
5.0% 2.8% 4.3% 7.0% 6.9% 16.9% 57.2% 
Table 43 - Steroid and IPEDs cohort, all individuals 2016-17, by year of first presentation 
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NEW INDIVIDUALS ONLY - BY AGE AND GENDER 
Around three-quarters (74%) of newly presenting steroid and IPED injectors are aged between 25 and 39 years, with some areas 
including Cheshire East and St. Helens reporting half or more of this cohort being aged under 30 years. Unlike the psychoactive 
IDU cohort, very small numbers of individuals present for the first time aged 50 years and over. Reflecting the profile of longer-
term injectors, the cohort as a whole is several years younger than their psychoactive IDU counterparts. 
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Cheshire East 
Female 20% 20% 0% 40% 0% 20% 0% 0% 0% 0% 0% 0% 5 
Male 0% 5% 23% 27% 23% 21% 0% 0% 0% 0% 0% 0% 359 
Total 1% 5% 23% 27% 23% 21% 0% 0% 0% 0% 0% 0% 364 
Cheshire West 
& Chester 
Female 0% 60% 0% 0% 20% 20% 0% 0% 0% 0% 0% 0% 5 
Male 0% 2% 16% 24% 30% 25% 1% 1% 0% 0% 0% 0% 622 
Total 0% 2% 16% 24% 30% 25% 1% 1% 0% 0% 0% 0% 627 
Halton 
Female 0% 0% 17% 67% 17% 0% 0% 0% 0% 0% 0% 0% 6 
Male 0% 3% 18% 25% 26% 20% 2% 3% 1% 1% 0% 0% 214 
Total 0% 3% 18% 26% 25% 20% 2% 3% 1% 1% 0% 0% 220 
Knowsley 
Female 0% 14% 0% 43% 0% 0% 29% 0% 0% 14% 0% 0% 7 
Male 0% 1% 14% 28% 26% 22% 4% 2% 1% 1% 0% 0% 205 
Total 0% 1% 13% 29% 25% 22% 5% 2% 1% 1% 0% 0% 212 
Liverpool 
Female 2% 3% 19% 21% 24% 10% 5% 3% 3% 5% 3% 0% 58 
Male 0% 1% 11% 23% 25% 28% 5% 3% 2% 1% 0% 0% 2,074 
Total 0% 1% 11% 23% 25% 28% 5% 3% 2% 1% 0% 0% 2,132 
Sefton 
Female 7% 7% 7% 7% 14% 21% 7% 7% 21% 0% 0% 0% 14 
Male 1% 1% 10% 23% 31% 22% 6% 4% 1% 1% 0% 0% 368 
Total 1% 2% 10% 23% 31% 22% 6% 4% 2% 1% 0% 0% 382 
St. Helens 
Female 0% 29% 0% 14% 43% 0% 0% 0% 0% 0% 0% 14% 7 
Male 0% 3% 18% 28% 19% 30% 1% 0% 0% 0% 0% 0% 465 
Total 0% 4% 18% 28% 19% 29% 1% 0% 0% 0% 0% 0% 472 
Warrington 
Female 0% 0% 0% 10% 50% 20% 10% 10% 0% 0% 0% 0% 10 
Male 0% 1% 17% 28% 23% 16% 6% 4% 2% 1% 0% 0% 349 
Total 0% 1% 17% 28% 24% 16% 6% 4% 2% 1% 0% 0% 359 
Wirral 
Female 0% 0% 33% 17% 17% 17% 17% 0% 0% 0% 0% 0% 6 
Male 0% 3% 16% 23% 24% 20% 6% 4% 2% 1% 0% 0% 427 
Total 0% 3% 16% 23% 24% 20% 6% 4% 2% 1% 0% 0% 433 
NSP Steroid 
cohort - All 
individuals 
Female 3% 9% 13% 21% 22% 12% 7% 3% 4% 3% 2% 1% 117 
Male 0% 2% 14% 24% 25% 25% 4% 3% 1% 1% 0% 0% 5,039 
Total 0% 2% 14% 24% 25% 25% 4% 3% 1% 1% 0% 0% 5,156 
Table 44 - Steroid and IPEDs cohort, new individuals 2016-17, by age and gender 
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PROPORTION OF NEW INDIVIDUALS BY AGE GROUP 
The chart below shows the proportion of new steroid and IPED injectors for each local authority area by age group. While this 
overall proportion reduces the older the cohorts become as people attending become more likely to have presented previously, 
there is some variation within different areas. Halton has the lowest number of new steroid and IPED injectors overall (40.8%), 
while Liverpool again has the highest number of this group at 72.5%. 
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Cheshire East 66.7% 90.9% 54.3% 46.0% 45.9% 38.0% 3.7% 6.3% - - - - 44.1% 
Cheshire West & 
Chester 
100% 82.4% 63.9% 49.5% 55.2% 55.6% 22.5% 26.1% 16.7% - - - 53.4% 
Halton - 77.8% 62.5% 45.2% 40.6% 42.6% 11.4% 21.2% 15.4% 22.2% 50.0% - 40.8% 
Knowsley 100% 100% 65.1% 53.0% 46.6% 45.1% 40.0% 30.8% 50.0% 60.0% - - 49.6% 
Liverpool 100% 87.5% 77.6% 75.2% 73.1% 74.0% 57.5% 54.3% 67.2% 70.6% 72.7% 87.5% 72.5% 
Sefton 100% 75.0% 77.1% 65.9% 70.9% 64.9% 44.9% 41.2% 53.3% 33.3% 50.0% - 64.2% 
St. Helens - 81.0% 63.9% 52.8% 47.2% 54.7% 15.2% 4.5% 10.0% - - 100% 51.2% 
Warrington 100% 100% 66.7% 48.8% 43.3% 45.4% 30.3% 34.8% 42.9% 50.0% - 50.0% 46.3% 
Wirral - 91.7% 54.3% 41.7% 46.4% 52.4% 32.2% 36.2% 33.3% 55.6% 66.7% 50.0% 45.9% 
NSP Steroid 
cohort - All 
individuals 
92.9% 85.7% 66.0% 57.2% 57.7% 59.5% 37.2% 37.6% 46.4% 50.0% 52.2% 66.7% 57.1% 
Table 45- Steroid and IPEDs cohort, new individuals 2016-17, as a proportion of total individuals, by age group 
 
Colour 
Key: 
7.0%  6.0%  5.0%  4.0%  3.0%  2.0%  1.0%  
Highest << Proportion of new 
individuals 
>> Lowest 
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4.7.  ANNUAL CLIENT NUMBERS 
Although still a minority of people who inject drugs overall, there was a 12.7% increase in the number of people who inject 
steroid and IPEDs from 2015-16. The figures stayed the same or increased slightly in most areas, and although there was a 
substantial increase in Cheshire West & Chester of 87.8% from the previous year, the figure represented just a 1.2% increase on 
the figure from 2014-15. 
 
 
Figure 28 - Steroid and IPEDs cohort, annual client numbers 2013-14 to 2016-17 
 
 
Figure 29 - Steroid and IPEDs cohort, annual client numbers by local authority, 2013-14 to 2016-17 
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IDU: Steroid & IPEDs 2013-14 2014-15 2015-16 2016-17 
Cheshire East 798 1,082 653 825 
Cheshire West & Chester 920 1,160 625 1,174 
Halton 524 726 626 539 
Knowsley 297 359 337 427 
Liverpool 2,149 3,901 2,506 2,940 
Sefton 701 997 583 595 
St. Helens 1,023 1,871 1,127 922 
Warrington 853 1,213 774 775 
Wirral 1,048 1,263 890 943 
Cheshire & Merseyside 7,993 12,395 8,009 9,022 
Table 46 - Steroid and IPEDs cohort, annual client numbers by local authority, 2013-14 to 2016-17  
 
PREVALENCE ESTIMATES 25 
Liverpool again has the highest prevalence of people who inject steroid and IPEDs with a rate of just over 0.6%, or 6.07 per 1,000 
population, although since 2013-14 prevalence has increased in both Cheshire areas, Halton and Knowsley, while decreasing in 
Sefton, St. Helens, Warrington and Wirral, mirroring the picture for psychoactive substance injectors. Overall prevalence is up 
slightly from 3.30 in 2013-14 to 3.68 in 2016-17, slightly below the prevalence for psychoactive substance injectors of 4.04. 
IDU: Steroid & IPEDs 2013-14 2014-15 2015-16 2016-17 
Cheshire East 2.14 2.89 1.74 2.19 
Cheshire West & Chester 2.78 3.49 1.87 3.50 
Halton 4.16 5.75 4.95 4.25 
Knowsley 2.03 2.45 2.29 2.89 
Liverpool 4.56 8.25 5.24 6.07 
Sefton 2.57 3.64 2.13 2.17 
St. Helens 5.81 10.56 6.35 5.17 
Warrington 4.16 5.88 3.73 3.71 
Wirral 3.27 3.94 2.77 2.94 
Cheshire & Merseyside 3.30 5.10 3.28 3.68 
Table 47 - Steroid and IPEDs cohort, annual prevalence estimates by local authority, 2013-14 to 2016-17 
 
Figure 30 - Annual prevalence estimates 2013-14 to 2016-17, steroid and IPEDs cohort, by local authority 
                                                                
25 Prevalence (per 1,000 population) is based on the ONS mid-year population estimates for each local authority area. 
https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/populationestimatesforukenglandandwalessc
otlandandnorthernireland 
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5. BRIEF INTERVENTION: DRUGS OR ALCOHOL (NON-INJECTING CLIENTS)  
5.1.  DEMOGRAPHIC PROFILE  
Individuals who appear in the IMS dataset but have no NSP transactions attached to them are included in the Brief Intervention 
(BI) cohort. BIs delivered by drug and alcohol services are recorded variably across different local authority areas and so cohorts 
are not directly comparable in the same way that NSP user cohorts are. However for all areas combined most individuals 
receiving BIs (65.6%) are aged 40 or over. Warrington and Liverpool both have higher proportions of individuals receiving BIs 
aged 60 or over, with figures of 27.3% and 22.9% respectively, while Wirral and Warrington have the youngest populations 
receiving BIs aged 24 or under, with figures of 41.6% and 25.0% respectively26. 
AGE AND GENDER 
 
    
0
 -
 1
7
 
1
8
 -
 1
9
 
2
0
 -
 2
4
 
2
5
 -
 2
9
 
3
0
 -
 3
4
 
3
5
 -
 3
9
 
4
0
 -
 4
4
 
4
5
 -
 4
9
 
5
0
 -
 5
4
 
5
5
 -
 5
9
 
6
0
 -
 6
4
 
6
5
 +
 
To
ta
l 
Cheshire East 
Female 0.0% 100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% ** 
Male 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% 0.0% 0.0% 0.0% 0.0% 0.0% ** 
Total 0.0% 50.0% 0.0% 0.0% 0.0% 0.0% 50.0% 0.0% 0.0% 0.0% 0.0% 0.0% ** 
Cheshire West 
& Chester 
Female - - - - - - - - - - - - 0 
Male - - - - - - - - - - - - 0 
Total - - - - - - - - - - - - 0 
Halton 
Female 0.0% 0.6% 2.9% 10.4% 12.7% 13.9% 19.1% 17.3% 8.1% 9.2% 4.0% 1.7% 173 
Male 0.0% 0.0% 6.1% 12.1% 11.2% 16.1% 17.6% 13.6% 11.5% 6.7% 3.3% 1.8% 330 
Total 0.0% 0.2% 5.0% 11.5% 11.7% 15.3% 18.1% 14.9% 10.3% 7.6% 3.6% 1.8% 503 
Knowsley 
Female 0.0% 0.7% 2.6% 12.6% 13.4% 16.4% 15.6% 11.9% 13.0% 5.9% 4.5% 3.3% 269 
Male 0.0% 1.1% 6.8% 8.8% 12.9% 14.5% 13.5% 17.8% 11.0% 7.2% 3.8% 2.7% 557 
Total 0.0% 1.0% 5.4% 10.0% 13.1% 15.1% 14.2% 15.9% 11.6% 6.8% 4.0% 2.9% 826 
Liverpool 
Female 1.5% 0.2% 2.7% 6.1% 8.1% 11.7% 13.7% 15.2% 12.3% 8.4% 7.0% 13.0% 1,093 
Male 1.4% 0.2% 1.8% 3.5% 6.1% 9.5% 11.4% 16.3% 12.9% 12.3% 8.6% 16.1% 1,848 
Total 1.4% 0.2% 2.1% 4.5% 6.9% 10.3% 12.3% 15.9% 12.6% 10.9% 8.0% 14.9% 2,941 
Sefton 
Female 0.0% 0.5% 2.7% 8.5% 8.2% 10.4% 17.9% 17.2% 14.8% 9.2% 5.3% 5.3% 413 
Male 0.0% 0.2% 3.3% 7.9% 8.5% 12.6% 15.2% 20.0% 16.1% 8.6% 5.2% 2.6% 660 
Total 0.0% 0.3% 3.1% 8.1% 8.4% 11.7% 16.2% 18.9% 15.6% 8.9% 5.2% 3.6% 1,073 
St. Helens 
Female 7.8% 4.8% 5.4% 8.4% 3.6% 7.8% 10.2% 14.5% 15.1% 9.6% 5.4% 7.2% 166 
Male 4.0% 2.7% 10.3% 13.8% 12.9% 6.3% 12.5% 14.3% 8.5% 6.7% 5.4% 2.7% 224 
Total 5.6% 3.6% 8.2% 11.5% 9.0% 6.9% 11.5% 14.4% 11.3% 7.9% 5.4% 4.6% 390 
Warrington 
Female 16.5% 0.6% 1.9% 4.4% 4.4% 5.7% 5.1% 12.0% 8.9% 10.1% 9.5% 20.9% 158 
Male 29.8% 0.0% 5.3% 3.2% 5.3% 5.3% 6.4% 7.4% 8.5% 6.4% 5.3% 17.0% 94 
Total 21.4% 0.4% 3.2% 4.0% 4.8% 5.6% 5.6% 10.3% 8.7% 8.7% 7.9% 19.4% 252 
Wirral 
Female 36.8% 7.4% 6.3% 5.3% 8.4% 7.4% 5.3% 10.5% 5.3% 4.2% 0.0% 3.2% 95 
Male 28.7% 2.8% 5.5% 12.2% 8.3% 12.7% 6.6% 7.2% 7.2% 5.0% 1.7% 2.2% 181 
Total 31.5% 4.3% 5.8% 9.8% 8.3% 10.9% 6.2% 8.3% 6.5% 4.7% 1.1% 2.5% 276 
Brief Interv 
cohort - All 
individuals 
Female 3.9% 1.0% 3.0% 7.6% 8.6% 11.3% 13.4% 14.8% 12.1% 8.4% 6.1% 9.7% 37.8% 
Male 3.0% 0.5% 4.0% 6.8% 8.3% 11.1% 12.5% 16.2% 12.1% 9.8% 6.3% 9.4% 62.2% 
Total 3.4% 0.7% 3.6% 7.1% 8.4% 11.1% 12.8% 15.7% 12.1% 9.3% 6.2% 9.5% 6,089 
Table 48 - Drugs or alcohol (non-injecting) cohort by age and gender, 2016-17 
  
                                                                
26 The Response Wirral counselling service which only deals with individuals aged between 13-18 accounts for most of this figure 
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ETHNICITY 
The ethnicity of individuals receiving BIs is on the whole White British (95.6%) with little variation by local authority area, with 
Other White (1.8%) and White Irish (0.6%) being the only other identified ethnic categories over 0.5%. Liverpool has the most 
ethnic diversity, and there is also a small but notable White Irish population (2.6%) receiving BIs in St. Helens. 
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White British - - 97.3% 97.5% 93.7% 97.5% 96.5% 96.7% 93.8% 95.6% 
Other White - - 1.1% 1.6% 2.5% 1.4% 0.3% 0.4% 2.2% 1.8% 
White Irish - - 0.5% 0.0% 0.7% 0.2% 2.6% 0.8% 0.4% 0.6% 
Other Mixed - - 0.2% 0.0% 0.6% 0.3% 0.0% 0.8% 1.5% 0.4% 
Other Black - - 0.2% 0.2% 0.4% 0.2% 0.0% 0.0% 0.7% 0.3% 
Other - - 0.2% 0.1% 0.4% 0.1% 0.0% 0.4% 0.0% 0.2% 
White and Black 
Caribbean 
- - 0.2% 0.0% 0.3% 0.1% 0.6% 0.0% 0.0% 0.2% 
Other White - Polish - - 0.0% 0.1% 0.3% 0.2% 0.0% 0.0% 0.7% 0.2% 
White and Black 
African 
- - 0.0% 0.0% 0.2% 0.0% 0.0% 0.8% 0.0% 0.1% 
White and Asian - - 0.0% 0.0% 0.1% 0.0% 0.0% 0.0% 0.7% 0.1% 
Indian - - 0.0% 0.1% 0.1% 0.0% 0.0% 0.0% 0.0% 0.1% 
African - - 0.0% 0.1% 0.1% 0.1% 0.0% 0.0% 0.0% 0.1% 
Chinese - - 0.2% 0.2% 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 
Other White - Czech - - 0.0% 0.0% 0.1% 0.0% 0.0% 0.0% 0.0% 0.0% 
Caribbean - - 0.0% 0.0% 0.1% 0.0% 0.0% 0.0% 0.0% 0.0% 
Pakistani - - 0.0% 0.0% 0.1% 0.0% 0.0% 0.0% 0.0% 0.0% 
Other Asian - - 0.0% 0.0% 0.1% 0.0% 0.0% 0.0% 0.0% 0.0% 
Other Black - Nigerian - - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Other - Gypsy - - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Bangladeshi - - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Other - Arab - - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Table 49 - Drugs or alcohol (non-injecting) cohort, percentage split by ethnicity, 2016-17 27  
                                                                
27 Percentage split is calculated as the proportion of only those clients who stated an ethnicity. 
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5.2.  MAIN SUBSTANCES 
PRIMARY SUBSTANCE 
Brief interventions have historically been used most extensively for individuals presenting with issues around their alcohol use 
and over 7 in 10 (71.5%) receiving BIs in 2016-17 identified alcohol as their main problem substance, followed by heroin (9.4%), 
cocaine (7.0%) and cannabis (6.4%). Within individual local authorities, over one in five individuals receiving BIs in Halton 
(20.4%) and Sefton (22.2%) identified heroin as their primary substance. 
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Alcohol 
- 0 234 478 2,380 575 79 0 114 3,717 
- 0.0% 53.5% 57.9% 89.7% 58.0% 42.0% 0.0% 43.7% 71.5% 
Amphetamines (excl 
Ecstasy) 
- 0 5 5 5 6 ** ** ** 29 
- 0.0% 1.1% 0.6% 0.2% 0.6% 1.6% 5.9% 1.5% 0.6% 
Barbiturates 
- 0 0 0 ** 0 0 0 0 ** 
- 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Benzodiazepines 
- 0 ** ** ** ** 0 0 0 5 
- 0.0% 0.2% 0.1% 0.0% 0.2% 0.0% 0.0% 0.0% 0.1% 
Cannabis 
- 0 42 64 50 65 22 0 92 332 
- 0.0% 9.6% 7.7% 1.9% 6.6% 11.7% 0.0% 35.2% 6.4% 
Cocaine (excl Crack) 
- 0 31 130 80 83 30 ** 17 364 
- 0.0% 7.1% 15.7% 3.0% 8.4% 16.0% 11.8% 6.5% 7.0% 
Crack Cocaine 
- 0 ** 5 32 14 ** 0 0 56 
- 0.0% 0.9% 0.6% 1.2% 1.4% 1.1% 0.0% 0.0% 1.1% 
Ecstasy 
- 0 0 0 ** 0 5 0 6 13 
- 0.0% 0.0% 0.0% 0.1% 0.0% 2.7% 0.0% 2.3% 0.3% 
Hallucinogens 
- 0 ** ** ** 0 ** 0 ** 7 
- 0.0% 0.2% 0.2% 0.0% 0.0% 0.5% 0.0% 0.8% 0.1% 
Heroin 
- 0 89 104 83 220 6 0 7 491 
- 0.0% 20.4% 12.6% 3.1% 22.2% 3.2% 0.0% 2.7% 9.4% 
Methadone 
- 0 14 13 ** 8 ** 0 ** 40 
- 0.0% 3.2% 1.6% 0.1% 0.8% 0.5% 0.0% 0.4% 0.8% 
Novel Psychoactive 
Substances 
- 0 0 ** 5 0 24 ** ** 34 
- 0.0% 0.0% 0.1% 0.2% 0.0% 12.8% 5.9% 1.1% 0.7% 
Other Drugs 
- 0 0 ** ** ** 14 0 ** 22 
- 0.0% 0.0% 0.1% 0.2% 0.1% 7.4% 0.0% 0.8% 0.4% 
Other Opiates 
- 0 9 17 ** 16 0 0 ** 45 
- 0.0% 2.1% 2.1% 0.1% 1.6% 0.0% 0.0% 0.4% 0.9% 
Prescription Drugs 
- 0 ** 5 ** ** ** 0 ** 13 
- 0.0% 0.9% 0.6% 0.0% 0.1% 0.5% 0.0% 0.4% 0.3% 
Solvents 
- 0 ** 0 0 0 0 0 0 ** 
- 0.0% 0.2% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Steroids & IPEDs 
- 0 ** 0 ** 0 0 13 11 30 
- 0.0% 0.5% 0.0% 0.2% 0.0% 0.0% 76.5% 4.2% 0.6% 
           
Effected by some-
one else’s use 28 
- 0 0 0 0 0 43 63 0 106 
- 0.0% 0.0% 0.0% 0.0% 0.0% 11.0% 25.0% 0.0% 1.7% 
Not Stated 29 
- ** 66 0 287 82 159 172 15 783 
- 100.0% 13.1% 0.0% 9.8% 7.6% 40.8% 68.3% 5.4% 12.9% 
Total Individuals 0 2 503 826 2,941 1,073 390 252 276 6,089 
Table 50 - Drugs or alcohol (non-injecting) cohort by primary substance and local authority, 2016-17 
                                                                
28 Individuals receiving interventions and support related to the substance use of others, such as family members or close friends. 
29 Percentages shown by substance excludes those individuals effected by some-one else’s use and those where the substance was not stated. Percentages 
shown for ‘some-one else’s use’ and ‘not stated’ is the percentage of all individuals. 
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SECONDARY SUBSTANCE 
Nine in ten (89.3%) individuals receiving a BI did not state a secondary substance, but of those who did, alcohol was the most 
commonly cited (28.2%) which for individuals also stating alcohol as their primary substance, might indicate a different type of 
alcohol (wine or beer for example). Cocaine was also cited as a secondary substance by 22.6% of individuals, mainly as a 
secondary substance to alcohol use, while cannabis was cited as a secondary substance by 16.2% of individuals, again mainly 
those citing alcohol as their primary problem substance. 
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Alcohol 
81 7 5 59 92 13 ** 26 9 7 **  92 3,321 
26.6% 2.3% 1.6% 19.4% 30.3% 4.3% 0.3% 8.6% 3.0% 2.3% 1.3%  - 89.3% 
Amphetamines (excl 
Ecstasy) 
** 0 0 ** ** 0 0 0 0 0 0  0 23 
66.7% 0.0% 0.0% 16.7% 16.7% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%  - 79.3% 
Barbiturates 
  
0 0 0 0 0 0 0 0 0 0 0  ** 0 
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%  - 0.0% 
Benzodiazepines 
0 0 ** 0 0 0 0 ** 0 0 0  0 ** 
0.0% 0.0% 50.0% 0.0% 0.0% 0.0% 0.0% 50.0% 0.0% 0.0% 0.0%  - 60.0% 
Cannabis 
18 0 0 0 12 0 12 ** 0 ** 0  32 256 
40.9% 0.0% 0.0% 0.0% 27.3% 0.0% 27.3% 2.3% 0.0% 2.3% 0.0%  - 77.1% 
Cocaine (excl Crack) 
34 ** 0 12 ** ** ** ** 0 ** 0  ** 303 
59.6% 5.3% 0.0% 21.1% 7.0% 1.8% 1.8% 1.8% 0.0% 1.8% 0.0%  - 83.2% 
Crack Cocaine 
5 0 0 6 0 ** 0 11 0 0 0  0 33 
21.7% 0.0% 0.0% 26.1% 0.0% 4.3% 0.0% 47.8% 0.0% 0.0% 0.0%  - 58.9% 
Ecstasy 
** ** 0 ** 0 ** 0 0 0 ** 0  0 5 
12.5% 12.5% 0.0% 50.0% 0.0% 12.5% 0.0% 0.0% 0.0% 12.5% 0.0%  - 38.5% 
Hallucinogens 
0 0 0 ** 0 0 0 0 0 0 0  0 6 
0.0% 0.0% 0.0% 100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%  - 85.7% 
Heroin 
** 0 ** ** ** 42 0 ** 7 ** **  ** 422 
4.6% 0.0% 6.2% 4.6% 3.1% 64.6% 0.0% 1.5% 10.8% 3.1% 1.5%  - 85.9% 
Methadone 
** 0 ** 0 0 0 0 0 0 0 0  0 38 
50.0% 0.0% 50.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%  - 95.0% 
Novel Psycho-active 
Substances 
** ** 0 0 7 0 ** 0 0 0 0  0 23 
9.1% 18.2% 0.0% 0.0% 63.6% 0.0% 9.1% 0.0% 0.0% 0.0% 0.0%  - 67.6% 
Other Drugs 
** 0 0 0 ** ** 0 0 0 0 0  0 18 
25.0% 0.0% 0.0% 0.0% 50.0% 25.0% 0.0% 0.0% 0.0% 0.0% 0.0%  - 81.8% 
Other Opiates 
** 0 0 0 0 0 0 0 0 ** 0  0 43 
50.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 50.0% 0.0%  - 95.6% 
Prescription Drugs 
0 0 ** 0 0 0 0 0 0 0 0  0 12 
0.0% 0.0% 100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%  - 92.3% 
Solvents 
0 0 0 0 0 0 0 0 0 ** 0  0 0 
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% 0.0%  - 0.0% 
Steroids & IPEDs 
0 0 0 0 0 0 0 0 0 ** 0  0 29 
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% 0.0%  - 96.7% 
Total 
150 13 12 86 120 59 15 41 16 15 5  133 5,424 
28.2% 2.4% 2.3% 16.2% 22.6% 11.1% 2.8% 7.7% 3.0% 2.8% 0.9%  - 89.1% 
Table 51 - Drugs or alcohol (non-injecting) cohort by primary and secondary substance, 2016-17 
  
                                                                
30 Percentages shown by substance excludes those individuals with no secondary substance or where the substance was not stated. Percentages shown for ‘Not 
Stated’ is the percentage of all individuals. 
31 The figures shown for the secondary substance ‘Other Drugs’ includes substances within the following drug groups; barbiturates, hallucinogens, novel 
psychoactive substances (NPS), other opiates, solvents, steroids & IPEDs, and other drugs. 
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5.3.  COHORT CHARACTERISTICS 
ACCOMMODATION STATUS 
For individuals receiving BIs, 18.4% cited a housing problem, although two thirds (64.7%) of individuals receiving BIs in St. Helens 
stated that they had a housing problem, and over half (50.8%) an urgent housing problem. Completion of this field at 61.1% is 
more widespread than for NSP services, reflecting the fact that pharmacies do not currently routinely capture this data item. 
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NFA - Urgent Housing 
Problem 
0 0 14 16 81 36 95 0 ** 232 
- - 3.2% 2.0% 6.7% 3.6% 50.8% 0.0% 0.8% 6.2% 
Housing Problem 
0 0 60 58 191 92 26 0 46 453 
- - 13.8% 7.1% 15.7% 9.3% 13.9% 0.0% 18.5% 12.2% 
No Housing Problem 
0 0 362 738 941 861 66 ** 201 3,033 
- - 83.0% 90.9% 77.6% 87.1% 35.3% 100.0% 80.7% 81.6% 
           
Not Known 32 
0 ** 67 14 1,728 84 203 250 27 2,371 
- 100.0% 13.3% 1.7% 58.8% 7.8% 52.1% 99.2% 9.8% 38.9% 
Total 0 2 503 826 2,941 1,073 390 252 276 6,089 
Table 52 - Drugs or alcohol (non-injecting) cohort by accommodation status, 2016-17 
 
 
Figure 31 - Drugs or alcohol (non-injecting) cohort by accommodation status (excludes status 'not known'), 2016-17 
 
  
                                                                
32 Percentages shown by accommodation status excludes those individuals where the accommodation status is not known. Percentages shown for ‘not known’ 
are the percentage of all individuals. 
3.2% 6.7% 3.6%
50.8%
6.2%
13.8% 7.1%
15.7%
9.3%
13.9%
18.5% 12.2%
83.0%
90.9%
77.6%
87.1%
35.3%
100.0%
80.7% 81.6%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Cheshire
East
Cheshire
West &
Chester
Halton Knowsley Liverpool Sefton St. Helens Warrington Wirral IMS total:
NFA - Urgent Housing Problem Housing Problem No Housing Problem
76  Integrated Monitoring System Annual Report 2016-17 
EMPLOYMENT STATUS 
Just over a third (37.9%) of individuals receiving a BI are unemployed and seeking work, with a further quarter (24.2%) long term 
sick or disabled. Just under one in five (18.3%) are in regular employment. Because a young person’s service records the majority 
of BIs for Wirral, a third (34.4%) of their individuals identify as a pupil/student. 
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Regular 
Employment 
0 0 88 153 120 196 36 0 39 608 
- - 20.6% 21.5% 11.8% 22.1% 18.5% - 16.2% 18.3% 
Pupil / Student 
0 0 0 5 11 8 ** 0 83 108 
- - 0.0% 0.7% 1.1% 0.9% 0.5% - 34.4% 3.2% 
Long term sick or 
disabled 
0 0 121 159 200 277 69 0 31 804 
- - 28.3% 22.3% 19.6% 31.3% 35.4% - 12.9% 24.2% 
Unemployed and 
seeking work 
0 0 137 334 405 299 72 0 76 1259 
- - 32.0% 46.9% 39.7% 33.7% 36.9% - 31.5% 37.9% 
Not receiving 
benefits 
0 0 14 27 23 26 13 0 5 106 
- - 3.3% 3.8% 2.3% 2.9% 6.7% - 2.1% 3.2% 
Other 33 
0 0 68 34 262 80 ** 0 7 440 
- - 15.9% 4.8% 25.7% 9.0% 2.1% - 2.9% 13.2% 
           
Not Known 34 
0 2 75 114 1,920 187 195 252 35 2,764 
- 100.0% 14.9% 13.8% 65.3% 17.4% 50.0% 100.0% 12.7% 45.4% 
Total 0 2 503 826 2,941 1,073 390 252 276 6,089 
Table 53 - Drugs or alcohol (non-injecting) cohort by employment status, 2016-17 
 
 
Figure 32 - Drugs or alcohol (non-injecting) cohort by employment status (excludes status 'not known'), 2016-17 
                                                                
33 The figures shown for employment status ‘Other’ include; unpaid voluntary work, retired from paid work, homemaker, and other. 
34 Percentages shown by employment status excludes those individuals where the employment status is not known. Percentages shown for ‘not known’ are the 
percentage of all individuals. 
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PARENTAL STATUS 
The parental status profile for individuals receiving BIs is similar to that for psychoactive substance IDU, with a majority of 
individuals with children under 18 having none of their children living with them. Liverpool had the highest proportion (84.2%) 
having none of their children living with them and the lowest proportion (13.5%) where all of their children lived with them. 
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All of the children 
live with client 
0 0 74 109 40 121 6 0 21 356 
- - 17.6% 13.7% 5.6% 13.5% 4.7% - 8.6% 11.7% 
Some of the children 
live with client 
0 0 16 38 7 40 0 0 9 107 
- - 3.8% 4.8% 1.0% 4.5% 0.0% - 3.7% 3.5% 
None of the children 
live with client 
0 0 125 202 250 288 34 0 28 871 
- - 29.8% 25.5% 34.9% 32.1% 26.8% - 11.4% 28.7% 
Not a parent of 
children under 18 
0 0 204 444 403 445 84 0 183 1,673 
- - 48.6% 56.0% 56.2% 49.6% 66.1% - 74.7% 55.1% 
Client declined to 
answer 
0 0 ** 0 17 ** ** 0 ** 28 
- - 0.2% 0.0% 2.4% 0.3% 2.4% - 1.6% 0.9% 
           
Not Known 35 
0 2 83 33 2,224 176 263 252 31 3,054 
- 100.0% 16.5% 4.0% 75.6% 16.4% 67.4% 100.0% 11.2% 50.2% 
Total 0 2 503 826 2,941 1,073 390 252 276 6,089 
Table 54 - Drugs or alcohol (non-injecting) cohort by parental status, 2016-17 
 
 
Figure 33 - Drugs or alcohol (non-injecting) cohort by parental status, only clients who stated they have children under 18, 2016-17 
  
                                                                
35 Percentages shown by parental status excludes those individuals where the parental status is not known. Percentages shown for ‘not known’ are the 
percentage of all individuals. 
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DISABILITIES OR CHRONIC CONDITIONS 
Where a disability or chronic condition record was completed, almost half (45.5%) the number of individuals receiving BIs stated 
that they have a chronic condition or disability, with mental health/depression accounting for 63.0%. Mobility issues and specific 
learning difficulties were also noted as conditions by a number of individuals.  
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Individuals with chronic 
condition or disability 
0 0 0 ** 95 58 106 0 35 281 
- - - 60.0% 37.7% 65.2% 77.9% - 21.3% 45.5% 
No chronic conditions or 
disabilities 
0 0 0 ** 157 31 30 0 129 336 
- - - 40.0% 62.3% 34.8% 22.1% - 78.7% 54.5% 
           
Not Stated 36 
0 ** 503 821 2,689 984 254 252 112 5,472 
- 100.0% 100.0% 99.4% 91.4% 91.7% 65.1% 100.0% 40.6% 89.9% 
Total 0 ** 503 826 2,941 1,073 390 252 276 6,089 
           
Recorded conditions:           
Arthritis    0 ** ** **  0 ** 
Asthma    0 ** ** 0  0 ** 
Chronic Pain    0 ** 0 **  0 ** 
COPD Chronic Obstructive 
Pulmonary disease 
   0 0 0 **  ** ** 
Depression    0 ** 9 13  5 28 
Diabetes    0 ** ** 0  0 ** 
Epilepsy    0 0 0 0  0 0 
Hearing impairment    0 ** 0 0  0 ** 
Liver disease / Cirrhosis    0 ** ** 0  0 ** 
Mental health    0 10 12 22  ** 43 
Mental ill health    ** 34 22 56  5 112 
Mobility issues    0 11 ** **  ** 18 
Specific learning difficulties 
(e.g. Dyslexia) 
   0 ** 0 **  8 12 
Visual impairment    0 ** ** **  ** ** 
Other    ** 23 5 6  10 42 
Table 55 - Drugs or alcohol (non-injecting) cohort, individuals stating any disability or chronic condition, 2016-17 
 
 
  
                                                                
36 Percentages shown is for those clients where a disability or chronic condition record was completed. Percentages shown for ‘not known’ are the percentage 
of all individuals. 
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5.4.  GEOGRAPHIC PROFILE  
LOCAL AUTHORITY OF RESIDENCE 
Services based within Knowsley, Liverpool and Sefton all saw over 8% of individuals who resided in a different local authority 
area, with Liverpool having the highest level of out of area attendees at 13.1%. All other areas saw at least 97% of their own 
residents use their locally provided services. 
 Local Authority of service provider  
Local Authority of 
residence 
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Cheshire East 0 0 0 0 ** 0 0 0 0 ** 
Cheshire West and 
Chester 
0 0 ** 0 ** 0 0 0 0 ** 
Halton 0 0 432 ** 5 ** 0 0 0 434 
Knowsley 0 0 0 756 76 13 0 0 0 811 
Liverpool 0 0 ** 57 2,418 40 ** 0 ** 2,462 
Sefton 0 0 0 ** 233 909 ** 0 0 1,073 
St. Helens 0 0 0 6 ** 0 316 ** 0 325 
Warrington 0 0 ** ** 0 0 0 78 0 80 
Wirral 0 0 0 0 38 24 ** 0 264 326 
West Lancashire 0 0 0 0 ** 9 0 0 0 10 
Newcastle-under-Lyme 0 0 0 0 0 0 0 0 0 0 
Staffordshire Moorlands 0 0 0 0 0 0 0 0 0 0 
Flintshire 0 0 0 0 0 0 0 0 0 0 
Manchester 0 0 0 0 ** ** 0 0 0 ** 
Salford 0 0 0 0 0 0 0 0 0 0 
Wigan 0 0 0 0 0 0 0 0 0 0 
Stockport 0 0 0 0 0 0 0 0 0 0 
Others 0 0 0 ** 5 0 0 ** 0 7 
Not Stated 0 ** 66 0 158 76 71 172 11 556 
Total 0 2 503 826 2,941 1,073 390 252 276 6,089 
Table 56 - Drugs or alcohol (non-injecting) cohort, individuals by local authority of residence and local authority of service provider, 2016-17 
 
 
Figure 34 - Drugs or alcohol (non-injecting) cohort, split by residence within the local authority of service provider (excludes 'not stated'), 2016-17 
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POSTCODE DISTRICT OF RESIDENCE 
 
Postcode 
district 
Number of 
Individuals 
Percentage 37  
Postcode 
district 
Number of 
Individuals 
Percentage 
L20 354 8.6%  CH46 17 0.4% 
WA7 231 5.6%  L18 17 0.4% 
PR8 205 5.0%  L24 16 0.4% 
PR9 198 4.8%  CH4 16 0.4% 
L21 190 4.6%  CH62 16 0.4% 
L36 186 4.5%  WA11 14 0.3% 
WA8 162 3.9%  CH49 12 0.3% 
L4 157 3.8%  L16 9 0.2% 
L32 148 3.6%  L38 8 0.2% 
L11 110 2.7%  CH48 6 0.1% 
L9 103 2.5%  CH47 6 0.1% 
L6 99 2.4%  CH63 6 0.1% 
L30 98 2.4%  L27 5 0.1% 
L17 96 2.3%  Other Postcodes 84 2.0% 
L23 91 2.2%     
L33 91 2.2%     
L8 80 1.9%     
L13 79 1.9%     
L35 76 1.9%     
L22 75 1.8%     
L14 73 1.8%     
L26 73 1.8%     
L31 64 1.6%     
L28 61 1.5%     
WA10 59 1.4%     
L10 57 1.4%     
L5 56 1.4%     
L7 52 1.3%     
L25 52 1.3%     
L12 51 1.2%     
L3 50 1.2%     
CH44 49 1.2%     
L15 48 1.2%     
L19 45 1.1%     
L34 41 1.0%     
L37 39 0.9%     
CH42 38 0.9%     
CH43 38 0.9%     
CH41 34 0.8%     
WA9 27 0.7%     
CH45 21 0.5%  Not Stated 1,981 - 
L1 19 0.5%  Total 6,089  
Table 57 - Drugs or alcohol (non-injecting) cohort, individuals by postcode district of residence, 2016-17 
 
Key: CHE CHW HAL KNW LIV SEF SHL WAR WIR 
  
                                                                
37 Percentage of those individuals who stated a valid postcode. 
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LOCATION MAPS 
 
 
 
 
 
 
 
 
 
 
  
Figure 35 - Drugs or alcohol (non-injecting) cohort, individuals by 
Local Authority area, 2016-17 
Figure 36 - Drugs or alcohol (non-injecting) cohort, prevalence 
(per 1,000 population) by Local Authority area, 2016-17 
Figure 37 - Drugs or alcohol (non-injecting) cohort, individuals by postcode district of residence, 2016-17 
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5.5.  ANNUAL CLIENT NUMBERS 
In recent years, the number of individuals who received a brief intervention has stayed more or less static until 2015-16 but 
dropped by 18.9% in 2016-17. The number of BIs recorded in Liverpool and Wirral has dropped by a substantial amount in the 
last two years in particular (27.4% and 68.1% respectively), although the number of BIs delivered in Halton and Knowsley has 
increased during the same time period (199.4% and 84% respectively).  
 
 
Figure 38 - Drugs or alcohol (non-injecting) cohort, annual client numbers 2013-14 to 2016-17 
 
 
Figure 39 - Drugs or alcohol (non-injecting) cohort, annual client numbers by local authority 2013-14 to 2016-17 
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BI: Drug or Alcohol 2013-14 2014-15 2015-16 2016-17 
Cheshire East 0 0 0 0 
Cheshire West & Chester 0 0 0 2 
Halton 0 31 168 503 
Knowsley 14 79 449 826 
Liverpool 5,062 4,510 4,052 2,941 
Sefton 429 1,075 1,682 1,073 
St. Helens 0 0 411 390 
Warrington 0 0 152 252 
Wirral 2,062 2,139 865 276 
Cheshire & Merseyside 7,567 7,575 7,509 6,089 
Table 58 - Drugs or alcohol (non-injecting) cohort, annual client numbers by local authority, 2013-14 to 2016-17  
 
PREVALENCE ESTIMATES 38 
While prevalence estimates for the number of individuals who have brief interventions should be treated with caution since 
some areas do not routinely record delivery of BIs, the estimates do give an illustration of the penetration of BI delivery to the 
overall population. Liverpool has the highest prevalence at 6.07 per 1,000 closely followed by Knowsley (5.58), Halton (3.96) and 
Sefton (3.91). Both Cheshire areas do not routinely report BIs to IMS. 
BI: Drug or Alcohol 2013-14 2014-15 2015-16 2016-17 
Cheshire East 0.00 0.00 0.00 0.00 
Cheshire West & Chester 0.00 0.00 0.00 0.01 
Halton 0.00 0.25 1.33 3.96 
Knowsley 0.10 0.54 3.05 5.58 
Liverpool 10.75 9.53 8.47 6.07 
Sefton 1.57 3.93 6.15 3.91 
St. Helens 0.00 0.00 2.31 2.19 
Warrington 0.00 0.00 0.73 1.21 
Wirral 6.44 6.67 2.70 0.86 
Cheshire & Merseyside 3.13 3.12 3.08 2.48 
Table 59 - Drugs or alcohol (non-injecting) cohort, annual prevalence estimates by local authority, 2013-14 to 2016-17 
 
 
Figure 40 - Annual prevalence estimates 2013-14 to 2016-17, drugs or alcohol (non-injecting) cohort, by local authority 
                                                                
38 Prevalence (per 1,000 population) is based on the ONS mid-year population estimates for each local authority area. 
https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/populationestimatesforukenglandandwalessc
otlandandnorthernireland 
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5.6.  AFFECTED OTHERS - SUPPORT SERVICES FOR FAMILY OR FRIENDS AFFECTED BY SUBSTANCE USE 
Within section 5.2 of this report (page 73) Table 50 shows the main substances recorded for ‘non-injecting - brief intervention 
only’ clients. This includes 889 individuals who either have no main substance recorded or who are only engaged with services 
for support due to substance use by others. This total of 889 amounts to 14.6% of all individuals in this cohort group. Unlike the 
cohorts of both psychoactive drug injectors, and steroid and IPED injectors for whom we are able to impute substance use from 
client characteristics and recorded syringe exchange transactions, we are unable to determine whether these individuals have 
used alcohol or other drugs. The majority of these individuals do not have any assessment information completed, so the main 
substance is ‘not stated’. However, a proportion of these individuals do have assessment information which confirms ‘no 
substance’ used, or ‘someone else’s use’ (Table 60). 
  
Not 
stated 
No substance 
used 
Someone else’s 
use 
Total Individuals 
Cheshire East 0 0 0 0 
Cheshire West & Chester 2 0 0 2 
Halton 66 0 0 66 
Knowsley 0 0 0 0 
Liverpool 216 71 0 287 
Sefton 77 5 0 82 
St. Helens 107 52 43 202 
Warrington 172 0 63 235 
Wirral 14 1 0 15 
All IMS individuals 654 129 106 889 
Table 60 - Drugs or alcohol (non-injecting) cohort, individuals with no recorded substance, 2016-17 
 
Table 61 shows the breakdown by age group and gender for each of these three groups. For those individuals where a substance 
was not stated, just over half 55.4% (n=362) were female and 44.6% (n=292) were male; for those where an assessment was 
completed stating ‘no substance used’ the split is reversed with just over half 57.4% (n=74) being male and 42.6% (n=55) female. 
For those individuals who are only in contact with support services due to someone else’s substance use, over three quarters 
(77.4%, n=82) were female, and when both genders are combined one third of all individuals (33.0%, n=35) were aged 60 or 
over.  
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Not  
stated 
Female 
38 6 23 30 20 33 33 44 38 31 19 47 
362 
5.8% 0.9% 3.5% 4.6% 3.1% 5.0% 5.0% 6.7% 5.8% 4.7% 2.9% 7.2% 
Male 
34 0 12 14 22 20 45 36 37 27 19 26 
292 
5.2% 0.0% 1.8% 2.1% 3.4% 3.1% 6.9% 5.5% 5.7% 4.1% 2.9% 4.0% 
Total 
72 6 35 44 42 53 78 80 75 58 38 73 
654 
11.0% 0.9% 5.4% 6.7% 6.4% 8.1% 11.9% 12.2% 11.5% 8.9% 5.8% 11.2% 
               
No  
substance 
Female 
10 ** 5 7 ** 6 6 ** 6 ** ** ** 
55 
7.8% 1.6% 3.9% 5.4% 2.3% 4.7% 4.7% 3.1% 4.7% 1.6% 0.8% 2.3% 
Male 
6 0 ** 10 ** 5 14 13 5 9 ** ** 
74 
4.7% 0.0% 3.1% 7.8% 3.1% 3.9% 10.9% 10.1% 3.9% 7.0% 2.3% 0.8% 
Total 
16 ** 9 17 7 11 20 17 11 11 ** ** 
129 
12.4% 1.6% 7.0% 13.2% 5.4% 8.5% 15.5% 13.2% 8.5% 8.5% 3.1% 3.1% 
               
Someone else’s 
use 
Female 
** 0 ** 6 0 8 ** 15 11 9 6 20 
82 
1.9% 0.0% 2.8% 5.7% 0.0% 7.5% 1.9% 14.2% 10.4% 8.5% 5.7% 18.9% 
Male 
** 0 ** 0 ** 0 0 ** 5 ** ** 8 
24 
0.9% 0.0% 0.9% 0.0% 0.9% 0.0% 0.0% 3.8% 4.7% 2.8% 0.9% 7.5% 
Total 
** 0 ** 6 ** 8 ** 19 16 12 7 28 
106 
2.8% 0.0% 3.8% 5.7% 0.9% 7.5% 1.9% 17.9% 15.1% 11.3% 6.6% 26.4% 
Table 61 - Drugs or alcohol (non-injecting) cohort, individuals with no recorded substance, by age and gender, 2016-17 
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6. INTEGRATED MONITORING SYSTEM - ACTIVITY (ALL CLIENTS) 
6.1.  INTERVENTIONS 
Interventions were delivered to individuals on 36,888 separate occasions (Table 62) to a total of 9,179 individuals, an average of 
4.0 interventions per person.  
Table 63 shows a breakdown by intervention category; the majority of interventions (91.3%, n=33,675) were categorised as a 
‘brief intervention’, while just over 1 in 10 occasions (11.6%, n=4,291) included ‘advice and information’. Where individuals have 
both categories recorded on the same date, this is counted as one intervention occasion, but they are counted in the two 
separate categories. 
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Number of individuals 73 674 998 1,022 3,278 1,478 736 300 828 9,179 
Interventions delivered 39 98 1,308 1,477 1,449 18,896 4,432 6,163 1,377 1,688 36,888 
Average of interventions  
per person 
1.3 1.9 1.5 1.4 5.8 3.0 8.4 4.6 2.0 4.0 
Table 62 - All IMS individuals, interventions delivered, 2016-17 
 
Intervention categories 
 
C
h
e
sh
ir
e
 E
as
t 
C
h
e
sh
ir
e
 W
e
st
 
&
 C
h
e
st
e
r 
H
al
to
n
 
K
n
o
w
sl
e
y 
Li
ve
rp
o
o
l 
Se
ft
o
n
 
St
. H
e
le
n
s 
W
ar
ri
n
gt
o
n
 
W
ir
ra
l 
A
ll 
IM
S 
Brief Intervention 92 482 1,404 1,369 18,047 4,386 5,987 581 1,327 33,675 
Advice & Information 6 826 75 97 1,796 55 188 871 377 4,291 
Table 63 - All IMS individuals, intervention categories recorded, 2016-17 40 
 
Service providers are able to define their own descriptions for ‘intervention type’ in order to meet local reporting requirements. 
Table 64 includes ‘intervention types’ summarised into 28 general descriptions, and these descriptions cover a range of activities 
as delivered by different providers. It is possible to record several different intervention types on the same date. These are 
counted individually in Table 64 but as one separate intervention occasion in Table 62 above. 
  
                                                                
39 In this report the total of interventions delivered has been counted as a maximum of one intervention per individual per day, therefore these figures may not 
be directly comparable with previous reports. 
40 Where both intervention categories are recorded for a client on the same date these will be counted once in Table 62 but separately in Table 63. 
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Intervention types 
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Alcohol brief intervention - - - - 2,404 1 3 2 93 2,503 
Anabolic steroid advice - 452 281 - 164 20 89 1 386 1,393 
Assessment, review, or 1 to 
1 counselling 
- - - 4 1,704 15 241 786 226 2,976 
Basic needs & personal care - - - - - - 5,961 - - 5,961 
BBV screening, or advice - 6 - 1 31 136 1 - 7 182 
Benefits, debt or financial 
advice 
- - - - - 568 69 4 - 641 
Creative session, or other 
activities 
- - 5 3 9,082 1 - - 47 9,138 
Detox and rehabilitation - - - 4 1,894 - - - - 1,898 
Drug & alcohol advice - - - - 36 - 3 - 101 140 
Education, training, or 
employment support 
- 9 63 66 594 440 104 8 319 1,603 
Family support - - 52 41 600 1,367 - - 2 2,062 
GP, dentist, or other health 
access 
- - - 2 143 16 22 - - 183 
Group session - - - - 241 - 26 111 - 378 
Harm reduction advice: 
general 
97 682 44 267 3,865 591 40 47 409 6,042 
Harm reduction: safer drug 
use or injecting advice 
1 240 495 50 23 712 186 2 505 2,214 
Health and wellbeing - - 6 13 1,059 14,311 157 163 10 15,719 
Housing support - - 69 16 126 65 155 5 22 458 
Mental health - - 4 15 23 94 57 - 2 195 
Mutual aid, or peer support - - 596 765 260 - - - - 1,621 
Other intervention 1 2 80 384 7,229 974 243 147 179 9,239 
Other support and advice - 4 15 11 51 302 303 520 50 1,256 
Outreach activity - general - - - 1 1,054 - - 8 28 1,091 
Recovery support, and 
relapse prevention 
- - 169 113 6,345 2,506 - - 6 9,139 
Safeguarding interventions - - - - - - 22 6 - 28 
Sexual health - 9 - - 106 42 - - 165 322 
Smoking cessation - - 2 1 - 144 - - - 147 
Transferred or treatment 
completed 
- - - 4 - - 31 62 5 102 
Volunteering, or work 
experience 
- - 2 15 40 24 3 - 8 92 
Table 64 - All IMS individuals, intervention types recorded, 2016-17 
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6.2.  REFERRALS 
REFERRAL SOURCE / INWARD REFERRALS 
A total of 797 inward referrals were recorded by service providers across four local authority areas, the majority of which were 
self-referrals (41.8%) or from another service provider (35.6%).  Where another provider was identified, The Brink were the main 
organisation named (n=99) followed by LCAS (n=63) and Action on Addiction – SHARP (n=52). 
Referral Category Liverpool St. Helens Warrington Wirral All IMS 
Self-referral 266 29 35 3 333 
Other service provider 246 10 9 19 284 
Drug service 23 6 70  99 
Jobcentre, or employer 8 10  18 36 
Probation service 19    19 
GP, Hospital, or other NHS 6 5   11 
Housing support 1 1  4 6 
Community Alcohol Team  5   5 
Relative, or others   2 2 4 
      
 Total:  569 66 116 46 797 
Table 65 - All IMS individuals, inward referrals, by referral category, 2016-17 
 
Referral Type or Organisation Liverpool St. Helens Warrington Wirral All IMS 
Self or Other services 291 49 103 11 454 
The Brink, support services 99    99 
Liverpool Community Alcohol Service 63    63 
Action on Addiction - SHARP 52    52 
The Social Partnership (TSP) 3   29 32 
Merseyside Probation Trust 19    19 
CGL 2  13 1 16 
Addaction 2 10  1 13 
NHS health services 5 7   12 
Park View Project 10    10 
Windsor Clinic 8    8 
Jobcentre 7    7 
Sexual Health service 3   1 4 
Bridge House 3    3 
Reach Out    3 3 
Waves of Hope 2    2 
      
 Total:  569 66 116 46 797 
Table 66 - All IMS individuals, inward referrals, by referral type or organisation, 2016-17 
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ONWARD REFERRALS 
A total of 877 outward referrals were recorded by service providers across five local authority areas, seven in ten of which were 
to another service provider (70.5%).  Where a specific organisation was named, the main services individuals were referred on 
to were The Brink (n=248), LCAS (n=86)  and Action on Addiction – SHARP (n=64). 
Referral Category Liverpool Sefton St. Helens Warrington Wirral All IMS 
Other service provider 551 20 12 4 31 618 
Community Alcohol Team 131 1 1   133 
GP, Hospital, or other NHS 59 1 2  3 65 
Education service 17 1   1 19 
Drug service 5 1  1 4 11 
Hospital, or other NHS  8   3 11 
Housing support 3 4   1 8 
Jobcentre, or employer 1 2   2 5 
Relative, or others   3 1  4 
Smoking cessation service  1   2 3 
       
Total: 767 39 18 6 47 877 
Table 67 - All IMS individuals, onward referrals, by referral category, 2016-17 
 
Referral Type or Organisation Liverpool Sefton St. Helens Warrington Wirral All IMS 
The Brink, support services 248     248 
Other services 128 24 10 6 19 187 
Liverpool Community Alcohol 
Service (LCAS) 
86     86 
Action on Addiction - SHARP 64     64 
NHS health services 50 8 2  2 62 
Lifeline 43     43 
Addaction 35  5  2 42 
Alcohol Liaison Nurse Service 22     22 
Windsor Clinic 18     18 
Whitechapel 11 5    16 
Sexual Health service 9    4 13 
CGL 5    7 12 
New Start 12     12 
Reach Out     12 12 
Bridge House 10     10 
Phoenix Futures 8     8 
Housing services 3 2 1  1 7 
Waves of Hope 6     6 
Park View Project 5     5 
Kevin White Unit 4     4 
       
Total: 767 39 18 6 47 877 
Table 68 - All IMS individuals, onward referrals, by referral type or organisation, 2016-17 
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6.3.  WELLBEING 
OVERVIEW OF WELLBEING 
Measuring wellbeing enables us to see how people feel (their emotions) and how they function (their competence and 
connectedness) on both a personal and social level, providing a subjective overview of their lives at a given point in time41. The 
Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS)42 was developed to enable the monitoring of mental wellbeing in the 
general population and the evaluation of projects, programmes and policies which aim to improve mental wellbeing. This tool 
has been validated for use in face-to-face interviews and showed good content validity43. WEMWBS was originally devised as a 
14 question scale and subsequently developed as the short-form WEMWBS which asks seven questions. The items are all 
worded positively and cover both feeling and functioning aspects of mental wellbeing. Responses are scored using a five item 
response scale (‘none of the time’, ‘rarely’, ‘some of the time’, ‘often’, ‘all of the time’). Responses to the seven question short-
form WEMWBS (used by IMS services) are converted to a numeric score which is then combined to provide a single score 
ranging from 7-35. 
 
 I’ve been feeling optimistic about the future  I’ve been thinking clearly 
 I’ve been feeling useful  I’ve been feeling close to other people 
 I’ve been feeling relaxed  I’ve been able to make up my own mind about things  
 I’ve been dealing with problems well  
WELLBEING REVIEWS 
During 2016-17 wellbeing reviews were completed for 1,489 individuals. Of these, a cohort of 320 individuals had completed 
WEMWBS on two separate occasions. For all individuals (n=1,489) who completed a wellbeing review the mean score at the 
latest review was 20.9. When scores are categorised as ‘low wellbeing’ (7-15), ‘medium wellbeing’ (16-25) and ‘high wellbeing’ 
(26-35), the majority 55.4% (n=825) were ranked as ‘medium wellbeing’. However there is some variation when comparing 
scores by main substance group, as 90.9% (n=40) of individuals recording the use of steroids & IPEDs reported a high level of 
wellbeing. Amongst other substances those most often reporting high wellbeing were people who used methadone (44.4%, 
n=9), while those using crack cocaine recorded the largest proportion with low wellbeing (35.8%, n=23) (Figure 41). 
 
Figure 41 - Split of scores recorded at latest Wellbeing review, shown by main substance group 44 
                                                                
41 Michaelson, J., Mahony, S. and Schifferes, J. (2012). Measuring wellbeing: A guide for practitioners. London: new economics foundation. 
42 More details about WEMWBS can be found at: https://warwick.ac.uk/fac/med/research/platform/wemwbs 
43 Stewart-Brown S (2007). The Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS): development and UK validation. Health and Quality of Life Outcomes 
44 Note: percentages shown may not total 100% due to rounding 
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WELLBEING CHANGE 
Where individuals (n=320) had completed wellbeing reviews on at least two separate occasions the change in score is calculated 
as a value difference between the total score at first and latest review. Changes in wellbeing score ranged from -20 to +24 with a 
mean change of +0.43 (Figure 42). 
 
Figure 42 - Change in wellbeing score between first and latest review 
 
For all individuals with multiple wellbeing reviews, just over half (50.6%, n=162) showed a positive change in score between 
their first and latest review, while 8.4% (n=27) had no change and 40.9% (n=131) recorded a negative change. Figure 43 shows 
the direction of change by main substance group. Those individuals receiving support related to ‘someone else’s drug or alcohol 
use’ recorded the largest proportion of wellbeing reviews with a positive change (70.6%, n=24), while those using ‘other drugs’ 
(including crack cocaine, and other opiates) recorded the largest proportion of reviews with a negative change in wellbeing 
(52.2%, n=12). 
 
Figure 43 - Direction of change in wellbeing score, by main substance group 
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7. NOVEL PSYCHOACTIVE SUBSTANCES (NPS) & CLUB DRUGS 
IMS has featured a module since April 2016 which allows services to record details on novel psychoactive substances (NPS, 
formerly known as legal highs) and club drugs where their use is reported by service users. Recording data on recreational 
substance use through structured drug treatment services is complicated by the fact that individuals do not necessarily view 
their use of such substances as problematic, and so lower threshold services would appear to provide a perhaps better 
opportunity to gather this information. However, recording of the information via IMS has been sporadic and while 11 agencies 
across Liverpool, Warrington and Wirral have reported NPS use, the data has so far been mainly collected from one young 
persons (YP) service based in St. Helens. 
The data shows that males were more likely to use both NPS and club drugs than females although with the exception of 
cocaine, the ratio of male to female was around 2:1, when this ratio is at least 3:1 for structured and standard low threshold 
services. Unsurprisingly given the age group the main reporting service catered for, most individuals (54.9%) were aged under 30 
with very little use (3.4%) by individuals aged over 49 years. Cocaine and ‘NPS – predominantly cannabis’ (referring to “Spice” in 
most cases where detail was noted) were the most commonly reported substances although of note there were also 17 reports 
of an NPS with a predominantly sedative or opioid like effect. Street names for NPS where noted included Bath Salts, Bombay, 
Blue Extreme, Ching, Clockwork Orange, DMT, Happy Joker, High Beams, MKAT, Sweet Leaf, 1plsdk, 25i, Amber leaf, Gold Bar, 
Rolls Royce and Silver Bar. 
 
NPS & 'Club Drugs' 
Count by Age Group  
Totals: 
0 - 18 19 - 29 30 - 39 40 - 49 50 - 59 
Amphetamines 1 3 3 3 1 11 
Cocaine 7 27 11 13 1 59 
Drug – not otherwise specified  2 2 4 2 10 
GHB/GBL  2 1 2  5 
Ketamine 8 7    15 
Lysergide (LSD) 1 2   1 4 
MDMA 22 4 5 4  35 
Mephedrone 1 2 3 2  8 
Methamphetamine 1 1 1 2  5 
Nitrous oxide 4 1    5 
NPS - effects different, or not stated    1  1 
NPS - predominantly cannabis 7 12 11 9 1 40 
NPS - predominantly hallucinogenic 3 2    5 
NPS - predominantly sedative or opioid  2 5 9 1 17 
NPS - predominantly stimulant 5  4 1 1 11 
Volatile Nitrate / Amyl Nitrate (Poppers)  1 1   2 
Totals:  60 68 47 50 8 233 
Table 69 - Novel Psychoactive Substances (NPS) & 'Club Drugs' 
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8. DRUG RELATED DEATHS 
The number of drug related deaths (DRDs) is increasingly a major public health concern for the UK, with recorded deaths 
reaching their highest ever level in 2016, with highest number since comparable statistics began in 1993 (ONS, 2017). The UK is 
not alone in this – the USA for instance also recorded its highest ever number of DRDs last year (New York Times, 2017) – but it 
is by no means comprehensive across Europe and so reflection on practice is of key importance. In 2016, a module was 
developed within IMS to monitor drug related deaths using an established template but streamlining the process so that key 
individuals including public health commissioners and service leads would receive automatic notification when a death occurred 
in their locality. DRD monitoring in its current form has been provided to Liverpool and Sefton local authority areas since 2015, 
and more recently Wirral, Knowsley and St. Helens, with interest expressed by a further two regions. The process reflects best 
practice in a number of areas as recommended by the Public Health England (PHE) (formerly NTA) document “Drug Related 
Deaths: Setting Up a Local Review Process” (NTA, 2010): 
 Most drug related review processes involve elements of quantitative and qualitative approaches, obtaining robust 
statistics and exploring aspects of service practice and delivery 
 Defining a drug related death for the purposes of the review process is essential, so it is clear which cases should be 
considered 
 A lead officer for reviewing deaths with a good range of skills is a common feature and ensures consistency.  
 Working jointly with neighbouring areas can provide better opportunities for learning and economies of scale 
 Involving a local coroner can greatly enhance a review process. 
 Although the aim of a review process isn’t to apportion blame as such, it may identify responsibility and there should be 
a system of feeding this back to appropriate managers within the relevant agency 
 Partnerships should keep a record of findings, with internal dissemination of findings to relevant agencies and drug 
related death review groups 
 Recommended actions from a review process can be written into treatment plans 
When a service receives information that an individual in treatment with them has died, nominated personnel at that service 
will log those details on to IMS including details of the individual’s substance use, prescribed medication, relationship with the 
treatment service, any health issues and other relevant information. Every quarter, a data analyst from PHI’s Intelligence and 
Surveillance Team visits the coroner office to collect both further information on individuals reported by the treatment service, 
including cause of death, and on individuals who have been identified by the coroner as a DRD but who were not active in 
treatment at the time of the death. Coupled with other information such as the individual’s IMS record and the Criminal Justice 
data set, a report is then compiled on an individual basis which goes out to DRD panels for discussion on a quarterly basis. 
Chaired by a member of PHI staff, membership of the panel includes representation from drug services, local authority leads and 
social services, as well as the lead prescriber from treatment services.  
The system has been beneficial in a number of ways. As PHE noted in 2016, the majority of individuals dying of a DRD have not 
been in treatment for the last five years (PHE, 2016), making the coroner element of the information flow crucial. IMS data 
recurrently identifies that individuals who state that they have previously or never injected have in fact had NSP transactions 
right up to the point of their death, a considerable number in some cases. To date by November 2017, 187 deaths were reported 
via the system and a number of actions have resulted from panel discussions and reflection on cases including improving the 
process for notification when an individual fails to pick up a prescription medication, examining the process of handover for new 
service commissions, improvement of links and pathways with primary care, regular Chronic Obstructive Pulmonary Disease 
(COPD) screening and a focus on the management of physical health. 
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DISCUSSION 
IMS data from 2016-17 demonstrate the importance of continuing to monitor low threshold interventions and NSP activity at a 
time when numbers using such services remain high. The data suggests that the number of individuals using a psychoactive 
substance and presenting to NSP services who are not in structured drug treatment is rising.  There have been substantial 
increases over the last 10 years in the number of individuals presenting to NSP services, although numbers appear to have 
levelled off in the most recent years.  Most of this change has been driven by large increases in the number of people using 
steroid and IPED presenting to NSPs since 2007-08, although the number of people injecting psychoactive IDU drugs has also 
increased in a majority of local authority areas. Across all local authority areas, the proportion of psychoactive substance 
injectors not in structured treatment within the past year was 80.1%, and even taking into account factors around the reliability 
of attributors as discussed below, this still represents a substantial increase on the figure of 52.6% last year (although this is 
calculated from those who identified a primary substance only). 
Using the principles around imputation outlined in the introduction and running the imputation for individuals for whom a 
primary substance was known showed that the model was accurate in 85% of cases. Accordingly it has been possible to allocate 
individuals who previously did not state a primary substance to one of these two groups and this allows us to look at data in 
more depth historically, the results of which are shown for the last 25 years in Figure 44 below. 
 
Figure 44 - Imputation of NSP activity, 1991-2017 
As Cheshire local authorities only began reporting to IMS in recent years and pharmacy activity was not routinely collected 
across all areas, we can compare like for like figures by examining NSP data from the last 10 years but this too comes with some 
caveats: data collection methods have changed significantly over the last decade, with most local authority areas now reporting 
data electronically whereas 10 years ago collection on paper forms was widespread. There have also been episodes where data 
collection was incomplete in some areas, and a different landscape in terms of delivery which has moved markedly towards 
more provision through pharmacies in recent years. 
Acknowledging these factors, Figure 45 shows that there have been substantial increases over the last 10 years in the number of 
individuals presenting to NSP services, although numbers appear to have levelled off in recent years with the exception of 2014-
1545. Table 70 shows that all local authority areas have seen increases since 2007-08 although some have been more 
considerable than others, ranging from an increase of 11% in Sefton and 29% in Halton to increases of more than 100% in 
Liverpool, St. Helens and Cheshire West & Chester. 
                                                                
45 The reasons for the spike in 2014-15 have not been clear despite repeated interrogation. 
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Figure 45 - NSP activity (number of individuals) 2007-2017 
 
Most of this change has been driven by large increases in the number of people using steroid and IPED presenting to NSPs since 
2007-08, ranging from an 87% increase in Wirral to a 2452% increase in Cheshire West and Chester (although this figure should 
be viewed with caution as it may represent a recording issue rather than genuine increase). The number of people who inject 
psychoactive drugs has also increased in a majority of local authority areas although less dramatically so, ranging from an 
increase of 4.7% in Wirral to 78% in Liverpool. 
 
  2007-08 2008-09 2009-10 2010-11 2011-12 2012-13 2013-14 2014-15 2015-16 2016-17 
Increase 
over 10 
years 
Cheshire East 863 836 653 390 944 1,115 1,283 1,425 1,371 1,336 55% 
Cheshire W & Chester 379 680 805 744 1,157 1,337 1,664 2,022 1,416 2,035 437% 
Halton 510 565 684 609 687 786 588 801 701 657 29% 
Knowsley 356 440 460 491 548 488 582 702 712 703 97% 
Liverpool 3,866 6,577 6,063 6,326 5,629 5,735 6,147 8,147 7,468 7,982 106% 
Sefton 1,384 1,619 1,510 1,460 1,623 1,806 1,860 2,757 1,382 1,536 11% 
St. Helens 843 1,266 1,773 1,777 1,853 2,029 2,383 2,714 2,262 1,856 120% 
Warrington 899 964 1,113 1,693 1,830 2,011 1,783 1,739 1,540 1,351 50% 
Wirral 1,294 1,568 1,636 1,725 1,637 1,877 2,201 2,674 1,668 1,769 37% 
Table 70 - Number of individuals using NSP services by Local Authority, 2007-2017 
10,128
14,210 14,445
15,001 15,661
16,952
18,193
23,671
18,688 18,935
0
5,000
10,000
15,000
20,000
25,000
2007-08 2008-09 2009-10 2010-11 2011-12 2012-13 2013-14 2014-15 2015-16 2016-17
Integrated Monitoring System Annual Report 2016-17  97 
Figure 46 shows the number of NSP 
visits continuing to rise, with an 
increase of 123% since we started to 
calculate NSP data in this way in 
2013-14, and an increase of 15% in 
the last twelve months. This again 
masks variations at local authority 
level with most areas seeing 
increases including a 48% increase in 
Cheshire West and Chester, although 
Warrington, Wirral and Halton saw 
slight decreases over the last year. 
We have not at this point historically 
attributed cohort groups to the 
number of visits made, but we will 
look at this in future years.  
 
One of the most important findings to come out of reallocation using the imputation is that previously it was thought that 
people who inject steroid and IPEDs formed more of the total NSP cohort in recent years than people who inject psychoactive 
drugs. Our imputation estimations however show that there have probably been more people who inject psychoactive drugs 
attending NSPs than those injecting IPEDs in every year since recording began in 1991 (Figure 47 and Figure 48). 
 
While the data shows a change to the overall landscape in terms of the IPED/psychoactive split, this change is very much driven 
by pharmacy provision as agencies have always reported main substance more comprehensively. In recent years pharmacies 
have seen a higher number of individuals than agencies by a factor of around 3:1, so have a marked impact on overall numbers. 
Even with imputed data included, the proportion of people injecting IPED attending agency NSPs remains substantially higher 
than those attending pharmacy services. This difference would appear to warrant further exploration, since while IPED injectors 
have many of the same health issues as psychoactive injectors, it is the latter group for whom drug related deaths have reached 
record levels in the last few years and who might most benefit from broader health-related interventions which agencies may be 
better placed to deliver. (The area with the lowest level of psychoactive injectors in structured treatment (13%) is Liverpool 
which has one of the highest proportions of NSP delivered in a pharmacy setting).  
Local drug related death monitoring systems have frequently found that individuals whose NDTMS record states that they have 
not injected, have a number of NSP transactions recorded in IMS, therefore indicating that they have injected. This would 
suggest that caution should be taken when using NDTMS data to indicate the proportion of the population in treatment who are 
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imputation 
Figure 48 - Number of psychoactive/IPED individuals by cohort, post 
imputation 
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injecting, particularly since this information is only collected at the start of an episode of treatment which may have commenced 
many years in the past. Furthermore, a report by PHE in 2016 stated that “the majority of opiate misuse deaths in the past five 
years occurred in those who were not identified as being in and had not recently been in community drug treatment”  (PHE, 
2016). Agencies being staffed by dedicated NSP workers with training and expertise in the field of substance use could 
potentially provide sustained health and lifestyle related interventions to the large group of opiate injectors currently not 
accessing treatment services. All but one area in this analysis had a mix of NSP provision between agency and pharmacy, and 
there is the opportunity too for pharmacies to make better links with their local drug teams and agency-based NSP services. 
Pharmacists have previously reported the need for further training for themselves and their staff (Sheridan et al, 2000); with the 
move for many local authorities nationally from agency to pharmacy provision during the last decade, this intensifies the need to 
ensure NICE’s recommendations that staff are competent to provide advice about the full range of drugs people may be using, 
reducing injecting related harm and preventing/managing overdoses are fully implemented (NICE, 2014). It may also be an 
opportunity for some individuals to engage with treatment should good links exist between the pharmacy based NSP and the 
local drug treatment provider. 
While the ACMD’s opioid related deaths report identifies a number of potential causes of the recent upsurge in deaths including 
the ageing drug using population, changes in the availability and purity of heroin at street level and socio-economic changes 
including increasing deprivation and cuts to support services in deprived areas, it also suggested that changes in the 
commissioning and provision of drug treatment might be a factor and it is accordingly vital that the large numbers of individuals 
outside of the treatment system do not go unnoticed by those commissioning services (ACMD, 2016). With research showing 
that heroin users become more vulnerable to death from overdose as they grow older, the increasing proportion of people who 
use NSP services that are older highlights the importance of ongoing engagement in order to encourage attendance in 
treatment services and monitoring numbers to ensure the problem is not becoming exacerbated. It is also important to note 
that treatment has been identified as a protective factor by PHE and other bodies: “There are risks associated with the move 
towards abstinence. For example, there is a higher risk of death for heroin users who have left Opiate Substitution Therapy 
(OST) than for those who stay in it, especially in the first few weeks.” (ACMD, 2016, p31). Consequently the high number of 
individuals outside of the treatment population makes them a particularly vulnerable group.  
The data shows that the proportion of individuals aged over 40 has continued increased; from 40% in 2015-16 to 43% to 2016-
17, and up from 26% ten years ago. There are variations between local authorities, with these largely reflecting the proportion 
of people using steroid and IPED. These range from 28% of NPS users being aged 40 or over in Halton to 48% aged 40 or over in 
Liverpool. All areas however have seen increases over the last 10 years, in particular Knowsley and Warrington who have seen 
their proportions of NSP users aged 40 years and over more than double. 
 
Figure 49 - Proportion of individuals in NSP cohorts aged 40 years or over 
One of the regular queries levelled at NSP data wherever it’s collected is the authenticity of attributors given by clients using 
exchanges, the theory being that random fictional initials and date of birth may be commonly being used for fear of anonymity 
being breached, particularly in the case of services where the NSP is located within the same building as the structured 
treatment provider. Two factors contradict this suggestion. In the first place, a piece of research undertaken by PHI over the 
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summer of 2017 surveyed IMS reporting agencies and pharmacies from across the spread of local authorities and asked them 
about this specific issue. Over two thirds (72%) responded by stating that they believed individuals using their service used the 
same consistent attributors on each visit. Moreover, as part of the drug related death monitoring process which as discussed 
earlier in this report is now operational in a majority of IMS reporting local authority areas, a substantial majority of individuals 
whose personal details are confirmed to be correct by both the treatment service and the coroner have matching IMS records, 
thus suggesting that use of genuine details is the norm and not the exception, and that the numbers reporting to the system 
should be taken as broadly accurate. Finally on this point, the average number of transactions per person who injects 
psychoactive drugs is 6.35 (ranging from 2.66 in Halton to 13.61 in St. Helens), a figure which has increased in recent years, 
suggesting that moves to electronic recording may have resulted in improvement to data quality and increased consistency in 
recording of client attributors.   
During 2016-17, 7.5% of individuals attending NSP services and citing heroin or another psychoactive drug as their main 
substance were aged under 30 years. While this does not contradict the ACMD’s view that “relatively few young people are 
initiating problematic opioid use” this figure of over 700 cases indicates that some individuals within Cheshire and Merseyside 
are starting to inject heroin at a relatively young age. 
 
RECOMMENDATIONS BASED ON IMS DATA 
Supporting the newly revised UK guidelines on clinical management which recommend that services should “deliver effective 
harm reduction interventions” (Department of Health, 2017), services should ensure that the client offer is inviting and 
accessible to all opiate users regardless of their readiness for recovery. Services should meet the needs of the community and 
provide packages of care for those for whom recovery is not yet an aim. In particular services should be relevant and 
appropriate for the injecting population. 
Local authorities should continue to monitor lower threshold activity. The 2017 guidelines on clinical management place a new 
focus on harm reduction and access to “sterile injecting equipment or other suitable equipment” and the most recent NICE 
guidance (PH52) recommends that various bodies including commissioners, DPHs (Directors of Public Health) and Health and 
Wellbeing Boards should regularly collate and analyse data from a range of sources to look at the types of drugs used, numbers, 
demographics and characteristics of people who inject. Local authorities should accordingly not lose sight of the large and 
growing number of individuals who may not be in treatment but who are making use of lower threshold services such as syringe 
exchanges. For those individuals who are in treatment, it is important to understand the prevalence of injecting particularly 
when data from drug related death monitoring suggests that NDTMS may be under recording the extent of injecting. The 
numbers engaged in structured treatment should be examined in the context of the potentially larger number using substances 
problematically outside of the treatment system. 
Use of screening and assessment tools should be expanded. Brief interventions in the form of screening tools such as the 
Alcohol Use Disorders Identification Tests (AUDIT or AUDIT-C) have been proven to be a cost effective way of engaging 
individuals at an early stage of their drug or alcohol use and be an opportunity for reflection on their behaviour. IMS provides a 
field for recording AUDIT and the potential to record other screenings using the interventions tab. 
Agency based NSP services should make better links with pharmacies. IMS data suggests that people who inject IPEDs may 
prefer agency based services but conversely, people injecting psychoactive drugs appear to prefer pharmacies. Since the 
pharmacies will be a regular contact for such individuals, it is important that strong links exist between agencies and pharmacies 
which provide NSP as a route into treatment, an opportunity to signpost and to engage individuals disengaged from the 
treatment system. 
Smoking cessation interventions should be routinely recorded. COPD has been identified as one of the main causes of death 
over recent years for the ageing cohort of drug users, and IMS demonstrates that NSP users across Cheshire and Merseyside are 
on average older than they have ever been. Most agency based IMS services have been issued with CO monitors in order to 
promote a conversation around smoking cessation. Individuals should be routinely engaged with using this and other tools such 
as text messaging programs and quit plans. 
Housing should be a key area for drug services at all tiers of provision. Evidence suggests that housing has become a bigger 
issue for society as a whole since 2010, with many accommodation services challenged to cope with the rise in demand. The IMS 
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data suggest that this is a particular issue for those who inject psychoactive drugs. NSP services have an important role to play in 
ensuring that individuals with substance use problems are appropriately supported and/or signposted to organisations who can 
support them with issues related to housing, and resources should be directed towards this group of individuals. 
Recording of data on the use of Steroid and IPED should continue. The number of people using Steroid and IPED has increased 
at more than the number using  psychoactive drugs over the past year. People using Steroid and IPED are largely invisible in 
national drug and alcohol monitoring statistics and accordingly IMS provides the only local indication of the extent their 
injection. It also provides commissioners with an opportunity to collect more data on this client group, as they are unlikely to 
appear in traditional ‘drug treatment’ settings. 
IMS data should be used for the purposes of local drug related death reviews. Drug related deaths are at their highest level 
both locally and across England since records began, with the number of deceased individuals in treatment now lower than in 
previous years. IMS data consistently features in DRD panel reviews, highlighting that previous and recent injecting is occurring, 
even when the individual’s NDTMS record states that they have never injected. Given that treatment is often described as being 
a protective factor against poorer health and death, the reason for the rise in numbers of deaths among those injecting 
psychoactive drugs locally should be explored, including the relevance of the recovery agenda to individuals who have not yet 
reached the point of wanting to “recover”. 
Use of the Novel Psychoactive Substance (NPS) module should be expanded. The capturing of information pertaining to NPS 
use via national systems has been patchy and given the nature of the client group, use of this module should be expanded, in 
particular when dealing with client groups known to have relative high levels of use of substances such as “Spice” including 
young people and homeless individuals. 
IMS should be used across local authority areas by any relevant organisation. IMS has already been rolled out to services who 
do not specialise in drug or alcohol use related interventions, and this should be expanded to allow for the recording of 
information from services who may provide important support to individuals using drugs or alcohol or individuals affected by 
others who use drugs or alcohol. 
New harm reduction initiatives should be explored where the evidence is substantive. This may include the extension of 
naloxone and, given the rise in NSP activity reported by IMS, the introduction of drug consumption rooms, notwithstanding the 
difficulties there may be in gaining support for novel approaches. In order to examine the benefits of such approaches in detail, 
evidence from other geographical areas should be considered.  
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APPENDIXES 
 
A. AGENCY BASED NSP SERVICES 
A.1.  NSP AGENCY ONLY - ALL INDIVIDUALS BY COHORT 
 
Local Authority IDU: Psychoactive Drugs IDU: Steroid & IPEDs All NSP Individuals 
Cheshire East 129 532 661 
Cheshire West & Chester 501 921 1,422 
Halton 127 539 666 
Knowsley 112 246 358 
Liverpool 236 239 475 
Sefton 250 157 407 
St. Helens 272 355 627 
Warrington 31 228 259 
Wirral 378 786 1,164 
Cheshire & Merseyside 1,995 3,977 5,972 
Table 71 - Number of individuals using agency based NSP service, by cohort group 
 
Local Authority IDU: Psychoactive Drugs IDU: Steroid & IPEDs All NSP Individuals 
Cheshire East 25% 64% 49% 
Cheshire West & Chester 58% 78% 70% 
Halton 100% 100% 100% 
Knowsley 37% 58% 49% 
Liverpool 5% 8% 6% 
Sefton 26% 26% 26% 
St. Helens 29% 39% 33% 
Warrington 5% 29% 19% 
Wirral 45% 83% 65% 
Cheshire & Merseyside 20% 44% 32% 
Table 72 - Proportion of individuals by cohort group who used agency based NSP services 
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A.2.  NSP AGENCY ONLY - NEW INDIVIDUALS BY COHORT 
 
Local Authority IDU: Psychoactive Drugs IDU: Steroid & IPEDs All NSP Individuals 
Cheshire East 46 219 265 
Cheshire West & Chester 236 447 683 
Halton 78 220 298 
Knowsley 41 109 150 
Liverpool 91 137 228 
Sefton 109 54 163 
St. Helens 90 111 201 
Warrington 16 54 70 
Wirral 194 340 534 
Cheshire & Merseyside 887 1,690 2,577 
Table 73 - Number of new individuals using agency based NSP service, by cohort group 
 
Local Authority IDU: Psychoactive Drugs IDU: Steroid & IPEDs All NSP Individuals 
Cheshire East 36% 41% 40% 
Cheshire West & Chester 47% 49% 48% 
Halton 61% 41% 45% 
Knowsley 37% 44% 42% 
Liverpool 39% 57% 48% 
Sefton 44% 34% 40% 
St. Helens 33% 31% 32% 
Warrington 52% 24% 27% 
Wirral 51% 43% 46% 
Cheshire & Merseyside 44% 42% 43% 
Table 74 - Proportion of individuals using agency based NSP services who are new during the 2016-17 year 
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B. PHARMACY BASED NSP SERVICES 
B.1.  NSP PHARMACY ONLY - ALL INDIVIDUALS BY COHORT 
 
Local Authority IDU: Psychoactive Drugs IDU: Steroid & IPEDs All NSP Individuals 
Cheshire East 432 310 742 
Cheshire West & Chester 500 277 777 
Halton 0 0 0 
Knowsley 211 186 397 
Liverpool 5,015 2,715 7,730 
Sefton 833 442 1,275 
St. Helens 850 617 1,467 
Warrington 558 561 1,119 
Wirral 566 170 736 
Cheshire & Merseyside 8,795 5,236 14,031 
Table 75 - Number of individuals using pharmacy based NSP service, by cohort group 
 
Local Authority IDU: Psychoactive Drugs IDU: Steroid & IPEDs All NSP Individuals 
Cheshire East 85% 38% 56% 
Cheshire West & Chester 58% 24% 38% 
Halton 0% 0% 0% 
Knowsley 70% 44% 55% 
Liverpool 99% 92% 96% 
Sefton 87% 74% 82% 
St. Helens 89% 67% 78% 
Warrington 97% 72% 83% 
Wirral 68% 18% 41% 
Cheshire & Merseyside 89% 58% 74% 
Table 76 - Proportion of individuals by cohort group who used pharmacy based NSP services 
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B.2.  NSP PHARMACY ONLY - NEW INDIVIDUALS BY COHORT 
 
Local Authority IDU: Psychoactive Drugs IDU: Steroid & IPEDs All NSP Individuals 
Cheshire East 161 147 308 
Cheshire West & Chester 214 184 398 
Halton 0 0 0 
Knowsley 124 105 229 
Liverpool 3,634 2,004 5,638 
Sefton 479 329 808 
St. Helens 436 370 806 
Warrington 343 306 649 
Wirral 243 97 340 
Cheshire & Merseyside 5,601 3,520 9,121 
Table 77 - Number of new individuals using pharmacy based NSP service, by cohort group 
 
Local Authority IDU: Psychoactive Drugs IDU: Steroid & IPEDs All NSP Individuals 
Cheshire East 37% 47% 42% 
Cheshire West & Chester 43% 66% 51% 
Halton - - - 
Knowsley 59% 56% 58% 
Liverpool 72% 74% 73% 
Sefton 58% 74% 63% 
St. Helens 51% 60% 55% 
Warrington 61% 55% 58% 
Wirral 43% 57% 46% 
Cheshire & Merseyside 64% 67% 65% 
Table 78 - Proportion of individuals using pharmacy based NSP services who are new during the 2016-17 year 
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C. DETAILED BREAKDOWN BY SERVICE 
C.1.  DETAIL BY SERVICE PROVIDER - IMS ALL INDIVIDUALS 
 
        Total by gender   Total by client cohort group 
IMS Code IMS service name 
Total 
Clients 
2016-17 
  Male Female   
IDU: 
Drugs 
IDU: 
Steroids 
BI: Drug 
or 
Alcohol 
CHE30029 Catherine House, Crewe 492   472 20   88 404 0 
CHE30030 Barnabas Centre, Macclesfield 174   168 6   44 130 0 
CHE50022 Boots - Nantwich 5   *** ***   3 2 0 
CHE50175 Clear Pharmacy - Crewe 137   115 22   85 52 0 
CHE50340 Andrews Pharmacy - Macclesfield 15   <14 ***   12 3 0 
CHE50632 Rowlands - Middlewich 23   18 5   16 7 0 
CHE50803 Boots - Sandbach 10   10 0   4 6 0 
CHE50805 Mannings Chemist, Knutsford 12   <12 ***   11 1 0 
CHE50816 Well (224193) - Park Lane, Macclesfield 58   52 6   31 27 0 
CHE50819 Well (224537) - Handforth 0   0 0   0 0 0 
CHE50822 Well (223032) - Sunderland St, Macclesfld 168   138 30   111 57 0 
CHE50840 Assan Pharmacy Ltd T/A Cohens Chemist 150   124 26   95 55 0 
CHE50849 The Weston Pharmacy (R H Swinn Ltd) 30   24 6   17 13 0 
CHE50874 Lloyds - Lawton Road, Stoke 59   51 8   28 31 0 
CHE50876 Lloyds - Wilmslow ***   *** 0   0 *** 0 
CHE50877 Lloyds - Charlotte St, Macclesfield 23   17 6   16 7 0 
CHE50878 Lloyds - Congleton 113   98 15   53 60 0 
CHE50883 AJ Hodgson T/A London Road pharmacy 34   28 6   27 7 0 
CHE56610 Boots - Grand Junction, Crewe 36   <34 ***   18 18 0 
CHE57006 Salus Pharmacy - Congleton 60   43 17   30 30 0 
  Cheshire East Local Authority 1,336   1,184 152   511 825 0 
          
        Total by gender   Total by client cohort group 
IMS Code IMS service name 
Total 
Clients 
2016-17 
  Male Female   
IDU: 
Drugs 
IDU: 
Steroids 
BI: Drug 
or 
Alcohol 
CHW30027 Aqua House, Chester 501   462 39   210 289 2 
CHW30028 Unity House, Ellesmere Port 581   538 43   182 399 0 
CHW30045 Old Council House, Northwich 386   361 25   133 253 0 
CHW50016 Boots - Foregate St, Chester 253   223 30   169 84 0 
CHW50258 Pondas Chemist, Winsford 25   <23 ***   15 10 0 
CHW50377 Swettenham Chemist - Blacon 95   80 15   79 16 0 
CHW50462 Well (228547) - Northwich 30   24 6   18 12 0 
CHW50628 Lloyds - Weaverham, Northwich 10   10 0   4 6 0 
CHW50801 Lloyds - Old Chester Rd, Ellesmere 36   29 7   31 5 0 
CHW50833 Well (228520) - Fountains Health 125   109 16   90 35 0 
CHW50875 Lloyds - Middlewich Road, Northwich 34   <32 ***   14 20 0 
CHW50879 Lloyds - Sainsbury’s Northwich 52   44 8   23 29 0 
CHW53023 L Rowland & Co (Retail) Ltd - Ellesmere 95   83 12   68 27 0 
CHW53043 Superdrug - Northgate St, Chester 193   169 24   131 62 0 
CHW53064 Well (228534) - Ellesmere Port 43   <40 ***   27 16 0 
CHW59169 Owen's Pharmacy Saltney 28   19 9   20 8 0 
CHW59170 Westminster Park, T/A Salrook Health 0   0 0   0 0 0 
Cheshire West and Chester Local Authority 2,038   1,861 177   862 1,174 2 
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        Total by gender   Total by client cohort group 
IMS Code IMS service name 
Total 
Clients 
2016-17 
  Male Female   
IDU: 
Drugs 
IDU: 
Steroids 
BI: Drug 
or 
Alcohol 
HAL10031 Halton Integrated Recovery Service - CGL 530   347 183   29 3 498 
HAL30031 Aston Dane SES, Halton - CGL 595   561 34   113 477 5 
HAL30053 Runcorn High Street SES, Halton - CGL 88   88 0   8 80 0 
  Halton Local Authority 1,169   958 211   127 539 503 
          
        Total by gender   Total by client cohort group 
IMS Code IMS service name 
Total 
Clients 
2016-17 
  Male Female   
IDU: 
Drugs 
IDU: 
Steroids 
BI: Drug 
or 
Alcohol 
KNW10041 Knowsley Integrated Rec Service 875   605 270   42 7 826 
KNW30051 Kirkby SES, Knowsley - CGL 107   97 10   54 53 0 
KNW30052 Huyton SES, Knowsley - CGL 227   213 14   37 190 0 
KNW53302 Boots Cables Retail Park 6   6 0   3 3 0 
KNW53303 Boots - The Halewood centre 97   82 15   69 28 0 
KNW53315 Newtown Pharmacy, Kirkby 159   146 13   79 80 0 
KNW53323 Rowlands (Prev GF O'Brien) Kirkby 115   102 13   54 61 0 
KNW53327 A.E. Sedem (Woolfall Pharmacy) 5   5 0   1 4 0 
KNW53328 Sedem Pharmacy, Huyton ***   *** 0   *** 0 0 
KNW53329 Stockbridge Pharmacy ***   *** 0   *** *** 0 
KNW53334 Tops Pharmacy, Kirkby 25   24 ***   8 17 0 
  Knowsley Local Authority 1,553   1,222 331   300 427 826 
          
        Total by gender   Total by client cohort group 
IMS Code IMS service name 
Total 
Clients 
2016-17 
  Male Female   
IDU: 
Drugs 
IDU: 
Steroids 
BI: Drug 
or 
Alcohol 
LIV10002 Armistead City ***   *** 0   0 0 *** 
LIV10003 Community Voice 78   60 18   *** 0 75 
LIV10005 Armistead Street 167   *** 164   31 0 136 
LIV10007 Whitechapel Centre 0   0 0   0 0 0 
LIV10009 Action on Addiction - SHARP 472   255 217   18 1 453 
LIV10014 Aintree Hospital 1,595   1,064 531   31 1 1,563 
LIV10018 Brownlow Practice 203   143 60   40 2 161 
LIV10020 Royal Liverpool Hospital LCAS 511   333 178   28 1 482 
LIV10050 Young Addaction Liverpool 42   28 14   0 0 42 
LIV10071 North ARC - Addaction Recovery Centre 293   266 27   45 162 86 
LIV10072 Central ARC - Addaction Recovery Centre 156   140 16   32 70 54 
LIV10073 South ARC - Addaction Recovery Centre ***   *** ***   0 *** *** 
LIV10076 Addaction COAST ***   *** 0   0 0 *** 
LIV10081 Addaction Pre Treatment 7   <7 ***   2 0 5 
LIV10085 Addaction Whitechapel Outreach 0   0 0   0 0 0 
LIV10084 Addaction REST Centre 0   0 0   0 0 0 
LIV10060 Transforming Choice 70   48 22   8 0 62 
LIV58343 Belle Vale Pharmacy 75   <74 ***   35 40 0 
LIV58350 Boots - Long Lane 24   <23 ***   13 11 0 
LIV58351 Boots - Boaler St 439   358 81   297 142 0 
LIV58353 Boots - London Rd 2,794   2,432 362   1,620 1,174 0 
LIV58394 Lloyds - Prospect Point 2,404   2,095 309   1,822 582 0 
LIV58398 Lloyds - West Derby Road 383   311 72   316 67 0 
LIV58403 Lloyds - Muirhead Ave East 118   108 10   65 53 0 
LIV58406 Lloyds - Townsend Lane 739   650 89   635 104 0 
LIV58409 Lloyds - St Oswald St 413   363 50   254 159 0 
LIV58415 Melwood Pharmacy, Deysbrook Lane 19   <19 ***   13 6 0 
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LIV58416 Norman Pharmacy, Walton Rd 785   625 160   635 150 0 
LIV58421 Rowlands - Speke Health Centre 109   94 15   43 66 0 
LIV58422 Rowlands - Somerfield, Garston 235   225 10   18 217 0 
LIV58437 Rowlands - Lodge Lane 191   175 16   141 50 0 
LIV58574 Riverside Pharmacy 36   5 31   32 4 0 
  Liverpool Local Authority 10,961   8,811 2,150   5,080 2,940 2,941 
          
        Total by gender   Total by client cohort group 
IMS Code IMS service name 
Total 
Clients 
2016-17 
  Male Female   
IDU: 
Drugs 
IDU: 
Steroids 
BI: Drug 
or 
Alcohol 
SEF10056 Independence Initiative 105   71 34   2 0 103 
SEF10077 Ambition Sefton, Southport - MerseyCare 743   552 191   165 144 434 
SEF10078 Ambition Sefton, Bootle - MerseyCare 691   450 241   94 13 584 
SEF55000 Aintree Pharmacy 41   <40 ***   14 27 0 
SEF55708 M L Davey Chemist, Litherland 49   41 8   32 17 0 
SEF56448 Bispham Road Pharmacy 101   <99 ***   24 77 0 
SEF56452 Boots - South Rd, Waterloo 56   46 10   37 19 0 
SEF56453 Boots - Liverpool Rd, Crosby 14   <12 ***   7 7 0 
SEF56456 Cohens - Marian Square, Netherton 96   73 23   72 24 0 
SEF56460 Haddens Pharmacy - Litherland Rd, Bootle 183   168 15   135 48 0 
SEF56462 Lloyds - Knowsley Rd 69   59 10   63 6 0 
SEF56464 Lloyds - North Park 0   0 0   0 0 0 
SEF56465 Merton Pharmacy - Stanley Road ***   *** 0   0 *** 0 
SEF56466 Netherton Park Pharmacy 29   <29 ***   11 18 0 
SEF56499 Higgins Pharmacy - Crosby Road North 71   59 12   28 43 0 
SEF56504 Lloyds - Crosby Rd North 37   31 6   14 23 0 
SEF56507 Rowlands - Upper Aughton Rd ***   *** ***   *** *** 0 
SEF56520 Superdrug - Eastbank Street, Southport 345   297 48   302 43 0 
SEF56525 Boots - Cambridge Rd, Southport ***   *** 0   *** *** 0 
SEF56526 Boots - Seaforth 170   148 22   89 81 0 
SEF56845 Bridge Road Pharmacy, Litherland 84   75 9   68 16 0 
  Sefton Local Authority 2,625   2,031 594   957 595 1,073 
          
        Total by gender   Total by client cohort group 
IMS Code IMS service name 
Total 
Clients 
2016-17 
  Male Female   
IDU: 
Drugs 
IDU: 
Steroids 
BI: Drug 
or 
Alcohol 
SHL10061 Hope House 292   235 57   110 10 172 
SHL10062 Hope Centre (Breathe) 50   21 29   0 0 50 
SHL10063 Footsteps, St. Helens 92   17 75   0 1 91 
SHL10075 YP Drug & Alcohol Team - St. Helens 110   71 39   30 0 80 
SHL30083 St. Helens SES - CGL 356   323 33   146 210 0 
SHL40063 Rowlands - Newton-Le-Willows 0   0 0   0 0 0 
SHL40119 Lloyds - Duke Street, St. Helens 180   160 20   131 49 0 
SHL40122 Lloyds - Junction Lane, Sutton Oak 187   169 18   109 78 0 
SHL40141 Rowlands - Thatto Heath 57   44 13   40 17 0 
SHL40143 St. Helens Millennium Centre 1,226   1,052 174   725 501 0 
  St. Helens Local Authority 2,262   1,872 390   950 922 390 
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        Total by gender   Total by client cohort group 
IMS Code IMS service name 
Total 
Clients 
2016-17 
  Male Female   
IDU: 
Drugs 
IDU: 
Steroids 
BI: Drug 
or 
Alcohol 
WAR10066 Footsteps, Warrington 127   47 80   0 0 127 
WAR10069 Footsteps, CGL Partnership 106   31 75   0 0 106 
WAR30039 Pathways, Warrington - CGL 278   269 9   31 228 19 
WAR40070 Well Pharmacy - Fearnhead Cross 132   125 7   59 73 0 
WAR40071 Rowlands - Thelwall Lane 332   315 17   104 228 0 
WAR40072 Well Pharmacy - The Baths 515   469 46   343 172 0 
WAR40073 Lloyds - Earl Street, Warrington 227   207 20   125 102 0 
  Warrington Local Authority 1,605   1,357 248   578 775 252 
          
          
        Total by gender   Total by client cohort group 
IMS Code IMS service name 
Total 
Clients 
2016-17 
  Male Female   
IDU: 
Drugs 
IDU: 
Steroids 
BI: Drug 
or 
Alcohol 
WIR10019 Response, Wirral 97   55 42   0 0 97 
WIR10049 TSP Second Chance Project 86   68 18   11 0 75 
WIR20059 Wirral CGL - NPS 7   <7 ***   3 0 4 
WIR10059 Wirral Integrated Recovery Service 80   50 30   1 0 79 
WIR30057 Birkenhead SES, Wirral - CGL 1,060   997 63   331 712 17 
WIR30058 Moreton SES, Wirral - CGL 84   83 ***   27 57 0 
WIR30067 Wallasey SES, Wirral - CGL 68   64 ***   26 41 1 
WIR50076 Rowlands (Branch: 1368) - Market St 119   110 9   108 11 0 
WIR50077 Lee's Pharmacy - Wood Church 17   16 ***   8 9 0 
WIR50079 Rowlands (Branch: 1284) - Moreton 26   21 5   16 10 0 
WIR50080 Old Chester Pharmacy, Rockferry 77   59 18   75 2 0 
WIR50087 Wilsons Chemist, West Kirby 6   <5 <5   6 0 0 
WIR50088 Boots (Branch: 5169 - Rockferry) 59   51 8   48 11 0 
WIR50090 Victoria Pharmacy, New Brighton 28   <27 ***   22 6 0 
WIR50097 Egremont Pharmacy, Wallasey 59   53 6   52 7 0 
WIR50105 Lloyds - (Branch: 6705) Arrowe Park 23   <23 ***   19 4 0 
WIR50106 Boots (Branch: 5989 - Bidston) 62   56 6   55 7 0 
WIR50108 Wyn Ellis and Son, Poulton Rd, Wallasey 67   60 7   54 13 0 
WIR50135 Claughton Pharmacy, Park Rd Nth, Birken 51   44 7   43 8 0 
WIR50153 MedicX Pharmacy, St Cath’s, Tranmere 251   229 22   165 86 0 
  Wirral Local Authority 2,054   1,820 234   835 943 276 
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C.2.  DETAIL BY SERVICE PROVIDER - IMS ALL ACTIVITY 
 
IMS Code IMS service name 
Brief 
Interventions 
Onward 
Referrals 
Wellbeing 
Reviews 
Syringe 
Exchange 
Transactions 
Syringe 
Exchange 
Returns 
CHE30029 Catherine House, Crewe 2 0 0 1,026 312 
CHE30030 Barnabas Centre, Macclesfield 97 0 0 338 54 
CHE50022 Boots - Nantwich 0 0 0 5 3 
CHE50175 Clear Pharmacy - Crewe 0 0 0 576 245 
CHE50340 Andrews Pharmacy - Macclesfield 0 0 0 123 23 
CHE50632 Rowlands - Middlewich 0 0 0 313 233 
CHE50803 Boots - Sandbach 0 0 0 60 43 
CHE50805 Mannings Chemist, Knutsford 0 0 0 41 5 
CHE50816 Well (224193) - Park Lane, Macclesfield 0 0 0 328 78 
CHE50819 Well (224537) - Handforth 0 0 0 0 0 
CHE50822 Well (223032) - Sunderland St, Macclesfld 0 0 0 1,614 159 
CHE50840 Assan Pharmacy Ltd T/A Cohens Chemist 0 0 0 1,641 796 
CHE50849 The Weston Pharmacy (R H Swinn Ltd) 0 0 0 175 33 
CHE50874 Lloyds - Lawton Road, Stoke 0 0 0 340 37 
CHE50876 Lloyds - Wilmslow 0 0 0 1 1 
CHE50877 Lloyds - Charlotte St, Macclesfield 0 0 0 26 12 
CHE50878 Lloyds - Congleton 0 0 0 342 162 
CHE50883 AJ Hodgson T/A London Road pharmacy 0 0 0 408 115 
CHE56610 Boots - Grand Junction, Crewe 0 0 0 141 15 
CHE57006 Salus Pharmacy - Congleton 0 0 0 171 137 
  Cheshire East Local Authority 99 0 0 7,669 2,463 
       
       
IMS Code IMS service name 
Brief 
Interventions 
Onward 
Referrals 
Wellbeing 
Reviews 
Syringe 
Exchange 
Transactions 
Syringe 
Exchange 
Returns 
CHW30027 Aqua House, Chester 484 0 0 1,376 801 
CHW30028 Unity House, Ellesmere Port 481 0 0 1,214 542 
CHW30045 Old Council House, Northwich 439 0 0 1,189 243 
CHW50016 Boots - Foregate St, Chester 0 0 0 1,201 606 
CHW50258 Pondas Chemist, Winsford 0 0 0 186 40 
CHW50377 Swettenham Chemist - Blacon 0 0 0 1,116 666 
CHW50462 Well (228547) - Northwich 0 0 0 172 112 
CHW50628 Lloyds - Weaverham, Northwich 0 0 0 41 41 
CHW50801 Lloyds - Old Chester Rd, Ellesmere 0 0 0 179 159 
CHW50833 Well (228520) - Fountains Health 0 0 0 300 158 
CHW50875 Lloyds - Middlewich Road, Northwich 0 0 0 85 39 
CHW50879 Lloyds - Sainsbury’s Northwich 0 0 0 349 218 
CHW53023 L Rowland & Co (Retail) Ltd - Ellesmere 0 0 0 634 431 
CHW53043 Superdrug - Northgate St, Chester 0 0 0 1,033 566 
CHW53064 Well (228534) - Ellesmere Port 0 0 0 256 115 
CHW59169 Owen's Pharmacy Saltney 0 0 0 233 110 
CHW59170 Westminster Park, T/A Salrook Health 0 0 0 0 0 
Cheshire West and Chester Local Authority 1,404 0 0 9,564 4,847 
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IMS Code IMS service name 
Brief 
Interventions 
Onward 
Referrals 
Wellbeing 
Reviews 
Syringe 
Exchange 
Transactions 
Syringe 
Exchange 
Returns 
HAL10031 Halton Integrated Recovery Service - CGL 1,054 0 74 0 0 
HAL30031 Aston Dane SES, Halton - CGL 762 1 0 1,116 198 
HAL30053 Runcorn High Street SES, Halton - CGL 67 0 0 156 22 
  Halton Local Authority 1,883 1 74 1,272 220 
       
       
IMS Code IMS service name 
Brief 
Interventions 
Onward 
Referrals 
Wellbeing 
Reviews 
Syringe 
Exchange 
Transactions 
Syringe 
Exchange 
Returns 
KNW10041 Knowsley Integrated Rec Service 1,409 0 159 0 0 
KNW30051 Kirkby SES, Knowsley - CGL 250 0 0 373 62 
KNW30052 Huyton SES, Knowsley - CGL 117 0 0 399 79 
KNW53302 Boots Cables Retail Park 0 0 0 7 7 
KNW53303 Boots - The Halewood centre 0 0 0 238 239 
KNW53315 Newtown Pharmacy, Kirkby 0 0 0 319 319 
KNW53323 Rowlands (Prev GF O'Brien) Kirkby 0 0 0 320 320 
KNW53327 A.E. Sedem (Woolfall Pharmacy) 0 0 0 8 8 
KNW53328 Sedem Pharmacy, Huyton 0 0 0 19 19 
KNW53329 Stockbridge Pharmacy 0 0 0 2 2 
KNW53334 Tops Pharmacy, Kirkby 0 0 0 33 33 
  Knowsley Local Authority 1,776 0 159 1,718 1,088 
       
       
IMS Code IMS service name 
Brief 
Interventions 
Onward 
Referrals 
Wellbeing 
Reviews 
Syringe 
Exchange 
Transactions 
Syringe 
Exchange 
Returns 
LIV10002 Armistead City 2 0 0 0 0 
LIV10003 Community Voice 185 1 53 0 0 
LIV10005 Armistead Street 812 10 0 0 0 
LIV10007 Whitechapel Centre 0 0 0 0 0 
LIV10009 Action on Addiction - SHARP 10,480 1,012 421 0 0 
LIV10014 Aintree Hospital 2,164 103 0 0 0 
LIV10018 Brownlow Practice 771 88 0 0 0 
LIV10020 Royal Liverpool Hospital LCAS 772 20 0 0 0 
LIV10050 Young Addaction Liverpool 84 1 3 0 0 
LIV10071 North ARC - Addaction Recovery Centre 653 42 54 470 196 
LIV10072 Central ARC - Addaction Recovery Centre 432 36 44 209 94 
LIV10073 South ARC - Addaction Recovery Centre 8 1 1 1 0 
LIV10076 Addaction COAST 1 0 1 0 0 
LIV10081 Addaction Pre Treatment 7 0 0 0 0 
LIV10085 Addaction Whitechapel Outreach 0 0 0 0 0 
LIV10084 Addaction REST Centre 0 0 0 0 0 
LIV10060 Transforming Choice 18,314 22 37 0 0 
LIV58343 Belle Vale Pharmacy 0 0 0 237 6 
LIV58350 Boots - Long Lane 0 0 0 84 11 
LIV58351 Boots - Boaler St 0 0 0 877 103 
LIV58353 Boots - London Rd 0 0 0 8,683 1,470 
LIV58394 Lloyds - Prospect Point 0 0 0 5,783 515 
LIV58398 Lloyds - West Derby Road 0 0 0 1,382 217 
LIV58403 Lloyds - Muirhead Ave East 0 0 0 251 103 
LIV58406 Lloyds - Townsend Lane 0 0 0 2,626 211 
LIV58409 Lloyds - St Oswald St 0 0 0 1,081 230 
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LIV58415 Melwood Pharmacy, Deysbrook Lane 0 0 0 164 18 
LIV58416 Norman Pharmacy, Walton Rd 0 0 0 2,253 592 
LIV58421 Rowlands - Speke Health Centre 0 0 0 332 252 
LIV58422 Rowlands - Somerfield, Garston 0 0 0 615 64 
LIV58437 Rowlands - Lodge Lane 0 0 0 1,025 138 
LIV58574 Riverside Pharmacy 0 0 0 246 27 
  Liverpool Local Authority 37,074 1,336 860 26,319 4,247 
       
       
IMS Code IMS service name 
Brief 
Interventions 
Onward 
Referrals 
Wellbeing 
Reviews 
Syringe 
Exchange 
Transactions 
Syringe 
Exchange 
Returns 
SEF10056 Independence Initiative 101 40 103 0 0 
SEF10077 Ambition Sefton, Southport - MerseyCare 17,134 0 65 986 34 
SEF10078 Ambition Sefton, Bootle - MerseyCare 4,551 0 0 114 17 
SEF55000 Aintree Pharmacy 33 0 0 129 66 
SEF55708 M L Davey Chemist, Litherland 22 0 0 1,039 223 
SEF56448 Bispham Road Pharmacy 0 0 0 148 0 
SEF56452 Boots - South Rd, Waterloo 17 0 0 296 2 
SEF56453 Boots - Liverpool Rd, Crosby 1 0 0 23 3 
SEF56456 Cohens - Marian Square, Netherton 15 0 0 781 159 
SEF56460 Haddens Pharmacy - Litherland Rd, Bootle 215 0 0 930 3 
SEF56462 Lloyds - Knowsley Rd 0 0 0 152 4 
SEF56464 Lloyds - North Park 0 0 0 0 0 
SEF56465 Merton Pharmacy - Stanley Road 1 0 0 2 1 
SEF56466 Netherton Park Pharmacy 6 0 0 60 8 
SEF56499 Higgins Pharmacy - Crosby Road North 0 0 0 116 0 
SEF56504 Lloyds - Crosby Rd North 27 0 0 48 4 
SEF56507 Rowlands - Upper Aughton Rd 3 0 0 3 1 
SEF56520 Superdrug - Eastbank Street, Southport 178 0 0 2,737 65 
SEF56525 Boots - Cambridge Rd, Southport 2 0 0 6 0 
SEF56526 Boots - Seaforth 20 0 0 291 9 
SEF56845 Bridge Road Pharmacy, Litherland 3 0 0 99 21 
  Sefton Local Authority 22,329 40 168 7,960 620 
       
       
IMS Code IMS service name 
Brief 
Interventions 
Onward 
Referrals 
Wellbeing 
Reviews 
Syringe 
Exchange 
Transactions 
Syringe 
Exchange 
Returns 
SHL10061 Hope House 6,783 2 106 0 0 
SHL10062 Hope Centre (Breathe) 59 27 32 0 0 
SHL10063 Footsteps, St. Helens 402 55 94 0 0 
SHL10075 YP Drug & Alcohol Team - St. Helens 110 0 1 0 0 
SHL30083 St. Helens SES - CGL 300 0 0 1,020 100 
SHL40063 Rowlands - Newton-Le-Willows 0 0 0 0 0 
SHL40119 Lloyds - Duke Street, St. Helens 0 0 0 1,311 611 
SHL40122 Lloyds - Junction Lane, Sutton Oak 0 0 0 906 40 
SHL40141 Rowlands - Thatto Heath 0 0 0 636 107 
SHL40143 St. Helens Millennium Centre 0 0 0 12,235 393 
  St. Helens Local Authority 7,716 84 233 16,325 1,288 
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IMS Code IMS service name 
Brief 
Interventions 
Onward 
Referrals 
Wellbeing 
Reviews 
Syringe 
Exchange 
Transactions 
Syringe 
Exchange 
Returns 
WAR10066 Footsteps, Warrington 852 38 142 0 0 
WAR10069 Footsteps, CGL Partnership 950 84 131 0 0 
WAR30039 Pathways, Warrington - CGL 70 0 0 355 98 
WAR40070 Well Pharmacy - Fearnhead Cross 0 0 0 456 101 
WAR40071 Rowlands - Thelwall Lane 0 0 0 862 154 
WAR40072 Well Pharmacy - The Baths 0 0 0 2,151 298 
WAR40073 Lloyds - Earl Street, Warrington 0 0 0 662 385 
  Warrington Local Authority 1,872 122 273 4,486 1,036 
       
       
       
IMS Code IMS service name 
Brief 
Interventions 
Onward 
Referrals 
Wellbeing 
Reviews 
Syringe 
Exchange 
Transactions 
Syringe 
Exchange 
Returns 
WIR10019 Response, Wirral 345 0 0 0 0 
WIR10049 TSP Second Chance Project 436 68 51 0 0 
WIR20059 Wirral CGL - NPS 7 0 0 0 0 
WIR10059 Wirral Integrated Recovery Service 111 0 29 0 0 
WIR30057 Birkenhead SES, Wirral - CGL 1,592 24 0 2,893 881 
WIR30058 Moreton SES, Wirral - CGL 4 0 0 128 41 
WIR30067 Wallasey SES, Wirral - CGL 72 1 0 97 33 
WIR50076 Rowlands (Branch: 1368) - Market St 0 0 0 952 165 
WIR50077 Lee's Pharmacy - Wood Church 0 0 0 201 12 
WIR50079 Rowlands (Branch: 1284) - Moreton 0 0 0 67 43 
WIR50080 Old Chester Pharmacy, Rockferry 0 0 0 998 333 
WIR50087 Wilsons Chemist, West Kirby 0 0 0 32 7 
WIR50088 Boots (Branch: 5169 - Rockferry) 0 0 0 551 365 
WIR50090 Victoria Pharmacy, New Brighton 0 0 0 175 79 
WIR50097 Egremont Pharmacy, Wallasey 0 0 0 310 71 
WIR50105 Lloyds - (Branch: 6705) Arrowe Park 0 0 0 138 90 
WIR50106 Boots (Branch: 5989 - Bidston) 0 0 0 251 128 
WIR50108 Wyn Ellis and Son, Poulton Rd, Wallasey 0 0 0 467 409 
WIR50135 Claughton Pharmacy, Park Rd Nth, Birken 0 0 0 598 396 
WIR50153 MedicX Pharmacy, St Cath’s, Tranmere 0 0 0 1,288 788 
  Wirral Local Authority 2,570 93 80 9,146 3,841 
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DATA METHODOLOGY 
The Integrated Monitoring System (IMS) is a live database, which allows service providers to add or amend client activity 
retrospectively. For the purpose of this report, a frozen data set was extracted from the IMS database on 1st October 2017. The 
data extract included all IMS clients who had indicated their consent to share data with Liverpool John Moores University. 
Guidance is available for both clients and service providers regarding informed consent in the IMS data sharing toolkit 
https://ims.ljmu.ac.uk/reference  
The IMS report data extract includes all consenting clients with a valid attributor, and with IMS activity recorded during the 
period 1st April 2016 to 31st March 2017. IMS activity includes at least one of an intervention, referral, wellbeing, syringe 
exchange transaction, or syringe exchange return. A valid attributor requires first and surname initials, gender, and a date of 
birth indicating that the client is aged between 6 and 100. 
Throughout this report where percentages are used these may not add up to 100% due to rounding. In some tables low 
numbers have been suppressed in order to protect client attributable data. 
NDTMS data matching included all clients engaged in a structured treatment programme at specialist drug services within 
Cheshire and Merseyside during 2016-17. Data was matched by client attributor only, it is therefore possible that a client’s 
structured and non-structured service provision may not necessarily have occurred within the same Local Authority area. 
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GLOSSARY 
 
BI Brief Intervention 
CJD Criminal Justice Dataset (also known as DIP) 
COPD Chronic Obstructive Pulmonary Disease 
DIP Drug Interventions Programme 
IBA Identification and Brief Advice 
IDU Injecting Drug Use 
IMS Integrated Monitoring System 
IPED Image and Performance Enhancing Drugs 
LJMU Liverpool John Moores University 
NTA National Treatment Authority (now part of PHE) 
NDTMS National Drug Treatment Monitoring System 
NPS New Psychoactive Substances 
NSP Needle and Syringe Programmes 
PHE Public Health England 
PHI Public Health Institute (formerly the Centre for Public Health) 
PWID People Who Inject Drugs 
WEMWBS Warwick Edinburgh Mental Well-being Scale 
WHO World Health Organization 
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